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  We have previously reported that 3-Deazaneplanocin A (DZNep) is a histone 
methylation inhibitor that can induce apoptosis in cancer cells but not in 
normal cells. To develop DZNep analogs toward druggability, we have 
collaborated with ICES (Institute of Chemical and Engineering Sciences of 
Singapore) to develop DZNep analogs through a phenotype-based structure 
and activity relationship (SAR) analysis. This collaboration led to a number of 
DZNep analogs that showed promising results. One of these compounds, 
named I-3, showed comparable cellular activity with DZNep but with much 
improved safety in mice. The main purpose of my project is to characterize the 
anti-cancer effects of I-3 in multiple cancer models, in particular acute 
myeloid leukemia (AML) and aggressive breast cancer.  
 
  Acute myeloid leukemia (AML) is characterized by clonal expansion of 
immature malignant myeloid hematopoietic cells. AML is the most common 
acute leukemia affecting adults, and its incidence increases with age. Although 
conventional chemotherapy is capable of producing complete remission (CR) 
in almost 70% of patients, many of them will ultimately relapse and succumb 
to their disease. Thus, there is great necessity to develop novel therapeutic 
approaches for refractory AML, such as targeted therapy and epigenetic 
therapy. The aim of this study is to test the efficacy of I-3 in AML using both 
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in vitro and in vivo mouse models.  The results showed that I-3 was able to 
induce robust anti-proliferative and pro-apoptotic effects in multiple AML cell 
lines and primary AML cells. It also effectively inhibited AML xenograft 
tumor growth with tolerable toxicity in mouse models. Moreover, I-3 elicited 
comprehensive gene expression changes related to various oncogenic 
signaling pathways (such as PI3K/AKT, MEK/ERK and JAK/STATs) which 
are correlated to its sensitivity in AML.  
  
  Furthermore, it was demonstrated that I-3 targeted not only bulk blasts in 
AML but also CD34+CD38- leukemia stem cells (LSCs) which have been 
proposed to be one of the main causes for chemoresistance and disease 
relapse. It was found that I-3 efficiently reduced chemotherapy-induced 
CD34+CD38- LSC population in TF-1a cells and inhibited the colony forming 
capacity of LSCs in vitro. In addition, treatment with the chemotherapy agent 
Ara-C in AML cells induced a rapid emergence of a subpopulation which 
displayed mesenchymal phenotype, such as increased capabilities in cell 
migration, adhesion and invasion. I-3 was found to significantly abrogate these 
mesenchymal-like properties as well as cell adhesion, migration and invasive 
properties induced by chemotherapy. Microarray data analysis revealed that a 
group of adhesion molecules (such as integrins, collagens, laminins, 
fibronectine, CD44, PECAM1, ICAM1, etc.) and leukocyte transendothelial 
migration related genes (IL8, MMP2 and MMP9) were significantly induced y 
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Ara-C, which could be reversed when co-treated with I-3. Accumulating 
evidences suggest that leukemic cancer cells in contact with bone marrow 
(BM) stromal cells and extracellular matrix (ECM) components may acquire 
resistance to chemotherapy by a process known as cell adhesion-mediated 
drug resistance (CAM-DR). Thus, I-3 may have the potential to target drug 
resistance and AML recurrence. We also compared I-3 with two other FDA-
approved epigenetic drugs, DNA methylation inhibitor Decitabine and histone 
deacetylase (HDAC) inhibitor SAHA in various anti-cancer aspects. Our 
results indicate that I-3 as a novel chromatin remodeling compound has a 
unique ability to target LSC and is more potent to suppress AML than DAC 
and SAHA.  
 
  In addition to AML, we also evaluated the anti-cancer effects of I-3 in 
aggressive breast cancer. MDA-MB-231 (MB231), a highly invasive breast 
cancer cell line, has been used to evaluate whether I-3 alone or in combination 
with HDAC inhibitor SAHA can affect its invasive capacity in vitro and 
metastatic ability in vivo. It was found that I-3 synergized with SAHA to 
induce a reversal of epithelial-mesenchymal-transition (EMT) with a strong 
induction of the epithelial marker E-cadherin, resulting in marked inhibition of 
cell invasion.  Furthermore, it was found that the anti-invasive efficacy of I-3 
in combination with SAHA was compromised under E-cadherin knock-down 
conditions. To determine if E-cadherin chromatin status was associated with 
xi 
 
its repression in MB231, CHIP assay coupled with quantitative PCR was 
utilized to characterize potential involved chromatin marks. Our data 
suggested that the repressive marks H3K27me3 and H3K9me3 were highly 
enriched in E-cadherin promoter of MB231, whereas the two major activating 
marks H3AC and H3K4me3 were almost absent, suggesting that E-cadherin 
repression in MB231 was mainly regulated through histone modification. 
Finally, in a MB231-derived lung metastasis mouse model, I-3 treatment was 
able to inhibit the lung metastasis of MB231 in a dose-dependent manner.  
 
   Collectively, our data demonstrated that I-3 was able to suppress both bulk 
blasts and LSCs in AML and inhibit cancer EMT, invasion and metastasis in 
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1.1 Epigenetics in cancer 
 
  Since the term ‘epigenetics’ was coined in early 1940s by Conrad 
Waddington, it has been used to define alterations in gene expression through 
mechanisms without the changes of DNA sequence. Accumulating evidences 
demonstrate that genetic and epigenetic alterations work coordinately to 
suppress tumor suppressor genes and activate oncogenes, leading to cancer 
initiation and progression. In addition to genetic alterations, cancer cells are 
also characterized by aberration of DNA methylation, overexpression of 
HDACs, global reduction of histone acetylation, deregulation of histone 
methyltransferases (HMTs) and histone demethylases (HDMs). Cancer cells 
utilize these aberrant epigenetic processes to escape various apoptotic insults 
to enhance their proliferation and survival. Unlike genetic alterations, 
epigenetic changes are reversible, making them attractive targets for cancer 
therapy. The investigation of epigenetic mechanisms and the development of 
epigenetic targeted therapy have reached the mainstream of human cancer 
study in recent years. Numerous compounds have been reported to be effective 
against cancer cells by inhibiting components of the epigenetic machineries. In 
this chapter, I will outline briefly the current understanding of epigenetic 
alterations of DNA methylation and the two most abundant histone 




1.1.1 DNA methylation 
1.1.1.1 Overview of DNA methylation 
  The most characterized epigenetic process is DNA methylation, which is 
mediated by a family of DNA methyltransferases (DNMT) enzymes. There 
are primarily three members in this DNMT family. DNMT1 is thought to be 
involved in methylation maintenance particularly after cell division, whereas 
DNMT3A and DNMT3B are considered to function in the de novo 
methylation process. DNMTs play central roles in gene transcription and 
cancer development (Jones and Baylin 2007). DNMTs catalyze the transfer of 
methyl groups to the 5’ position of the cytosine rings specifically in CpG 
(cytosine and guanosine separated by a phosphate in DNA) islands. CpG 
islands are the genomic regions with highly enriched CpG dinucleotide 
sequences and are commonly found near 5’ promoter regions of genes (Razin, 
Urieli et al. 1980; Robertson 2001). Cancers display typical features of 
methylation, such as genome-wide hypomethylation resulting in genome 
instability and hypermethylation in the promoter regions of tumor suppressor 
genes. A number of well-established tumor suppressor genes such as 
CDKN2A (cyclin-dependent kinase inhibitor 2A), MLH1 (mutL homolog-1), 
BRCA1 (breast cancer–associated-1) and VHL (von Hippel-Lindau tumor 
suppressor) were found to be silenced by promoter hypermethylation in 
various cancers (Jones and Baylin 2007; Esteller 2008). 
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1.1.1.2 Epigenetic biomarkers of DNA methylation 
 
  There is substantial evidence that validates the use of DNA methylation gene 
signature as a biomarker to detect cancer. In early stage tumors, specific 
promoters are hypermethylated that enable early detection of cancer, 
especially in patients who carry BRCA1 and BRCA2 mutations and those who 
are exposed to carcinogens. One of the most promising biomarkers for prostate 
cancer is glutathione S-transferase gene (GSTP1) that is hypermethylated in 
more than 80% of prostate cancer tissues but not in non-cancerous prostate 
tissues with hyperplasia (Jeronimo, Usadel et al. 2001). Therefore, the 
presence of GSTP1 hypermethylation in urine (Hoque, Topaloglu et al. 2005) 
and serum (Richiardi, Fiano et al. 2009) allows the clinical distinction between 
non-cancerous tissues and prostate cancer. 
 
  In recent years, increasing number of hypermethylated genes that correlate 
significantly with prognosis has also been identified. Hypermethylated genes 
such as histone methyltransferase (HMT) NSD1, death-associated protein 
kinase (DAPK), epithelial membrane protein-3 and CDKN2A have been 
linked to worse prognosis for patients suffering neuroblastoma, lung, brain and 
colorectal cancer, respectively (Esteller 2008; Berger, Kouzarides et al. 2009). 
Despite the promising use of these single genes as prognostic biomarkers, 
prospective studies recruiting more patients have to be conducted to validate 
5 
 
the correlation between DNA hypermethylation of these genes and clinical 
outcomes. 
 
  Another application of identifying hypermethylation of target genes is to 
predict the susceptibility of cancers to chemotherapy. One such target gene 
belongs to the DNA repair pathway, which can be epigenetically inactivated in 
cancers. For example, hypermethylation of O6-methylguanine-DNA 
methyltransferase-encoding gene (MGMT), DNA mismatch repair protein-
encoding gene (MLH1) and BRCA1 can predict response to chemotherapy in 
gliomas, ovarian and breast cancer respectively (Esteller, Garcia-Foncillas et 
al. 2000; Plumb, Strathdee et al. 2000; Veeck, Ropero et al. 2010). These 
DNA repair genes, in their wild-type form, can repair cytotoxic insults to the 
genome. However, if these genes are hypermethylated and inactivated, DNA 
damage cannot be reversed, leading to increased response to chemotherapy, 
especially for drugs that induce DNA breakage. 
 
  The major advance in the field is fuelled by the development of high-
throughput sequencing technologies that exhibit high sensitivity. The hybrid of 
bisulphite modification of DNA and PCR allows the detection of minute 
quantity of abnormal DNA methylation in various clinical samples including 
biopsies and body fluids. Genome-wide detection of DNA methylation in 
human cells at single nucleotide resolution is also possible with the use of 
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methylated DNA (methylC-seq) or immunoprecipitation of methylated DNA 
with antibodies against methylated cytosine (MeDIP-seq) in combination with 
next-generation sequencing. Such large scale approach in the detection of 
DNA hypermethylation in cancer has revolutionized and benefited not only 
bench science but also clinical research.  
1.1.1.3 Inhibitors targeting DNA hypermethylation 
  The first two DNA hypomethylating drugs which have been approved by 
U.S. Food and Drug Administration (FDA) for the treatment of high-risk 
myelodysplastic syndrome (MDS) are Azacitidine (5-Aza-CR, Vidaza, 
Azacitidine) and Decitabine (5-Aza-CdR, Dacogen, DAC). These two drugs, 
which are nucleoside analogs, have also been proven useful in the treatment of 
acute myeloid leukemia (AML). Once incorporated into DNA, both agents 
covalently bind and sequester DNMTs, leading to the depletion of DNMTs, 
subsequent promoter demethylation and reactivation of silenced genes 
(Stresemann and Lyko 2008). In the early phase of the drug development, 
using high dose, these two drugs caused direct cytotoxicity which had posed a 
limitation for their clinical application. Fortunately, low dose of Decitabine 
has been demonstrated to be particularly effective in high-risk of MDS 
without overt cytotoxicity (Wijermans, Lubbert et al. 2000; Fenaux, Mufti et 
al. 2010). This schedule of lower dose and longer exposure was then usually 
used in the “unfit” AML patients who couldn’t tolerate intensive 
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chemotherapy. Further optimization of the doses and schedules of these two 
agents in AML are still under investigation. 
 
   In order to improve the therapeutic efficacies, combination of DNMT 
inhibitor with conventional chemotherapy may be promising. It has been 
reported that pretreatment of Decitabine one to two weeks before conventional 
therapy resulted in much better outcome in a human tumor xenograft model 
(Plumb, Strathdee et al. 2000). This could be explained by the finding that 
DAC could reactivate some tumor suppressor genes that may sensitize the 
traditional cytotoxic agents (Marks and Jiang 2005). 
 
1.1.2 Histone acetylation 
 
  The repeated ‘beads-on-a-string’ structural unit of chromatin is nucleosome 
comprising of 147 bp of DNA wrapped around an octamer of two units of 
each core histone proteins (H2A, H2B, H3 and H4). Histones are subjected to 
multiple post-translational modifications, which mainly occur along the 
protruding N-terminal histone tails. Histone post-translational modifications 
mainly include acetylation, methylation, phosphorylation and ubiquitination of 
histones through various enzymes that add or remove such modifications. 
Together, these modifications are thought to constitute the so-called ‘histone 
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code’ to result in a more ‘open’ or ‘closed’ state of chromatin structure, 
leading to gene activation or repression (Li, Carey et al. 2007).  
 
  Histone acetylases (HAT) use acetyl-CoA as a cofactor and acetylate lysine 
residues in histone tails. This neutralizes the positive charge on lysine, thus 
reducing the affinity of the histone tail to negatively charged DNA. As a 
result, chromatin adopts a more open and more transcriptionally active 
chromatin. On the other hand, histone deacetylases (HDAC) remove the acetyl 
groups from the lysine residues and restore their positive charge, leading to a 
compact and transcriptionally repressive chromatin. Hence, HDAC inhibitors 
block this action, leading to histone hyperacetylation and gene expression 
(Thiagalingam, Cheng et al. 2003; Dokmanovic, Clarke et al. 2007).  
 
  There are four phylogenetic classes (I-IV) for HDAC: HDAC1, 2, 3 and 8 are 
class I; HDAC 4, 5, 7 and 9 are class IIa; HDAC 6 and 10 are class IIb; 
SIRT1-7 are class III; HDAC 11 is class IV. Class I, II and IV HDAC are 
catalytically dependent on a divalent metal ion whereas class III HDAC 
(sirtuins) are structurally and biochemically distinct from other classes 
because sirtuins are NAD+-dependent and mediate both deacetylation and 




  The classical HDAC inhibitors can be divided into four chemically distinct 
groups: hydroxamic acids (e.g., trichostatin A and suberoylanilidehydroxamic 
acid (SAHA)), cyclic tetrapeptides (e.g., depsipeptide (romidepsin)), 
benzamide derivatives (MGCD-0103), and the short-chain fatty acids (e.g., 
valproic acid). All the HDAC inhibitors are characterized by their binding to 
substrate-Zinc catalytic domain of the HDACs (Keppler and Archer 2008). A 
number of structurally diverse HDAC inhibitors have shown potent anti-tumor 
efficacy by inducing cell cycle arrest, differentiation and/or apoptosis in 
various pre-clinical studies (Joseph, Mudduluru et al. 2004; Nebbioso, Clarke 
et al. 2005). However, only two HDAC inhibitors, vorinostat (SAHA) and 
romidepsin (FK228) have been approved by FDA for cutaneous T cell 
lymphoma (CTCL) (Byrd, Marcucci et al. 2005; Piekarz, Frye et al. 2009). 
Like other HDAC inhibitors, vorinostat and romidepsin yield global changes 
in histone acetylation and exhibit little specificity between different HDACs. 
 
  Overall, monotherapy of HDAC inhibitors has yielded disappointing results 
with low response rates in clinical trials, although some selected patients 
appear to obtain significant benefit from these compounds. It has been found 
that increase in histone acetylation in most cases has no correlation with 
clinical responses. Given the complex interplay of different epigenetic 
mechanisms in cancer, it appears that combination of HDAC inhibitors with 
hypomethylating drugs may synergistically enhance the anti-cancer effects. 
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Numerous trials combining DNMT inhibitors and HDAC inhibitors have 
already taken place (Ma, Ezzeldin et al. 2009; Yang, Lay et al. 2010). 
Moreover, HDAC inhibitors may synergize with chemotherapy agents, as they 
may offer improved access to chromatin. A phase II clinical trial utilizing 
valproic acid (a HDAC inhibitor), hydralazine (a demethylating agent), and 
different chemotherapies for various solid malignancies refractory to 
chemotherapy showed some promising results (Candelaria, Gallardo-Rincon et 
al. 2007). 
 
  Though HDAC inhibitors hold great potential as targeted therapy, two major 
issues have to be addressed to improve clinical application of HDAC 
inhibitors. First, the mechanisms of action of HDAC inhibitors have to be fully 
characterized. Second, reliable biomarkers have to be identified to predict 
response to HDAC inhibitors. Combination treatment using HDAC inhibitors 
with other epigenetic drugs might synergistically target multiple aberrant 
epigenetic pathways. This provides optimisms for the development of novel 
targeted therapy.  
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1.1.3 Histone methylation 
1.1.3.1 Overview of histone methylation 
  Histone methyltransferases (HMTs) are histone modifying enzymes that 
catalyze the transfer of one to three methyl groups from the co-factor S-
adenosyl methionine (SAM) to specific lysine residues predominantly on 
histones H3 and H4. Conversely, histone demethylases (HDMs) remove the 
methyl group(s). Unlike histone acetylation which usually leads to active 
transcription, histone methylation is more complex in terms of gene regulation. 
Histone lysine methylation can be associated with either transcriptional 
activation or repression. For example, histone lysine methylations such as 
methylation of histone 3 (H3) at lysine (K) 9 or 27 are usually associated with 
transcriptional repression, whereas methylation of other lysine residues such 
as H3K4, K36 or K79 lead to transcriptional activation (Barski, Cuddapah et 
al. 2007; Li, Carey et al. 2007; Rosenfeld, Wang et al. 2009).  
 
  After decades of research, numerous structurally distinct histone lysine 
methyltransferases (HMTs) have been identified. The most well characterized 
H3K27me3 specific histone methyltransferase EZH2 (KMT6) has been 
demonstrated to play an important role in cancer development, which will be 
reviewed in the following sections in more detail. Apart from EZH2, other 
HMTs are also aberrantly regulated, making these HMTs attractive therapeutic 
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targets. For instance, one of the most widely studied HMTs is Mixed-Lineage 
Leukemia (MLL) that catalyses H3K4 methylation. Partial tandem duplication 
(MLL-PTD) and at least 50 gene fusions of MLL are detected in four-fifths of 
infant leukemias, and one-tenth of adult AML and lymphocyte leukemias 
(Krivtsov and Armstrong 2007). Moreover, MLL fusions can recruit DOTL, a 
HMT without SET domain that catalyses H3K79 methylation, resulting in the 
activation of leukemia-promoting genes (Bernt, Zhu et al. 2011). Another 
HMT that catalyses H3K4 methylation, SMYD3 promotes cell proliferation 
and transformation and it is overexpressed in colorectal and hepatocellular 
carcinomal cell lines (Hamamoto, Furukawa et al. 2004). There is also a 
negative correlation between the expression level of G9a, a HMT that 
catalyses H3K9 methylation, and the prognosis of patients with lung and 
hepatocellular cancers patients (Kondo, Shen et al. 2008; Chen, Hua et al. 
2010).  
 
  Several inhibitors targeting aberrant HMT in cancer are available. For 
example, EPZ004777, a potent and selective DOT1L inhibitor that blocks 
H3K79 methylation, can be used to treat MLL-translocated leukaemias 
(Daigle et al., 2011). The compound selectively targets MLL-rearranged cells 
and improves survival of a mouse xerograft model of MLL. In addition, a 
selective G9a inhibitor (BIX-01294) that increases demethylation of 
H3K9me2 in mouse embryonic stem cells, has also been developed (Kubicek, 
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O'Sullivan et al. 2007). There has been intensive research focussing on the 
development of small molecule inhibitors of HMTs, especially on 
characterising their mechanisms of action. In the near future, their safety and 
efficacy will be validated in clinical trials. 
   
1.1.3.2 H3K27 specific HMT EZH2 
 
  Enhancer of Zeste homolog 2 (EZH2) is a HMT that catalyzes methylation of 
H3K27. Along with cofactors SUZ12, EED, and RbAp46/48, EZH2 forms the 
Polycomb Repressive Complex 2 (PRC2). EZH2 has multiple domains, 
comprising an N-terminal domain which interacts with EED and SUZ12, a 
central nuclear localization signal (NLS) and a C-terminal SU(VAR)3–9, 
Enhancer of zeste, Trithorax (SET) domain that is responsible for its 
methyltransferase activity. Following the recruitment of PRC2 complex to 
chromatin, EZH2 catalyzes H3K27 trimethylation, which subsequently serves 
as the binding site for PRC1 complex comprising five core subunits including 
PCGF, CBX, PHC, SCML, and RING1. Binding of PRC1 monoubiquitylates 
H2AK119ub1, which was proposed to prevent recruitment of transcriptional 
activation factors and facilitate transcriptional repression (Zhou, Zhu et al. 
2008). Thus, PRC1 and 2 cooperate to repress gene transcription mainly 
through histone modification and chromatin compaction. 
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1.1.3.2.1 Biological roles of EZH2 in cancers 
 
 Initially, EZH2 and PRC2 were found to be critical for the control of gene 
expression in embryonic stem cells, maintaining self-renewal while inhibiting 
differentiation (A2-16). Recently, it was discovered that EZH2 is 
overexpressed in a broad range of human cancers including prostate cancer 
(Yu, Cao et al. 2007), breast cancer (Collett, Eide et al. 2006), lymphoma 
(Dukers, van Galen et al. 2004), colon (Fluge, Gravdal et al. 2009), bladder 
(Weikert, Christoph et al. 2005), lung (Breuer, Snijders et al. 2004) and liver 
(Sudo, Utsunomiya et al. 2005). Furthermore, higher EZH2 level is often 
associated with poor prognosis in advanced-stage and high-grade prostate (Yu, 
Cao et al. 2007) and metastasis breast cancers (Bachmann, Halvorsen et al. 
2006). 
 
In addition, ectopic overexpression of EZH2 promotes anchorage-
independent growth of immortalized epithelial cells, suggesting its role in 
neoplastic transformation (Kleer, Cao et al. 2003; Karanikolas, Figueiredo et 
al. 2009). Furthermore, ectopic overexpression of EZH2 can enhance the 
metastatic potential of cancer cells, which is consistent with the strong 
correlation between EZH2 expression and cancer metastasis (Bryant, Cross et 




Moreover, overexpression of EZH2 has also been linked to cancer initiation 
and progression through a cancer stem cell model. A genome-wide study 
showed that a number of EZH2 target genes in prostate cancer are also the 
targets of PRC2 in ES cells and their repression is correlated with poor 
outcomes (Yu, Cao et al. 2007). EZH2 is a common transcriptional regulator 
for stem cells and poorly differentiated human cancer cells because there are 
shared gene signatures between these cell types (Piunti and Pasini 2011). A 
recent study demonstrates the involvement of high level of EZH2 in cancer 
stem cell formation and expansion in aggressive breast cancer (Chang, Yang et 
al. 2011). 
 
Transcriptional repression of tumor suppressor genes by PRC2 mediated 
H3K27 trimethylation is the most well-established mechanism of oncogenic 
roles of EZH2. Accumulating evidences indicate that EZH2 plays important 
functions by regulating a myriad of target genes involved in various aspects of 
cancer development, such as cell-cycle checkpoints, DNA damage repair, 
epithelial-mesenchymal transition (EMT) regulation, metastasis, cell 
differentiation, senescence, and apoptosis. These target genes include cell 
cycle suppressor INK-ARF that drives cell cycle progression and prevents cell 
senescence (Bracken, Pasini et al. 2003); BIM (Wu, Zheng et al. 2010), 
FBXO32 (Wu, Lee et al. 2011) and DACT3 (Jiang, Tan et al. 2008) that 
promote apoptosis of cancer cells; CDH1 that regulates EMT (Cao, Yu et al. 
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2008); ADRB2 that inhibits cancer metastasis in prostate (Yu, Cao et al. 
2007); RAD51 that regulates DNA damage repair (Chang, Yang et al. 2011) 
and BMPR1B that represses differentiation in glioma (Lee, Son et al. 2008). 
 
Besides transcriptional repression, EZH2 could switch to act as a 
transcriptional activator that promotes tumorigenesis with histone methylation 
independent functions. In estrogen receptor (ER) positive luminal-like breast 
cancer cells, EZH2 was demonstrated to interact directly with ER and β-
catenin thus connecting the ER and Wnt signaling pathways, leading to the 
gene transactivation of c-Myc and cyclin D1 and the promotion of cell cycle 
progression (Shi, Liang et al. 2007). Interestingly, in ER-negative 
mesenchymal-like breast cancer cells, EZH2 interacts with RelA and RelB to 
form a ternary complex to promote the expression of NF-κB targets (Lee, Li et 
al. 2011). Recently, it was reported that EZH2 acts as a co-activator with 
androgen receptor (AR) to promote cancer progression in castration-resistant 
prostate cancer (Xu, Wu et al. 2012). 
 
Together, EZH2 functions as essential and multi-faceted molecule in 





1.1.3.2.2 Pharmacological inhibition of EZH2  
 
  S-adenosylhomocysteine (SAH) hydrolase inhibitor 3-Deazaneplanocin A 
(DZNeP) was the first reported EZH2 inhibitor, resulting in EZH2 depletion 
and decreased H3K27me3 (Tan, Yang et al. 2007). Increasing number of 
studies demonstrated that DZNep exhibited potent anti-cancer effects in 
various cancer types, such as breast (Tan, Yang et al. 2007), colon (Jiang, Tan 
et al. 2008), lung (Crea, Hurt et al. 2011), leukemia (Zhou, Bi et al. 2011) etc. 
I will outline briefly the anti-cancer effects of DZNep in the section 1.4 to 
underscore the need and promise for further characterize the anti-cancer 
mechanism of DZNep and its analog. 
 
  Recently, emerging evidence demonstrates that hot-spot mutations of Y641 
and A677 residues within SET domain of EZH2 occur in approximately 30% 
of diffuse large B-cell lymphoma (DLBCL) and 10% of follicular lymphoma 
(Morin, Johnson et al. 2010). EZH2 mutations have always been found to be 
heterozygous in DLBCL patients and the mutant cells contain much higher 
levels of H3K27me3 than wild-type cells (Morin, Mendez-Lago et al. 2011; 
Pasqualucci, Trifonov et al. 2011; McCabe, Graves et al. 2012). Wild-type 
EZH2 has weak activity for H3K27me2 and H3K27me3, whereas it has much 
higher catalytic efficiency for unmethylated H3K27 and H3K27me1. 
However, EZH2-Y641 mutants are inactive as a monomethyltransferase but 
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are effective in converting H3K27me2 to H3K27me3 (Sneeringer, Scott et al. 
2010; Yap, Chu et al. 2011). Therefore, wild-type and mutant EZH2 may 
cooperate in cells to maintain a high level of H3K27me3. Importantly, it was 
found that DLBCL tumor growth is dependent on the enzymatic activity of 
EZH2. Recently, there have been increased efforts to identify specific inhibitor 
targeting EZH2 enzymatic activity. In 2012, three independent groups 
published the development of  three different small-molecule inhibitors of 
EZH2, EPZ005687 (Knutson, Wigle et al. 2012), GSK126 (McCabe, Ott et al. 
2012) and EI 1 (Qi, Chan et al. 2012) (Figure 1.1). All these three inhibitors 
specifically inhibit H3K27 methylation while sparing other histone methyl 
marks through direct binding to EZH2 SET domain. Interestingly, all these 
three inhibitors exhibit equal activity against wild-type and Y641 mutant 
EZH2 although the cells harboring mutant EZH2 but not wide-type cells are 
specifically inhibited by these inhibitors. These findings suggest that EZH2 
mutation in DLBCL may be an oncogenic driver. Selective EZH2 inhibitor 
provides a useful tool to test the dependency of cancer cells on EZH2 













Figure 1.1 Chemical structure of three EZH2 inhibitors, EPZ005687 
(Knutson, Wigle et al. 2012), GSK126 (McCabe, Ott et al. 2012) and EI 1 






















1.2 Acute Myeloid Leukemia (AML) 
 
1.2.1 Overview of Acute Myeloid Leukemia (AML) 
 
  Acute myeloid leukemia (AML) is characterized by the proliferation of 
immature malignant myeloid hematopoietic cells that may involve blood, bone 
marrow and in some cases other organs, such as spleen and liver. The growing 
leukemic blasts suppress the normal haemotopoietic elements and result in 
symptoms of anemia, neutropenia and thrombocytooenia. AML is a highly 
heterogeneous disease with variable long-term survival ranging from 20%-
90%, depending on the subtypes of leukemia and the underlying genetic 
defects (Tallman, Gilliland et al. 2005). The treatment of leukemia has 
undergone little changes in over several decades with the chemotherapy as the 
main treatment option for AML patients (Stone 2007). However, the outcomes 
for AML patients are unsatisfactory because half of the patients died of the 
disease. Novel therapeutic strategies are clearly needed to maximize the rate of 
complete remission (CR) and minimize the rate of recurrence. 
 
  AML can be classified in different ways. The most traditionally used criteria 
is FAB classification proposed by French-American-British (FAB) group 
(Bennett, Catovsky et al. 1976). This system provides clear guidelines to 
distinguish different AML subtypes by morphologic characteristics and 
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cytochemical features (Bennett, Catovsky et al. 1991). Basically, the 
subcategories of AML by FAB classification depend on the type of cells from 
which the leukemia develops and how mature the cells are. FAB classification 
divides AML into 8 subtypes, M0 to M7. Subtypes M0 to M5 are derived 
from white blood cell precursors. M6 AML is originated from precursors of 
red blood cells, while M7 AML arises from early forms of cells that make 





Figure 1.2 French-American-British (FAB) Classification of AML 
(Bennett, Catovsky et al. 1991) 
 




  As mentioned earlier, AML is a heterogeneous disease with variable survival 
ranging from months to years. Among the 8 subtypes, M3 Acute 
promyelocytic leukemia (APL) has the best clinical outcomes. APLs result 
from an abnormal fusion protein termed PML/RAR through chromosome 
translocation. Studies have shown that differentiation therapy with all-trans 
retinoic acid (ATRA) or arsenic trioxide, used alone or combined with 
chemotherapy achieved complete remission (CR) rate of over 90% and cure 
rate of roughly 80% (Petrie, Zelent et al. 2009; Sanz and Lo-Coco 2011). 
However, the cure rate of other subtypes remained elusive in general. 
 
1.2.2 Treatment of AML 
 
1.2.2.1 Conventional chemotherapy 
 
  The first-line treatment of AML is primarily chemotherapy, which can be 
divided into two phases, namely induction and consolidation. The aim of 
induction is to attain complete remission (CR) and the goal of consolidation is 
to eliminate any residual undetectable blasts and achieve a cure. The regimen 
‘7+3’, cytarabine continuously given for 7 days combined with an 
anthracycline given for 3 consecutive days, remains largely unchanged since 
its first introduction four decades ago (Yates, Wallace et al. 1973). About 50 
to 70% of newly diagnosed patients treated with ‘7+3’ can achieve CR. 
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However, almost all the patients who achieved CR will eventually relapse 
without consolidation treatment. High dose or intermediate dose of cytarabine 
is usually used in this phase.  
 
  There are ongoing efforts to improve the chemotherapy regimens in both 
induction and consolidation phases. The optimizations mainly include the 
modification in the doses of both chemotherapy agents (Bishop, Matthews et 
al. 1996) and in the type of antracycline (Berman, Heller et al. 1991; Wiernik, 
Banks et al. 1992). In addition, researcher also put efforts on the optimization 
of the delivery and tolerability of these two cytotoxic agents. Elacytarabine 
(CP-4055) is a conjugated form of cytarabine to the lipid moiety elaidic acid. 
This product, which bypasses of the nucleoside transporter protein showed 
statistically significant superior efficacy in a phase II trial in patients with late-
stage acute myeloid leukemia (AML) in 2009 sponsored by Clavis Pharma 
ASA (OSE: CLAVIS). Similarly, CPX-351 is a liposomal formulation that 
combines cytarabine and daunorubicin in a 5:1 molar ratio. Clinical data has 
shown that this formulation accumulates in the bone marrow of relapse AML 
patients with greater efficacy compared with the traditional combination of the 
two drugs (Feldman, Lancet et al. 2011). Moreover, other chemotherapy has 
also been combined with the conventional ‘7+3’regimen. For instance, the two 
purine analogs, both Clofarabine (Kantarjian, Erba et al. 2010) and Cladribine 
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(Holowiecki, Grosicki et al. 2012) have resulted in higher rate of CR and 
overall survival when combined with low dose of cytarabine. 
 
  In summary, current chemotherapy for AML is yielding disappointing 
outcomes to date, but recent advances in molecular genomics and ‘epigenetic 
priming’ hold significant promise in the development of more effective 
therapeutic strategies in the future. 
 
1.2.2.2 Molecular targeted therapy 
 
  A variety of signaling molecules and pathways are deregulated and may 
serve as potential therapeutic targets in AML. The best studied upstream 
signaling molecules such as FMS like tyrosine kinase 3 (FLT3), KIT and RAS 
family members are commonly activated through gain-of-function mutation, 
impaired negative regulation, overexpression, or auto-paracrine stimulation. 
Aberrant activation of upstream signaling molecules has been demonstrated to 
reflect activation of a more limited number of canonical downstream effector 
pathways, such as the RAF/MEK/ERK and PI3K/AKT cascades, resulting in 
enhanced proliferation and survival of hematopoietic progenitor cells as 
indicated in Figure 1.3. Targeting these unifying pathways may represent a 
more broadly applicable therapeutic strategy. In this study, I will outline 
 briefly the molecular biology of AML and the






Figure 1.3 Deregulated signal transduction in AML 
al. 2008). Aberrant activation of upstream signaling molecules
KIT, and RAS family members) leads to constitutive signaling through a 
limited number of downstream effector pathways (eg, the RAF/MEK/ERK 
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  The FLT3 RTK and its ligand are important in normal hematopoiesis. The 
binding of its ligand to extracellular domain of FLT3 induces receptor 
dimerization, leading to activation of the receptor through phosphorylation of 
the FLT3 kinase domain (KD) and several downstream signaling pathways, 
primarily PI3K/AKT and RAS/RAF/MEK/ERK pathways. FLT3 is expressed 
on the leukemic cells of 70–100% of AML patients. It functions as an 
oncogene to maintain the survival and stimulate the proliferation of these 
leukemic blasts (Parcells, Ikeda et al. 2006). The two leading types of 
activating mutations have been found in AML include internal tandem 
duplications (ITDs) in the jutamembrane (JM) domain and mutations in the 
activation loop in the carboxy-terminal lobe of the kinase domain (KD). The 
former has been identified in 25-30% of adult AML cases (Stirewalt and 
Radich 2003) and the latter has been observed in approximately 7% of AML 
patients. Both types of mutations result in ligand-independent receptor 
dimerization and autophosphorylation, subsequently leading to the activation 
of downstream signaling pathways (Parcells, Ikeda et al. 2006). Compared to 
FLT3 wild type, mutations in FLT3 confers a worse prognosis when treated 




  To date, there are several FLT3 inhibitors undergoing various stages of 
clinical trials, including Midostaurin (PKC412), Sorafenib (BAY 43-9006), 
Lestaurtinib (CEP701), Sunitinib (SU11248), Tandutinib (MLN518), KW-
2449 and second-generation FLT3-TKI Quizartinib (AC220). In general, all 
these compounds are well tolerated at doses that inhibit FLT3. However, the 
clinical responses of these FLT3 inhibitors as monotherapy have been shown 
to be transient and variable in AML patients, with the exception of Quizartinib 
(AC220). In a phase I study, Quizartinib induced complete or partial remission 
in 10 of 18 (56%) relapsed or refractory FLT3-ITD AML cases (Cortes et al., 
2009). The following phase II study conducted in FLT3-ITD AML patients 
has shown a CR rate of 45% and median overall survival of 24.7 weeks 
(Cortes et al., 2011). Due to the limited single agent activity of FLT3 
inhibitors, several clinical trials examined the efficacy of FLT3 inhibitors in 
combination with chemotherapy in AML patients. For instance, midodtaurinin 
combined with chemotherapy resulted in high CR rate (92%) in newly 
diagnosed FLT3 mutated patients and achieved similar overall survival (OS) 
rates to those FLT3 wild type patients (Stone, Fischer et al. 2012). Sorafenib 
has been safely combined with induction chemotherapy and produced a higher 
CR rate (93%) in FLT3-ITD AML compared with the CR rate (66%) in FLT3 
WT in a phase I/II study. However, the responses were not durable in the 




  Taken together, studies of FLT3 inhibitors alone or combined with 
chemotherapy have yet produced measurable and sustained therapeutic 
improvements in AML. Further studies with novel and more potent inhibitors 
hold significant promise in the future. 
 
1.2.2.2.2 PI3K/AKT/mTOR cascades 
 
  The PI3K/Akt/mammalian target of rapamycin (mTOR) signaling pathway is 
crucial in regulating cell growth, proliferation and survival not only in normal 
cells but also in a variety of tumor cells. It has been demonstrated to be one of 
the most frequently influenced pathways in human cancer (Yuan and Cantley 
2008). The aberrant activation of PI3K/Akt/mTOR signaling is detectable in at 
least half of acute myeloid leukemia samples, displaying phosphorylation of 
Akt on either Thr 308 or Ser 473 (or both) (Martelli, Tazzari et al. 2007; 
Muranyi, Dedhar et al. 2009). Numerous studies have demonstrated that high 
level of p-Akt correlates with poor prognosis (Gallay, Dos Santos et al. 2009; 
Kornblau, Tibes et al. 2009).  
 
  Multiple factors result in the upregulation of PI3K/Akt/mTOR signaling, 
such as gain-of-function mutation of FLT3 or K or N Ras, overexpression of 
phosphoinositide-dependent kinase 1 (PDK1) or PI3K p110 β or δ and several 
others. Using cell lines or mouse models, PI3K/Akt/mTOR inhibitors have 
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shown to be efficacious in inhibiting proliferation of cancer cells. PI3K 
inhibitors such as Wortmannin and LY294002 have been widely used in 
preclinical studies of AML and demonstrated to be effective in vitro (Xu, 
Simpson et al. 2003; Birkenkamp, Geugien et al. 2004). However, none of 
these inhibitors have entered clinical trials probably due to the high toxicity 
and the insolubility. Since PDK1 phosphorylates Akt at Thr 308, PDK1 may 
be a potential target to inhibit PI3K/Akt/mTOR signaling. However, there are 
few PDK1 inhibitors used in clinical trial thus far due to the off-target effects 
(Peifer and Alessi 2008). To date, two Akt inhibitors have been tested in 
clinical trials. Perifosine is a synthetic alkylphospholipid inhibitor targeting 
Akt PH domain. A phase II clinical trial of Perifosine as a single agent 
(NCT00391560) and a phase I trial of the combination of Perifosine with 
PDK1 inhibitor UCN01 (NCT00301938) have been conducted in 
relapsed/refractory AML patients, but the results have not yet disclosed. 
Triciribine (API 2) is another selective Akt inhibitor that inhibits all three Akt 
isoforms in vitro (Yang, Dan et al. 2004). A phase I clinical trial of Triciribine 
performed in relapsed/refractory AML patients has demonstrated encouraging 
results (Ravandi et al. 2008). mTOR inhibitors are the most developed class of 
compounds targeting PI3K/Akt/mTOR pathway. They include rapamycin 
(sirolimus), everolimu (RAD001), temsirolimus (CCI-779) and deforolimus 
(AP23573) (Fasolo and Sessa 2008). Several phase I/II clinical trials with 
rapamycin (Recher, Beyne-Rauzy et al. 2005), everolimu (Yee, Zeng et al. 
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2006) or deforolimus (Rizzieri, Feldman et al. 2008) have been conducted in 
relapsed/refractory AML patients. However, the effects of all these tested 
compounds as monotherapy were mild and transient. A number of clinical 
trials combining mTOR inhibitor with chemotherapy are underway.   
 
1.2.2.2.3 RAS/RAF/MEK/ERK cascades 
 
  RAS family members play important roles in the proliferation and survival of 
many cancer cells by acting as signaling intermediates that relay stimuli from 
cell membrane receptors activated by extracellular growth factors to 
downstream pathways, such as RAF/MEK/ERK cascades (Milella, Precupanu 
et al. 2005). Aberrant activation of RAS proteins in AML could be due to 
either elevated upstream signaling molecules such as FLT3-ITD or somatic 
mutation of RAS. Activating K-RAS or N-RAS are observed in approximately 
10 to 20 % of AML, whereas H-RAS mutations are rare (Bowen, Frew et al. 
2005). Despite the critical role RAS plays in the regulating cancer cell 
survival, RAS has not been proven to be a therapeutic target. Instead, the 
downstream molecule, MEK is considered as a potentially druggable target in 
AML. Clinical studies for two MEK inhibitors, GSK1120212 and 




  In summary, researchers have put tremendous efforts into the development of 
inhibitors targeting the aberrant signaling molecules in recent years. However, 
the results of clinical trials in most cases are not satisfactory. There is an 
urgent need to develop better treatments for AML patients. 
 
1.2.2.3 Epigenetic therapy 
 
1.2.2.3.1 Targeting DNA methylation 
 
  As mentioned before, two DNA methylation inhibitors, azacitidine (5-Aza-
CR) and a deoxy-analog of azacitine, decitabine (5-Aza-CdR) have been 
approved by FDA to treat patients with high-risk myelodysplastic syndromes 
(MDS) and they have also been proven useful in clinical trials of acute 
myeloid leukemia (AML).  
 
  Three phase II/III clinical trials recruiting 309 patients who suffered from 
MDS and AML showed 10-17% complete remission (CR) rate after treatment 
with azacitidine (Silverman, McKenzie et al. 2006). In addition, when 
compared with conventional therapy, azacitidine has been demonstrated in 
another phase III trial to improve the overall survival of 358 MDS patients 
(24.5 vs 15 months) (NCT00071799). Moreover, azacitidine could 
significantly improve the overall survival (OS) of elderly AML patients 
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(n=55) versus those treated with conventional care regimens (CCRs) (n=58). 
The median OS for patients receiving azacitidine was 24.5 months versus 16 
months for those receiving CCR. The 2-year OS rates were also higher for 
azacitidine-treated patients compared with CCR-treated patients (50% vs. 
16%) (Fenaux, Mufti et al. 2010).        
   
  Decitabine (a deoxy-analog of azacitine) has also been demonstrated with 
positive outcomes for MDS and AML patients. After reaching disease 
remission within one year, AML patients treated with decitabine showed 
increased Relapse-Free Response rate. Of note, the Relapse-Free Response 
rate for patients receiving decitabine and “No Study Drug” is 50% and 40% 
respectively. In a phase II trial (NCT00882102, n=40), decitabine given with 
Gemtuzimab Ozogamicin resulted in 25% CR rate in AML and high-risk 
MDS patients.  
 
  Although the abovementioned DNA methylation inhibitors achieve positive 
clinical outcomes, further development to improve their specificity is 
necessary. Current DNA methylation inhibitors remove DNA methylation 
globally by blocking the access of DNMT to DNA. Novel inhibitors that act 
on specific genomic loci could reduce toxicity and non-specific targeting 
which may be the limitations of current DNA methylation inhibitors. In 
addition, azacitidine or decitabine induced DNA demethylation is reversible 
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(Egger, Liang et al. 2004), suggesting the need to develop long-
acting/irreversible DNA methylation inhibitors. Therefore, more potent and 
specific DNA methylation inhibitors are needed to improve clinical efficacy 
and reduce toxicity.     
 
1.2.2.3.2 Targeting histone modification 
 
  Aberrant epigenetic regulation of cancers include misregulated histone 
methyltransferases and histone demethylases, overexpressed histone 
deacetylases (HDACs) and reduced global levels of histone acetylation (Jones 
and Baylin 2007; Sharma, Kelly et al. 2010).  Two HDAC inhibitors, 
vorinostat (SAHA) and romidepsin (FK228) have already been approved by 
FDA for the treatment of cutaneous T cell lymphoma (CTCL) (Byrd, 
Marcucci et al. 2005; Piekarz, Frye et al. 2009). More HDAC inhibitors are 
being developed and evaluated at various stages to assess their clinical 
applications.  
 
  In general, single treatment with HDAC inhibitor has resulted in inferior 
response rates in clinical trials. Since multiple epigenetic mechanisms are 
responsible for cancer progression, targeting several pathways together might 
improve clinical efficacy. For example, combining HDAC inhibitors with 
DNA methylation inhibitors could achieve synergistic effects in cancer 
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therapy. Combination treatment with DNMT and HDAC inhibitors has been 
employed in various clinical setting. Gore et al reported a study of a DNA 
methylation inhibitor azacitidine combined with a HDAC inhibitor sodium 
phenylbutyrate (PB) in AML/MDS led to a 14% CR rate seen in 29 patients. 
Three of four responders showed increased P15 INK4B at transcriptional level 
and decreased promoter hypermethylation (Gore, Baylin et al. 2006). 
Subsequently, Garcia-Manero et al studied decitabine and valproic acid (VPA) 
in AML/MDS and observed 19% CR rate in a group of 54 patients (Garcia-
Manero, Kantarjian et al. 2006). Similar results were found in a combination 
study of azacitidine with VPA (Soriano, Yang et al. 2007). In a phase I study 
of patients with MDS and refractory AML, suberoylanilidehydroxamic acid 
(SAHA, Vorinostat) was combined with azacitidine and achieved CR rate of 
43% (Silverman LR et al. Blood 2008; 112, abstract 3656). HDAC inhibitor 
MGCD0103 was also combined with azacitidine in a phase I/II trial with 56 
AML/MDS patients. The clinical responses have been seen in 30% of patients 
(Garcia-Manero G, et al. 2007).   
 
  Similar to conventional DNA methylation inhibitors, HDAC inhibitors 
induce global changes in histone acetylation levels.  Despite high tolerability 
and minimal side effects of HDAC inhibitors, the development of more 
specific inhibitors is desired. In addition, the mechanisms of actions of HDAC 
inhibitors are not completely delineated as they appear to affect the regulation 
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of other classes of proteins. Therefore, compared with kinase inhibitors or 
monoclonal antibodies, HDAC inhibitors might not be regarded as targeted 
therapy. In near future, the development of more potent and specific HDAC 
inhibitors will improve the therapeutic efficacy of this type of epigenetic drugs 
in cancer.    
     
  As mentioned, DNA methylation inhibitors and HDAC inhibitors have been 
intensively studied and used in clinical setting as potential epigenetic therapy. 
However, targeting histone methylation is still in its infancy. To date, there are 
no such drugs approved by FDA or used in clinical trials in any cancer 
diseases. 
 
1.2.3 Drug resistance in AML 
 
  It is believed that cancer relapse is mainly caused by drug resistance. There 
are two types of drug resistance, de novo drug resistance and acquired drug 
resistance. The former happens at the early phase of drug treatment and allows 
the cancer cells to endure the stresses caused by chemotherapy. The latter 
occurs after long-term treatment of chemotherapy and is usually associated 
with genetic and epigenetic changes. De novo drug resistance is regarded to be 
an attractive target to prevent the acquired drug resistance since de novo 
resistance of cancer cells to genotoxic stress is the prerequisite for cancer cells 
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to survive and develop acquired drug resistance. De novo drug resistance can 
be categorized as two types, the intrinsic and extrinsic environment mediated 
drug resistance. Here, I will summarize the studies of intrinsic properties of 
Leukemia Stem Cell (LSC) that regulate drug resistance and 
microenvironment mediated drug resistance, especially cadherin-mediated 
drug resistance (CAM-DR) in leukemia. 
 
1.2.3.1 Intrinsic properties of LSC that regulate drug resistance 
 
  Although the treatment of AML has significantly improved over the past 30 
years, there is still considerable room for improvement. Most patients relapse 
and around 60% will eventually die even though current treatment regimes 
significantly decrease tumor burden (i.e. the total blast population) and 
achieve a complete remission in nearly 70% of patients (Roboz 2011). 
   
  Since the relapse rate is high in AML patients, there could be a rare subset of 
malignant cells that could not be effectively eliminated by conventional drugs. 
These atypical cells may have stem-cell like features and have been coined as 
the leukemia stem cells (LSCs). Many features of normal hematopoietic stem 
or progenitor cells (HSCs/HPCs) can also be observed in LSCs, making LSCs 
particularly hard to be eliminated by conventional chemotherapy. This is 
largely due to the quiescence of LSCs, which may allow them to evade the 
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cytotoxicity caused by chemotherapy. Self-renewal and diverse differentiation 
capabilities of LSCs are their fundamental properties. Increasing evidence has 
indicated that LSCs are invasive because LSCs can substitute for HSCs and 
utilize their resources for self-maintenance in bone marrow (Guan, Gerhard et 
al. 2003; Clarke, Dick et al. 2006).  
    
  Bonnet and Dick (1997) first isolated a subpopulation of cells from AML 
patients, characterized the cells based on their immunophenotypes, and 
generated AML xenografts in NOD/SCID mice. They observed that a 
subpopulation of CD34+CD38- cells could be serially transplanted into 
NOD/SCID mice, indicating that these cells might be leukemia initiating cell 
(LIC) (Lapidot, Sirard et al. 1994). Since this discovery, more evidence has 
surfaced to support the existence and importance of LSCs in leukaemogenesis. 
One study particularly demonstrates a correlation between LSCs level and 
survival: AML patients with > 3.5% of CD34+CD38- cells in their bone 
marrow had fewer months of median relapse free survival compared to 
patients who had lower level of the cells (5.6 and 16 months respectively) (van 
Rhenen, Feller et al. 2005). Using flow cytometry to determine aldehyde 
dehydrogenase (ALDH) activity, Gerber et al. (2012) isolated a subpopulation 
of ALDH+CD34+CD38- cells that could form AML in NSG mice after 




  Probably, the quiescence of LSCs is the most crucial characteristic that may 
affect drug resistance. It was reported that most of LSCs are maintained in a 
quiescent state and the quiescent cells isolated from human AML samples 
initiate the disease successfully in NOD/SCID mice (Guan, Gerhard et al. 
2003). Moreover, a mostly quiescent population of LSCs was also reported in 
chronic myeloid leukemia (CML) (Holyoake, Jiang et al. 2001; Holyoake, 
Jiang et al. 2002). Since most of the chemotherapeutic agents target only 
active cycling cells, the LSCs in quiescent state may not respond to the 
chemotherapy. Hence, agents that induced LSCs to enter into cell cycle before 
chemotherapy may be achievable for LSCs eradication (Saito, Uchida et al. 
2010).  
 
  Since LSCs are intrinsically resistant to traditional chemotherapeutics 
(Costello, Mallet et al. 2000; Ishikawa, Yoshida et al. 2007), novel approaches 
targeting LSCs are being pursued.  Due to the unique property of LSCs, a 
number of studies have been conducted, focusing on the specific pathways in 
LSCs that are absent in normal hematopoietic stem cells. For instance, NF-κB 
pathway was found to be highly activated in LSCs of human AML samples 
and this pathway was proven to play an important role in LSCs survival. 
Proteasome inhibitors, which inhibit IκB degradation, have been shown to 
inhibit NF-κB pathway and induce apoptosis in AML cells while sparing 
normal progenitors (Guzman, Neering et al. 2001). Combination of the 
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proteasome inhibitor MG-132 with the anthracycline idarubicin induced rapid 
and extensive apoptosis of LSCs, sparing normal HSCs, via inhibition of NF-
κB and activation of p53-regulated genes (Guzman, Swiderski et al. 2002). 
Clinical trials combining anthracyclines and proteasome inhibitors in AML 
patients have been ongoing. Moreover, aberrant activation of PI3K/AKT 
pathway has also been frequently observed in human AML specimens and the 
small molecules targeting PI3K have been found to be effective against LSCs 
(Xu, Simpson et al. 2003; Xu, Thompson et al. 2005). In addition, Wnt/β-
catenin pathway also regulates LSCs survival. Several recent studies suggested 
that Wnt/β-catenin signaling pathway played an essential role in mouse LSCs 
from MLL-AF9 AML leukemia (Wang, Krivtsov et al. 2010) as well as in 
LSCs from CML (Zhao, Blum et al. 2007). Moreover, small molecule-
mediated disruption of Wnt/β-catenin dependent signaling has been under 
intensive investigation (Chen, Dodge et al. 2009; MacDonald, Tamai et al. 
2009). 
 
  Taken together, the regimen targeting the intrinsic properties of LSCs holds 






1.2.3.2 Microenvironment mediated drug resistance  
 
  Besides the intrinsic properties of LSC that regulate drug resistance, 
emerging lines of evidence suggests that extrinsic factors mediated by 
microenvironment in bone marrow (BM) are also crucial for the survival of 
LSCs. 
   
  Bone marrow is a major hematopoietic and lymphoid organ within the 
central hollow of long and axial bones. The normal hematopoietic stem cells 
(HSCs) reside in two distinct niches of bone marrow, endosteal bone surface 
and vascular niches (Perry and Li 2007). The endosteal bone surface niche, 
which consists of abundant bone-forming osteoblasts, is considered to 
maintain the long-term quiescent HSCs (Calvi, Adams et al. 2003; Arai, Hirao 
et al. 2004). On the other hand, the vascular niche, localized at the single layer 
of endothelium of sinusoidal blood vessels, provides a microenvironment for 
the short-term, relatively more actively cycling short term HSCs (Kopp, 
Avecilla et al. 2005). The development of HSCs in these niches is tightly 
regulated through the production of cytokines and chemokines by a broad 
range of bone marrow cells including bone lining cells (e.g., osteoblasts), 
endothelial cells, mesenchymal stromal cells (MSCs), perivascular stromal 




  There is great similarity shared between HSCs and LSCs in the localization 
of BM niches. Both endosteal bone surface and vascular niches are also 
crucial for LSCs survival and maintenance (Calvi, Adams et al. 2003; Kiel, 
Yilmaz et al. 2005; Nilsson, Johnston et al. 2005) as illustrated in Figure 1.6. 
It has been proposed that in immunodeficient mice, transplanted CD34 (+) 
human leukemia cells initially localize on the endosteal bone surface niche in 
the epiphysial region and then spread out to the vascular endothelium niche 
within one month. The treatment with Ara-C reduced the tumor burden 
significantly but leaving certain residual leukemia cells to survive and reside 
in endothelium and endosteal niches (Ninomiya, Abe et al. 2007). Another 
study using human AML xenotransplantation NOD/SCID/IL2rg null mouse 
model also demonstrated that LSCs lodge in osteoblast-rich endosteal region, 
where the cells are protected from the toxicity induced by chemotherapy 
(Ishikawa, Yoshida et al. 2007). Thus, affecting homing and subsequent 
adhesion through interference with chemokines and adhesion molecules in the 
bone marrow microenvironment are very important for the survival of LSCs. 
Emerging lines of evidence suggests that the acquisition of drug resistance 
could also be mediated  through a process known as cell adhesion-mediated 
drug resistance (CAM-DR) (Li and Dalton 2006). There are a large number of 
cytokines, chemokines, adhesion molecules, ECM components and their 
related receptors which comprise a complex microenvironment to confer 
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protection to LSCs against chemotherapy. In this study, only a few key classes 
of adhesion molecules will be discussed due to the space limitation. 
 
1.2.3.2.1 CXCL12-CXCR4 signaling 
 
  The chemokine CXCL12, also known as stromal cell–derived factor-1 alpha 
(SDF-1α), and its receptor CXCR4 play important roles in LSCs homing to the 
BM microenvironment and subsequent adhesion of LSCs to the protective 
niches (Burger and Peled 2009). CXCL12 is secreted from the BM stromal 
cells and it is critical for the survival and retention of AML cells within the 
BM. It has been demonstrated that CXCL12 could stimulate the migration of 
the primary cells from AML patients. Moreover, the immature CD34+ cell are 
more responsive to CXCL12 stimulation compared with CD34- cells 
(Voermans, van Heese et al. 2002). It was reported that  CXCR4 was highly 
expressed in CD34+ subset and the expression level of CXCR4 was associated 
with the poor prognosis (Mohle, Schittenhelm et al. 2000); Rombouts et al., 
2004). Another study reported that CXCR4 was negatively correlated with 
overall survival (OS) by analyzing the “adhesive phenotype” of 36 AML 
patients (Tavernier-Tardy, Cornillon et al. 2009). The role of CXCR4 in 
leukemia progression is illustrated by a study which demonstrated that the 
human AML cells previously engrafted in NOD/SCID/B2m (null) mice could 
be dramatically reduced with neutralizing CXCR4 antibodies. Interestingly, 
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there was no significant decrease the level of normal human CD34+ cells 
under the same treatment (Tavor, Petit et al. 2004). Moreover, it has been 
shown that a CXCR4 inhibitor, AMD3465, interfered with chemotaxis 
induced by CXCL12, mobilized the human leukemia cells in immunodeficient 
mice, and enhanced the efficacy of kinase inhibitor sorafenib in AML (Zeng, 
Shi et al. 2009). Another CXCR4 inhibitor AMD3100 in combination with 
cytarabine has been demonstrated to mobilize human acute promyelocytic 
leukemia (APL) cells into the blood stream and dramatically reduce tumor 
burden and improve the animal overall survival (Nervi, Ramirez et al. 2009).  
  Taken together, these findings demonstrated the importance of interfering the 
CXCL12/CXCR4 axis in AML progression by either neutralizing antibody or 




  Integrins are the most well characterized adhesion molecules. Integrins are 
transmembrane proteins that mediate the attachment between cell-cell and 
cell-extracellular matrix (ECM). Integrins are heterodimeric cell surface 
receptors that consist of two distinct subunits, one α and one β chain. In 
mammals, at least 18 α and 8 β subunits forming 24 distinct integrin 
heterodimers have been characterized (Miranti and Brugge 2002). α4β1 
(VLA-4) and α5β1 (VLA-5) are the typical integrins expressed on 
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hematologic malignancy. The majority of the ligands of integrins are ECM 
protein, such as fibronectin, laminins, collagens etc. Among that, fibronectin is 
the most common ligand, which binds to at least 10 integrin heterodimers 
(Jensen et al., 1993). Integrins on the leukemia cells also interact with the 
other adhesion molecules such as VCAM and ICAM, which are expressed on 
the bone marrow stromal cells (Pulido, Elices et al. 1991). 
 
  Integrin signaling is a very complex network. Upon their engagement by the 
respective ligands, integrin clustering triggers autophosphorylation of focal 
adhesion kinase (FAK) at Y397 and subsequently the binding of Fyn and Src 
for further activation. Activated FAK interacts with other signaling proteins 
such as integrin-linked kinase (ILK), PI3K, Grb2, Graf which in turn elicit 
cascades of events to collectively transduce cellular responses; mediate cell 














Figure 1.4 Integrin signaling 
(http://www.unifr.ch/pathology/en/background/tumorangiogenesis) 
Integrins are transmembrane receptors that mediate the attachment between 
cell-cell and cell-ECM. Upon their engagement by their respective ligands (eg. 
fibronectin, collagen and laminin), integrins clustering triggers the assembly 
of numerous cytosolic kinases [focal adhesion kinase (FAK), Src and integrin-
linked kinase (ILK)] and activate RAS MEK ERK and PI3K/AKT that 
collectively transduce cellular responses, mediating cell shape, migration, cell 
cycle progression and survival. 
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  Bone-marrow minimal residual disease (MRD) causes relapse after 
chemotherapy in AML patients. It has been demonstrated that the interaction 
of α4β1 (VLA)-4 on leukemic cells with fibronectin on bone-marrow stromal 
cells played an important role in relapse from MRD in bone marrow after 
chemotherapy in AML patients. It has also been showed that such interaction 
triggered the activation of PI3K/AKT/Bcl-2 signaling pathway, resulting in 
VLA-4 mediated drug resistance. In addition, VLA-4 neutralizing antibody 
conjugated with cytosine arabinoside (Ara-C) dramatically improved the 
prognosis in a mouse model of MRD. Furthermore, it was found that the 5 
year survival for VLA-4 negative patients was much higher than VLA-4 
positive patients, suggesting that the importance of the VLA-4 in the 
persistence of MDR in AML (Matsunaga, Takemoto et al. 2003). Numerous 
studies indicated that agents that block the adhesion mediated through VLA-4, 
such as fibronectin peptide (Matsunaga et al., 2008), soluble VCAM-1(Becker 
et al., 2009), VLA-4 inhibitor (Nervi, Ramirez et al. 2009) all suppressed 
adhesion mediated drug resistance. In addition, multiple studies demonstrated 
that α5β1 (VLA-5) may also play important role in protection of AML cells 
from apoptosis induced chemotherapy (Matter and Ruoslahti, 2001; Zhang et 
al., 1995). 
 
  Of note, quite a number of recent studies indicated other types of integrin 
heterodimers are also crucial in cell adhesion-mediated drug resistance (CAM-
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DR). It has been reported that integrin β2 mediates spleen tyrosine kinase 
(Syk)/STAT signaling and promotes the survival and proliferation of AML 
blasts (Oellerich, Oellerich et al. 2013). Interestingly, Integrin β3 was found to 
be critical for murine MLL-AF9 acute myeloid leukemia (AML) in vivo 
through small hairpin RNA (shRNA) screening.  Integrin β3 via the 
intracellular kinase Syk regulated the homing of LSCs and repressed LSC 
differentiation (Miller, Al-Shahrour et al. 2013). Moreover, integrin β3 has 
been shown to activate both FAK/AKT and ERK pathways to promote drug 
resistance to a BCR-ABL inhibitor, imatinib, in a chronic myelogenous 
leukemia (CML) model (Puissant, Dufies et al. 2012). Taken together, the 
findings above established the importance of integrins mediated drug 




  CD44, another adhesion molecule, is a cell-surface glycoprotein involved in 
cell–cell interactions, cell adhesion and migration. Hyaluronan is the major 
ligand of CD44 and is highly expressed in the endosteal niche of bone 
marrow. Other ligands of CD44 include fibronectin, selectin, and osteopontin 
etc. (Avigdor, Goichberg et al. 2004). In human breast cancers, CD44+CD24- 
cells are able to sustain the tumorigeneicity and engraft the tumor when 
transplanted in immuno-deficient mice (Al-Hajj, Wicha et al. 2003). CD44 has 
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also been demonstrated to be involved in LSCs homing to niches of bone 
marrow and acting as a key regulator of LSCs. John Dick and the team 
reported that in vivo administration of an activating antibody of CD44, H90, to 
NOD/SCID mice engrafted with human AML cells could reduce the leukemic 
burden in a dose-dependent manner. The failure of serial transplantation in 
mice treated by H90 demonstrated LSCs were significantly diminished. On the 
other hand, H90 had no appreciable effect on normal human CD34+ cells 
transplanted into the mice (Jin, Hope et al. 2006). Moreover, high level of 
CD44 expression was sufficient to result in leukemia relapse even after 
withdrawal the initial oncogene HoxA10 overexpression (Quere, Andradottir 
et al. 2011). Recently, Sansonetti et al. showed that CD44 activation promoted 
the survival of primary AML5 blasts through the up-regulation of Mcl-1 
(Sansonetti, Bourcier et al. 2012). Rick Van Etten and colleagues 
demonstrated the importance of CD44 in LSCs homing and survival in CML. 
It was found that BCR-ABL1 transduced progenitor cells from CD44- mutant 
donors were defective for homing to recipient bone marrow and initiating the 
disease. In addition, antibody against CD44 also abrogated the induction of 
CML-like leukemia in mice (Krause, Lazarides et al. 2006). The above 
findings indicated that LSCs depend to a great extent on CD44 for the homing 
and engraftment but not normal HSCs, raising the therapeutic potential of 




1.3 Aggressive breast cancer 
 
1.3.1 Epidemiology of TNBC 
 
  At present, breast cancer has the highest incidence among all cancers in 
women and is the second leading cause of cancer death after lung cancer. In 
medical terms, the breast refers to the front of the chest which comprises the 
mammary glands. A mammary gland consists of a complex network of 
branching ducts or channels which have tube-like structures. These ducts 
branch out from sac-like structures known as lobules. The lobules generate 
milk when they receive appropriate hormonal signals. Each lobule is made up 
of acini, or glands, embedded within loose connective tissue and connects to 
the intralobule duct. The acinus is composed of two cells types, namely 
epithelial and myoepithelial cells. Epithelial cells form glandular lumens and 
are surrounded by myoepithelial cells which rest on the basement membrane. 
These two cell types also present in the ductal tissues. There is a higher 
frequency of breast cancers originating from the duct (ductal cancer), while 
the less common breast cancer types begin in the lobules (lobular carcinoma).  
 
  Breast cancer is a heterogeneous disease that originates from the breast and 
can be classified according to histo-morphology and clinical prognosis. The 
analysis of breast cancer gene expression profile has led to the stratification of 
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four major subtypes. The intrinsic subtypes include hormone receptor (HR)-
positive Luminal A and B, human epidermal growth factor receptor 2 (HER2)-
positive and basal-like breast cancer (Perou, Sorlie et al. 2000; Sorlie, Perou et 
al. 2001). The basal-like breast cancer (BLBC) expresses basal cytokeratins 
but is negative for the expression of luminal, estrogen receptor (ER), 
progesterone receptor (PR) and HER2-related genes. BLBC is notorious for its 
aggressive tumor growth and has the poorest patient survival of all breast 
cancer subtypes (Peddi, Ellis et al. 2012). 
 
  Due to the high costs involved, stratification by gene expression array is 
currently not practical for clinically routine identification of breast cancer 
subtypes. The canonical approach to subtype classification is through 
immunohistochemical (IHC) staining and the analysis of ER, PR or HER2 
expression. By using this simple and cost-effective approach, it is possible to 
identify breast cancer into three major subtypes: the ER/PR-positive, or 
hormone receptor-positive (HR) subtype, which includes the Luminal A and B 
intrinsic subtypes; the HER2-positive subtype; the triple-negative subtype, 
which lacks expression of all three receptors (ER, PR and HER2) (Nielsen, 
Hsu et al. 2004; Arslan, Dizdar et al. 2009). Compared with HR-positive and 
HER2-positive patients, patients with triple-negative breast cancer (TNBC) 




  The TNBC subtype shares significant similarities with BLBC in terms of 
genetic makeup, clinical prognosis and therapeutic response. About 70-80% of 
BLBC are TNBC and more than 80% of TNBC belong to BLBC (Badve, 
Dabbs et al. 2011). Although it is generally recognized that the overlap 
between these two breast cancer types is not perfect, many researchers use the 
term BLBC and TNBC interchangeably and do not distinguish between the 
two. For practical purposes, in the introduction, I will summarize the findings 
in BLBC and TNBC in a collective manner.  
 
  Overall, TNBC and BLBC account for 12-17% of all breast cancer types 
(Cleator, Heller et al. 2007). The Patients of both of two types tend to have 
poor prognosis and suffer from early relapse within five years after treatment 
(Rakha, Reis-Filho et al. 2008). The recurrent tumors are mostly found at 
distal organs from breast, particularly in the lungs, brain and liver, suggesting 
the occurrence of metastatic events (Nam, Kim et al. 2008; Foulkes, Smith et 








1.3.2 EMT and metastasis 
 
1.3.2.1 EMT in cancer metastasis 
 
  Metastasis is an event when tumor cells disseminate from its primary niche to 
other sites of the body to form secondary tumors. 90% of cancer-associated 
death can be attributed to metastasis (Nguyen, Bos et al. 2009). A biological 
phenomenon, namely epithelial-mesenchymal transition (EMT) has been 
proposed to significantly influence the metastasis of breast cancer (Thiery 
2002; Kang and Massague 2004). Under normal conditions, epithelial cells are 
well-organized and reside within the basement membrane with regular apical 
basolateral polarity. During cancer progression, cells undergo EMT in which 
they gradually lose expression of cell-cell junction molecules (such as E-
Cadherin), which results in the disorganization of cell polarity and gain of cell 
motility. The cells would then invade the surrounding tissue, migrate through 
the blood or lymphatic system and colonize distal organs to form secondary 
metastases. It was discovered that EMT events happen more frequently in 
TNBC (Sarrio, Rodriguez-Pinilla et al. 2008) than the other breast cancer 
subtypes. Many of the TNBC cell lines are locked in a mesenchymal-like state 
with characteristics such as highly motility, invasiveness, lack of cell-cell 
adhesion junction, and often appear spindle-shaped. 
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1.3.2.2 E-caherin regulation in EMT 
 
  The adhesion protein E-cadherin plays an important role in EMT. E-cadherin, 
encoded by the CDH1 gene, is a central adhesion molecule located at cell-cell 
junctions and has been described as the guardian of the epithelial phenotype. 
E-cadherin protein is normally expressed in the cytoplasmic membrane of the 
ductal epithelial cells of mammary gland (Nielsen, Hsu et al. 2004; Broeks, 
Schmidt et al. 2011). Loss of E-cadherin expression is generally recognized as 
a hallmark of EMT and is considered a crucial step in the progression from 
benign to invasive carcinoma. Reducing adhesion between carcinoma cells 
promotes their ability to migrate and invade surrounding tissue (Oka, Shiozaki 
et al. 1993; Umbas, Isaacs et al. 1994; Perl, Wilgenbus et al. 1998). It is 
demonstrated that the expression of E-cadherin had an inverse correlation 
tumor patient survival (Birchmeier and Behrens 1994; Perl, Wilgenbus et al. 
1998). Deregulation of E-cadherin in breast cancer can occur through different 
means, including transcriptional repression, epigenetic inactivation and 
genetic alterations. Since genetic mutation of E-cadherin is irreversible, we 
only focus on the mechanisms of E-cadherin downregulation through 





1.3.2.2.1 Transcriptional repression  
 
  There is accumulating evidence to suggest that EMT can be triggered by 
certain signals to activate the malignant behavior of epithelial cancer and 
result in the acquisition of increased migratory ability, invasiveness and 
dissemination (Kalluri and Neilson 2003). The full spectrum of signals that 
contribute to EMT of carcinoma cells to date remains unclear. One possibility 
is that the tumor-associated stroma of primary tumor undergoes genetic and 
epigenetic alterations to provide specific EMT-inducing signals. Inducers of 
EMT, such as transforming growth factor beta (TGF-β), hepatocyte growth 
factor (HGF) and tumor necrosis factor alpha (TNF-α) are produced by  
stromal cells or the tumor cells (Kalluri 2009).  
 
  These factors interact directly or indirectly with E-boxes (with sequence 
motif: CANNTG) located in the proximal CDH1 promoter and inhibit E-
cadherin transcription activity. The most well-understood of these 
transcriptional repressors include members of the Snail family, SNAI1 and 
SNAI2/Slug (Batlle, Sancho et al. 2000; Hajra, Chen et al. 2002; Thiery 2002; 
Bolos, Peinado et al. 2003), the basic helix-loop-helix (bHLH) family 
members TWIST1 and TWIST2 (Kang and Massague 2004; Puisieux, 
Valsesia-Wittmann et al. 2006; Ansieau, Bastid et al. 2008) and members of 
the zinc finger homeobox family of repressors, ZEB1 (also known as TCF8 
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and δEF1)  and ZEB2 (also known as ZFXH1B and SIP1) (Comijn, Berx et al. 
2001; Eger, Aigner et al. 2005; Aigner, Dampier et al. 2007). A number of 
reports have suggested that these factors act as CDH1 repressors and 
enhancers of EMT in different types of human tumors and are important for 
tumor invasion and metastasis (Thiery 2002; Kalluri and Weinberg 2009). 
 
1.3.2.2.2 Epigenetic regulation 
 
Epigenetic regulation encompasses at least two elements: DNA methylation 
and histone modifications, each of which has been shown to play a key role in 
controlling CDH1 transcription and cancer metastasis. 
 
Hypermethylation of the CDH1 gene promoter is a well-studied silencing 
mechanism of E-cadherin. Aberrant methylation of 5’-CpG islands in the 
promoter region of CDH1 has been reported for many types of aggressive 
breast cancer and was shown to increase with malignant progression (Graff, 
Herman et al. 1995; Nass, Herman et al. 2000; Caldeira, Prando et al. 2006). 
Methylation of the CpG islands in the CDH1 gene was reported to increase 
during malignant progression of breast and hepatocellular carcinomas (Kanai, 
Ushijima et al. 2000; Nass, Herman et al. 2000). The fact that E-cadherin 
repression can be reactivated by DNA demethylating agent 5’-Aza-dC 
suggests DNA hypermethylation plays an important role in E-cadherin 
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silencing in cancer cell lines (Graff, Herman et al. 1995; Yoshiura, Kanai et al. 
1995; Brock, Gou et al. 2003). Moreover, E-cahherin induction by 5’-Aza-dC 
also reduce cell motility and inhibit cancer metastasis, suggesting the negative 
correlation E-cadherin and metastasis (Nam, Ino et al. 2004).  
 
In human cancer, the repression of E-cadherin has been linked extensively 
to histone lysine methylation. Lines of evidence have suggested the role of 
histone methylation H3K27me3, mediated by EZH2, in the silencing of E-
cadherin during cancer progression, which provides evidence for the 
functional link between EZH2 deregulation and E-cadherin repression during 
EMT and cancer metastasis (Cao, Yu et al. 2008; Herranz, Pasini et al. 2008). 
Recently, in three of TGF-β-induced EMT cell line models, it is found that 
G9a, a HMT responsible for H3K9me2 recruits SNAI1 and DNA 
methyltransferases to the E-cadherin promoter, leading to E-cadherin silencing 
(Dong, Wu et al. 2012). SET8 (also known as PR-Set7/9) is a member of the 
SET domain-containing methyltransferase family that specifically targets 
H4K20 for monomethylation (Fang, Feng et al. 2002; Xiao, Jing et al. 
2005).Similarly, it is also reported that SET8 binds with TWIST1 at CDH1 
promoter and exerts the transcriptional repression role on E-cadherin 




  Histone acetylation is catalyzed by a class of enzymes known as histone 
acetyl transferases (HAT). It is thought histone acetylation lead to a relaxed 
chromatin structure and, therefore, an enhanced rate of transcription. On the 
contrary, deacetylation of histone proteins by histone deacetylases (HDACs) is 
believed to cause chromosomal condensation and gene repression. The HDAC 
inhibitor, butyrate, was discovered to induce E-cadherin expression in breast 
cancer cell lines (Kondo, Kohno et al. 1998) and colon cancer cell lines 
(Barshishat, Polak-Charcon et al. 2000). Interestingly, at the E-cadherin 
promoter, HDAC1 and HDAC2 form a complex with SIN3A and SNAI1 to 
repress E-cadherin transcription (Batlle, Sancho et al. 2000; Cano, Perez-
Moreno et al. 2000). Similarly, HDAC3 represses E-cadherin but recruits a 
different combination of co-repressors, such as C-terminal binding protein 
(CtBP) co-repressor complex and Slug (Hemavathy, Guru et al. 2000; Hajra, 
Chen et al. 2002). The fact that HDAC complexes recruit transcriptional 
repressors such as SNAI1 or Slug supports a dynamic link between epigenetic 
silencing and the transcriptional repression of CDH1 during EMT and cancer 
metastasis. It is also shown that HDACs work in concordance with CpG 
methylation to induce E-cadherin silencing in cancer cells (Koizume, 





1.3.3 Treatment of TNBC 
 
  Luminal A and B breast cancers are usually sensitive to hormonal treatment. 
The HER2-positive subtype is potentially sensitive to trastuzumab, lapatinib 
and other HER2-targeting drugs. However, TNBC is insensitive to targeted 
therapy due to the lack of all three receptors (Rouzier, Perou et al. 2005). 
Therefore, the only systemic treatment option available for TNBC patients is 
conventional chemotherapy (Liedtke, Mazouni et al. 2008). Novel therapeutics 
is urgently needed for TNBC patients. 
 
1.3.3.1 Conventional chemotherapy 
 
A common strategy used in the design of chemotherapy drugs exploits the 
fact that tumor cells proliferate much faster than normal cells. Several types of 
chemotherapeutic agents which are frequently used in neoadjuvant or adjuvant 
therapy of TNBC (Cleator, Heller et al. 2007; Santana-Davila and Perez 
2010), include (i) anthracyclines, which act by intercalating DNA/RNA and 
interfering with cell replication (e.g., doxorubicin); (ii) taxanes, which act by 
disrupting microtubule function (e.g., paclitaxel); and (iii) platinum-based 
drugs, which act by inducing DNA repair mechanisms, triggering apoptosis 




 Although TNBC patients are shown to have higher pathological complete 
response (pCR) compared with other subtypes of breast cancer, the overall 
survival rate of TNBC patients does not appear to be favorable due to early 
cancer recurrence (Dent, Trudeau et al. 2007). Recurrent TNBC tumors were 
usually metastatic and appeared more aggressive. As a result, less than 30% of 
the women with TNBC survived more than five years (Rakha, Reis-Filho et al. 
2008). Therefore, intensive research efforts are focused on the identification of 
druggable targets in TNBC and development of better pharmaceutical 
strategies in TNBC treatment. 
 
1.3.3.2 Targeted therapy 
 
The use of molecular targeted therapy has shown limited success in the 
clinical trials for the treatment of TNBC. So far, not a single targeted therapy 
has been approved by the FDA for clinical use. 
 
  The poly-(ADP ribose) polymerase (PARP) inhibitor was once believed to be 
a promising targeted drug in treating TNBC. PARP1 is an enzyme that plays 
an important function in the DNA repair. Another protein, BRCA1, has also 
been known to be responsible for homologous DNA repair. The loss of 
BRCA1 expression leads to error-prone DNA repair, increasing the risk of 
genetic mutations and hence predisposes cells to cancer initiation. 
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Intriguingly, about 20% of TNBC was reported to have BRCA1-deficiency, 
either via gene mutation or gene underexpression. Studies have reported that 
tumors without BRCA1 showed synthetic lethality upon PARP inactivation 
(Glendenning and Tutt 2011). However, during the phase III clinical trials of 
Iniparib (PARP sinhibitor), treatment with the drug did not result in favorable 
outcomes in BLBC patients (Fojo, Amiri-Kordestani et al. 2011; Guha 2011). 
Hence, careful selection of patient population and appropriate combination 
regimens are needed for disease control.  Therapy combining PARP inhibition 
and chemotherapy has been challenged with toxicity issue, but is currently 
being actively investigated in clinical trials (NCT01506609). 
 
Targeting epidermal growth factor receptor (EGFR) including using EGFR-
specific antibodies (eg. Cetuximab) and small-molecule inhibitors (e.g. 
Gefitinib and Erlotinib) is another example of targeted therapy for TNBC 
(Harari 2004).  Upon the binding of its ligand, EGFR activates multiple 
downstream oncogenic signalings such as PI3K/AKT and MEK/ERK, leading 
to proliferation, invasiveness, and survivability of cancer cells. It is shown that 
EGFR overexpression and hyperactivation can be observed in more than 50% 
of TNBC (Hudis and Gianni 2011). However, EGFR inhibitors showed only 
limited responses during clinical trials (Hudis and Gianni 2011). Mutations of 
EGFR that affect the binding of the inhibitors and nuclear localization of 
EGFR that renders inefficient cell surface binding of Cetuximab are the 
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possible mechanisms of disappointing clinical outcomes of EGFR inhibitors 
(Wheeler, Dunn et al. 2010). 
 
In addition to the approaches above, other oncogenic factors known to be 
overactivated in TNBC have also been targeted (Berrada, Delaloge et al. 2010; 
Fornier, Morris et al. 2011; Tryfonopoulos, Walsh et al. 2011; Peddi, Ellis et 
al. 2012), for instance, the SRC inhibitor (Dasatinib), VEGFR inhibitor 
(Bevacizumab) and inhibitors targeting PI3K/AKT/mTOR are currently under 
clinical trials to access the efficacy in TNBC/ BLBC therapy. 
 
1.3.3.3 Epigenetic therapy 
 
The targeting of epigenetic modifications is another novel approach to treat 
TNBC. Preliminary evidence has shown that BRCA1 inactivation by promoter 
methylation may drive tumor progression towards TNBC phenotypes (Galizia, 
Giorgetti et al. 2010; Stefansson, Villanueva et al. 2012). A recent study on 
whole genome methylation analysis reported that TNBCs have a methylation 
pattern that is different from hormone receptor-positive breast cancer 
(Dedeurwaerder, Fumagalli et al. 2011). Panobinostat, a HDAC inhibitor was 
demonstrated to inhibit growth of TNBC cell lines and decrease tumorigenesis 
in vivo (Tate, Rhodes et al. 2012). It was also shown that  the combination 
treatment of panobinostat and the DNA methylation inhibitor decitabine can 
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reactivate the expression of  estrogen receptor (ER) and progesterone receptor 
(PR) in TNBC (Sharma, et al. 2009). Thus, the reactivation of genes in the 
endocrine pathway by epigenetic drugs may result in subsequent sensitivity to 
hormonal therapies. Currently, there is an ongoing clinical trial using single-
agent decitabine in TNBC patients followed by examination for ER expression 
and treatment with Tamoxifen (NCT01194908). 
 
So far, chemotherapy is the only systemic treatment option for TNBC 
patients. A better understanding of the biological complexity of TNBC and the 
discovery of novel treatments is essential for successful targeted therapies in 
TNBC in the future. 
 
1.4 DZNep as a new class of anti-cancer agent 
 
Epigenetic modifications work in concert with genetic mechanisms to 
regulate transcriptional activity in normal tissues and are often dysregulated in 
human cancers.  Unlike the disabling genetic mutations, modifications of 
DNA and histones are reversible, making them attractive targets for 
therapeutic intervention. Several inhibitors of DNA methylation and histone 
deacetylation are approved for hematological malignancies by FDA and have 
been in clinical use for several years. Recently, significant effort is under way 
to find new molecules able to target histone methylation. To date, no drugs 
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targeting histone methylation are FDA approved or in clinical trials as 
illustrated in Figure 1.5. Even so, preclinical studies in various cancer types 
suggested that the S-adenosylhomocysteine hydrolase inhibitor 3-dea-




































Figure 1.5 Chemical structures of selected compounds that target 









1.4.1 DZNep as a S-Adenosylhomocysteine (AdoHcy) hydrolase inhibitor  
 
    S-Adenosylmethionine (AdoMet) is a universal methyl donor in a wide 
variety of biological functions. S-Adenosylhomocysteine (AdoHcy) is formed 
after the donation of the methyl group of AdoMet to a methyl acceptor by 
methyltransferases. AdoHcy is then converted into adenosine (Ado) and L-
homocysteine (Hcy) by AdoHcy hydrolase (Cantoni 1975). AdoHcy hydrolase 
inhibitors have been shown to work in animal and cell models to increase the 
level of AdoHcy, which also increases AdoMet in the cells because of the 
feedback inhibition by AdoHcy on methyltransferases as illustrated in Figure 
1.6. Therefore, AdoHcy hydrolase has emerged as a drug target because of its 
regulation on diverse metabolisms which can alter methylation of 
phospholipids, proteins, small molecules, DNA and RNA. Inhibitors targeting 
AdoHcy hydrolase induce a diverse range of biological and biochemical 
effects, for example, expression of transcription factors and cellular 
differentiation (Chiang 1998). Moreover, these inhibitors display high antiviral 
effects in both in vitro and in vivo systems (Bray, Driscoll et al. 2000; De 
Clercq 2005). Till now, 3-Deazaneplanocin A (DZNep) remains the most 












Figure 1.6 Schematic diagram of S-adenosylmethionine (AdoMet) 
metabolism (AdoMet) metabolism and its inhibition (upper), chemical 
structure of DZNep and another AdoHcy hydrolase inhibitor adenosine 
dialdehyde (Adox) (lower), adapted from the study of Miranda et al (Miranda, 













DZNep Adenosine dialdehyde (Adox)                        
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1.4.2 Anti-cancer effects of DZNep 
 
As mentioned above, although a variety of biological effects have been 
observed for DZNep, its anti-cancer effects have not been explored until 2007. 
Tan and colleagues firstly reported that DZNep induced efficient apoptotic cell 
death in breast cancer cells but not in normal cells. It was also found that 
DZNep effectively depleted cellular levels of PRC2 components EZH2, 
SUZ12 and EED and inhibited associated histone H3 Lys 27 methylation 
(Tan, Yang et al. 2007). In 2008, this team demonstrated that DZNep 
synergized with histone deacetylation (HDAC) inhibitor TSA in reversing 
malignant tumor chromatin from its ‘repressive’ state to ‘active’ state, causing 
apoptosis in colon cancer cells (Jiang, Tan et al. 2008). Thereafter, there were 
emerging lines of evidence to demonstrate DZNep as a new class of epigenetic 
compounds with therapeutic potential in multiple cancers. Numerous studies 
have shown that DZNep has multifactorial anti-cancer effects including pro-
apoptosis, growth inhibition, cell cycle arrest, anti-metastasis, targeting cancer 
stem cell, induction of differentiation, etc as discussed below. 
 
  It has shown that the deficiency of BRCA1 (a tumor suppressor gene) 
correlates with high level of EZH2 and poor prognosis in breast cancers. 
Interestingly, BRCA-deficient cells are much more sensitive to DZNep than 
BRCA1-proficient cells (Puppe, Drost et al. 2009). Therefore, DZNep can be 
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rationally used to target these cancers which are likely to be more stem-like 
and less differentiated.  DZNep has also been shown to inhibit cell growth and 
arrest cell cycle, induce apoptosis and differentiation, and synergise with TSA 
(HDAC inhibitor) and trastuzumab (HER2 targeted antibody) in breast cancer 
(Hayden, Johnson et al. 2011).  
 
  DZNep is also efficacious for the treatment of AML where it can induce 
apoptosis in both AML cell lines and patient’s primary cells. In addition, 
DZNep shows synergy with panobinostat (HDAC inhibitor) against human 
AML cells and extends the survival of HL-60 leukemia transplanted 
NOD/SCID mice (Fiskus, Wang et al. 2009). Zhou et al. also demonstrates 
that DZNep works in vitro and in vivo AML models. DZNep acts by depleting 
PRC2 and H3K27me3 which results increases expression of thioredoxin-
binding protein 2 (TXNIP). TXNIP inhibited Trx activity and produced more 
reactive oxygen species (ROS) that triggers apoptosis. It has also been shown 
that DZNep exerts differential action on LSC-enriched subpopulation and 
normal HSCs (Zhou, Bi et al. 2011). Together, these studies show that DZNep 
is effective in inducing apoptosis in vitro and in vivo AML models as well as 
inhibiting LSC.   
     
  Partly through downregulating cyclin A and inducing p27(Kip1), DZNep can 
also inhibit proliferation, induce apoptosis and cell cycle arrest in non-small 
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cell lung cancer (NSCLC) cell lines (Kikuchi, Takashina et al. 2012). Similar 
to what has been observed in NSCLC, DZNep can also suppress the growth of 
small cell lung cancer (SCLC) (Sato, Kaneda et al. 2013). 
 
  DZNep or EZH2 depletion severely limited self-renewal of glioblastoma 
multiforme (GBM) cancer stem cell (CSC) in vitro and tumor-initiating 
capacity in vivo by modulating c-myc, which is an EZH2 target and crucial for 
GBM CSCs (Suva, Riggi et al. 2009). Apart from inhibiting GBM, DZNep 
could eliminate prostate cancer (PC) cells by inhibiting LNCaP and DU145 
prostatosphere formation and lowering the expression of CSC markers 
significantly. In addition, DZNep inhibited cell invasion of PC cells (Crea, 
Hurt et al. 2011). Furthermore, both EZH2 depletion and DZNep treatment 
reduced cell growth and anchorage-independent sphere formation of 
hepatocellular carcinoma cells (HCC) cells. In particular, the number of 
epithelial cell adhesion molecule (EpCAM) (+) tumor-initiating cells was also 
reduced. Either 5-fluorouracil (5-FU) or DZNep can reduce the tumor burden 
of HCC cells transplanted in NOD/SCID mice. However, only DZNep mainly 
lowered the number of EpCAM (+) cells and inhibited their self-renewal 




  Collectively, these studies suggest that DZNep could be usefully employed to 
inhibit both bulky cancer cells and cancer stem cells (CSC) in multiple cancer 
types. 
 
1.4.3 Mode of action 
 
  Despite these promising results, the underlying mechanisms by which 
DZNep depletes PRC 2 complex and acts as an anti-cancer agent remained 
unclear.    
 
  Several studies showed that DZNep partly acts by downregulating the PRC2 
complex. Since the mRNA level of PRC2 subunits remained constant, it was 
thought that DZNep did not induce transcriptional repression of these 
components. Indeed, DZNep might induce protein degradation through the 
proteasome because proteasome inhibitors could partly rescue the 
downregulation of PRC2 subunits (Tan, Yang et al. 2007). Since depleting any 
of the PRC2 subunits will also decrease the expression level of other binding 
partners (Bracken et al. 2003; Pasini et al. 2004; Montgomeryet al. 2005), 
DZNep might affect one of the core PRC2 components and weaken the 
stability of the whole complex, leading to decrease of H3K27me3. Recently, it 
has been shown that the ubiquitin (Ub)–proteasome system (UPS) regulates 
the degradation of PRC2 subunits. DZNep not only induces the dissociation of 
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the PRC2 complex and degradation but also upregulates the expression of 
several Ub ligases, suggesting that the Ub ligases might be trancriptionally 
repressed by PRC2. One of the DZNep-induced Ub ligases, PRAJA1, has been 
shown to ubiquitinate PRC2 subunits and target them for proteasomal 
degradation (Zoabi, Sadeh et al. 2011). 
 
  Another AdoHcy hydrolase inhibitor, adenosine dialdehyde (as shown in 
Figure 1.7) could act like DZNep to reduce EZH2 protein levels and induce a 
global reduction of H3K27me3 in cancer cell lines (Miranda, Cortez et al. 
2009), implying that EZH2 and H3K27me3 depletion are not a specific action 
of DZNep. Thus, DZNep might indirectly act on EZH2 through increasing 
AdoHcy level that inhibits EZH2 activity.     
 
  Even though DZNep was considered as a selective inhibitor that depletes 
H3K27 and H4K20 trimethylation (Tan, Yang et al. 2007), it can have a global 
effect on both repressive and active histone methylation marks (Miranda, 
Cortez et al. 2009). Despite the lack of specificity, DZNep could still be useful 
in the clinic. For instance, HDAC inhibitors also induce a global effect on 
histone acetylation marks. Yet, HDAC inhibitors have been successfully 
administered in cancer patients (Xu, Parmigiani et al. 2007; Su, Altucci et al. 
2008). Therefore, this study was initiated to further investigate the mechanism 
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of action of DZNep to expand its therapeutic potential in cancer and to 
understand how gene expression is regulated by the chromatin structure.     
  
1.4.4 Development of DZNep analogs 
 
  Although DZNep gives promising results both in vitro and in vivo, DZNep 
itself may not be an ideal drug candidate. It has a short half-life, poor 
bioavailability, and thus a better compound needs to be developed to 
overcome these pitfalls. It is expected that the development of DZNep-like 
analogs will provide not only a research tool to help dissect the molecular 
pathway governing the cancer epigenetics but also a potential therapeutic 
approach for cancer therapy.  
 
  To this end, the pharmacologists from Genome Institute of Singapore (GIS) 
and medicinal chemists from Institute of Chemical and Engineering Sciences 
(ICES) in Singapore collaborated to develop the second generation of DZNep 
analogues.  Structure and Activity Relationship (SAR) analysis and correlation 
of chemical and physical properties of the analogues lead to several candidate 
compounds that are further tested in mice experiments to determine their 
toxicity and preliminary anti-tumor activity. One of the leading compounds, 
named I-3, was selected for further investigation as it showed comparable 





















1.5 The Objective 
 
    Epigenetics is an expanding field in biomedical research and shows great 
promise in cancer therapy. Numerous compounds which inhibit components of 
epigenetic machineries have been reported to be effective against cancer. 
Examples include DNA methylation and HDAC inhibitors, which have been 
shown to be effective in clinical settings. However, targeting histone 
methylation is still in its infancy. To date, there are currently no such drugs 
approved by FDA or advanced to late stage clinical trials. 
 
   In 2007, our lab demonstrated for the first time that DZNep effectively 
depleted PRC2 complex and inhibited associated histone H3 Lysine (K)27 
methylation and induced apoptosis in breast cancer cells (Tan et al., 2007). In 
2008, our lab reported that DZNep synergized with histone deacetylation 
(HDAC) inhibitor TSA in reversing malignant tumor chromatin from its 
‘repressive’ state to ‘active’ state, causing apoptosis in colon cancer cells 
(Jiang et al., 2008). Thereafter, there were emerging lines of evidences that 
demonstrate DZNep as a new class of epigenetic compounds with therapeutic 
potential in multiple cancers. Although DZNep has exhibited promising anti-
cancer effects both in vitro and in vivo, DZNep itself may not be an ideal drug 
candidate due to its short half-life and high toxicity. In view of such adverse 
properties of DZNep, there is a pressing need to develop more druggable 
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DZNep analogs. To this end, we collaborated with the Institute of Chemical 
and Engineering Sciences (ICES) and tested nearly 300 DZNep analogs for 
Structure and Activity Relationship analysis (SAR). In the initial screening, 
cell-based apoptosis and growth assays were used to evaluate the compounds 
synthesized by ICES. Promising compounds were selected for in vivo 
evaluation to determine their toxicities and anti-cancer properties. One of the 
leading compounds, namely I-3, was identified to exhibit improved 
therapeutic index than DZNep. The objective of this study is to 
comprehensively investigate the potential anti-cancer effects of I-3 by using 
both in vitro and in vivo models of acute myeloid leukemia (AML) and 





































2.1 Cell culture 
 
  All the breast cancer cell lines used in this study were purchased from 
American Type Culture Collection (ATCC, Manassas, VA) including MDA-
MB-231, MCF7, T47D, MDA-MB-361, MDA-MB-415, BT549, BT474, 
SKBR3, MDA-MB-468, MDA-MB-436, SUM159PT, HS578T. Breast cancer 
cell lines were cultured in DMEM medium supplemented with 10% fetal 
bovine serum (FBS), 1% penicillin and streptomycin (PS). 
 
  A panel of Acute Myeloid Leukemia (AML) cell lines, that is, MV4-11, 
Kasumi-1, KG-1, KG-1a, TF-1, TF-1a, MOLM-14, THP-1, HL-60 and Mono-
Mac-1 were kindly generously provided by Dr. Chng Wee-Joo of Cancer 
Science Institute, National University of Singapore. These AML cell lines 
were cultured in either RPMI 1640 (Invitrogen) or IMDM (Invitrogen) 
medium supplemented with 10 or 20% FBS and 1% PS. The culture medium 
for TF-1 cell line was supplemented 10% FBS, PS and 5 ng/ml of IL-3 
(R&D).  
 
2.2 Recovery and maintenance of primary AML cells from patients 
  Frozen bone marrow (BM) blasts from newly diagnosed AML patients were 
obtained at the National University Hospital in Singapore with informed 
consent. Immediately after recovery, primary AML cells were cultured in 
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IMDM supplemented with 10% FBS as well as a series of growth factors 
(R&D) including FLT3 ligand (20 ng/ml), SCF (20 ng/ml), IL-3 (20 ng/ml), 
G-CSF (50 ng/ml), thrombopoietin (TPO; 50 ng/ml) for only 24 hours before 
experiment. The dead cells were removed by using Dead Cell Removal Kit 
(Miltenyi Biotec) and only live cells were used for experiments. 
 
2.3 Cryopreservation of cell lines 
 
  The exponentially grown cells were spun down at 1000rpm for 3 minutes. 
Freezing medium (90% culture medium and 10% DMSO) was used to 
suspend cell pellets to achieve cell suspension as 1 x 10^6/ml. Cryotubes 
containing 1 ml cell suspension were transferred into Mr. Frosty cylinder 
(NALGENE), which was filled with 99% isopropanol for overnight in -80°C 
freezer. After 24 hours, the frozen vials were transferred into liquid nitrogen 
tank for long-term storage. 
 
2.4 Drug treatment 
 
  I-3 was synthesized and provided by Dr. Christina Chia from Institute of 
Chemical and Engineering Sciences (ICES), Singapore. I-3 (MW: 308.16) was 
reconstituted as 10mM stock using DMSO and stored in -20°C. All the rest of 
drugs including Suberoylanilide hydroxamic acid (SAHA), 5-Aza-2′-
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deoxycytidine (Synonym: Dacitabine, or DAC), Doxorubicin (Synonym: 
ADR) and Cytosine β-D-arabinofuranoside (Synonym: Ara-C) were ordered 
from Sigma. SAHA, DAC and ADR were reconstituted with DMSO to make 
10mM stock, while Ara-C was reconstituted with MilliQ water sterilized by 
passage through 0.2 µm filter unit (Millipore, Singapore).  All the 
reconstituted drugs were kept at -20°C. 
 
  1 x 10^5/ml cells in culture medium were seeded for drug treatment. Cells 
were harvested after I-3 48 hours treatment for Western blot analysis and 72 
hours for Flow Cytometric Analysis. For combination treatment, I-3 was 
administered first. Following 24 hours I-3 treatment, chemo drug, either ADR 
or Ara-C was given for 48 hours before harvesting the cells. 
 
2.5 Cell viability assay  
 
  1000 cells suspended in 100µl culture medium were seeded in each well of 
96 well optical bottom plate (Costar 3917) the day before I-3 treatment. I-3 
10mM DMSO stock was diluted by basic IMDM medium to make 10-fold 
drug stocks (100 µM, 10 µM, 5 µM, 1 µM, 0.5 µM, 0.1 µM, 0.01 µM and 
0.001 µM).  10µl of 10-fold drug stock of I-3 was added directly into the well 
containing around 90 µl cell suspension 24 hours post seeding. Cells were 
incubated with I-3 for 96 hours before detection. CellTiter-Glo® Luminescent 
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Cell Viability Assay was used (Promega, G7573) to evaluate the viable cell 
numbers based on quantification of the ATP present in the cells, which signals 
the presence of metabolically active cells. Basically, 50 µl of CellTiter Glo 
reagent was added into the well to lyse the cells.  The plate was then gently 
shaken for 5 minutes and then kept static for another 5 minutes to allow the 
luminescence signal stabilize before measured by MicroLumat Plus LB96V 
system (BERTHOLD TECHNOLOGIES). Six replicas were conducted for 
each sample. Control samples were treated with 10 µl basic IMDM medium. 
To calculate EC50, nonlinear regression sigmoidal dose response curves were 
generated using GraphPad PRISM. The X values were the logarithm of the 
concentration of I-3 and the Y values are response percent of DMSO control.  
 
2.6 Soft agar assay 
 
  Soft agar colony formation assay was a well-established in vitro assay to 
evaluate the anchorage-independent capacity of cells. 3% agar in PBS was 
heated up in microwave discontinuously to make a clear and homogenous 
solution. 0.6% agar diluted from 3% agar using warm complete culture 
medium was added into the wells of 6-well plate as bottom layer.  Once the 
bottom layer became solidified, approximately 1000 single cells in 1ml were 
mixed with equal volume of 0.6% agar and added into the pre-coated 6-well 
plate.  After two weeks, 1ml of p-Iodonitrotetrazolium Violet (INT) at 4 µg/ml 
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was added into the well and incubated for overnight.  The images were taken 
and the colony numbers were enumerated by GELCOUNT (Oxford Optronix). 
Duplicates were performed for each sample, and three independent 
experiments were conducted. 
  
2.7 PI staining and Flow Cytometric Analysis 
 
  Adherent cells were detached by trypsin, washed twice with cold PBS before 
fixing by 70% ethanol for at least 1 hour at 4ºC. The fixed cells were washed 
twice with PBS, treated by 100 µl RNase (100 ng/µl) for 5 minutes, and then 
stained with 400 µl propidium iodide (PI) (50 mg/ml) for 30 minutes in the 
dark. The DNA contents were measured by FACS analysis (Becton Dickson), 
and 10000 cells from each sample were analyzed by using Cell Quest software 
(BD bioscience).  
 
2.8 Active Caspase3 staining and Flow Cytometric Analysis 
 
  After drug treatment, cells were harvested as usual. Cytofix/cytoperm 
fixation/permeabilization kit (BD Biosciences) coupled with FITC rabbit anti-
active Caspase-3 antibody (BD Biosciences) were used to stain the cells. Cells 
were fixed and permeabilized by 800 µl Cytofix buffer at room temperature 
for 20 minutes and then followed by washed twice using 1 x Cytoperm buffer. 
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The spun down cell pellet was suspended and incubated with 20 µl anti-active 
Caspase-3 FITC for 1 hour at room temperature under light protection. Stained 
cells were washed with 1× Cytoperm buffer one time then suspended in 300 to 
500 µl of the same buffer for Flow Cytometric Analysis.   
 
2.9 Immunofluorescent staining and Flow Cytometric Analysis 
 
  TF-1a cells were harvested by centrifuging at 300 x g for 3 minutes. The 
supernatant was aspirated completely before adding the antibodies.  Staining 
buffer (PBS, PH 7.2, 0.5% BSA and 2 mM EDTA) was used to dilute CD34-
APC antibody (Miltenyi Biotec 130-090-954) or CD38-FITC antibody 
(Miltenyi Biotec 130-092-259). Up to 10^7 cells were incubated with 100 µl 
10-fold diluted CD38-FITC antibody for 10 minutes in the dark at 4°C. The 
cells were washed by adding 2 ml of staining buffer and centrifuged at 300 x g 
for 3 minutes. CD34-APC staining was conducted as same as CD38-FITC 
staining. After washing, the cell pellets were suspended with 0.5 ml of 1 µg/ml 
propidium iodide (PI) just before analysis by FACScalibur (BD Bioscience). 
Cell debris and dead cells were excluded from the analysis based on scatter 
signals and PI fluorescence. The stained cells were analyzed by using 




2.10 CD34+CD38- cell isolation by MACS® Separations  
 
  TF1a cells were harvested and stained with CD38-FITC antibody as section 
2.9. After 10 minutes incubation in the dark, cells were washed twice using 
staining buffer.  Cell pellet was suspended by 80 µl staining buffer with 20 µl 
anti-FITC MACS Microbeads and incubated for 15 minutes in the refrigerator 
(2-8°C) in subdued light. The magnetically labeled cells were washed twice 
and then loaded onto a MACS MS Column, which is placed in the magnetic 
field of a MACS Separator. The magnetically labeled CD38-FITC positive 
cells were retained in the column, while the unlabeled CD38-FITC negative 
cells run through the column and collected as CD38- cell population. CD38- 
cells then were stained with CD34-APC antibody and followed by anti-APC 
MACS Microbeads and loaded into MACS Column. The retained cells were 
CD34+CD38- subpopulation, and flow-through cells were CD34-CD38- 
subpopulation.  The column was removed from the magnetic field of MACS 
Separator and was then added with 0.5ml staining buffer. The retained 







2.11 Dead cell removal 
 
  1 x 10^5 cells/ml of TF-1a cells were treated with I-3 100 nM with or without 
chemo drugs (Ara-C 20 nM or ADR 20nM). The drugs and culture medium 
were replenished every 3 to 4 days.  After 2 weeks, the dead cells under each 
condition were removed by using Dead cell removal kit (Miltenyi Biotec). All 
the cells including both dead and live cells were collected by centrifuging at 
300 x g for 3 minutes. The cells were suspended in 100 µl Dead Cell Removal 
Microbeads and incubated for 15 min at room temperature.  MS MACS 
columns were placed in the magnetic field of a suitable MACS® Separator 
and prepared by rinsing with 0.5 ml 1 x Binding Buffer before use. The cells- 
Microbeads mixtures were added with 1 ml 1 x Binding Buffer and the whole 
suspensions were applied onto the column.  The magnetically labeled dead 
cells were retained in the column. The unlabeled cells passed through and 
were collected into the collection tubes as live cell fraction. The columns were 
then rinsed with 0.5 ml 1 x Binding Buffer four times.  The collected cells 
were centrifuged at 300 x g for 3 minutes.  Cell viability was evaluated by 
trypan blue staining. Cells will go through Dead cell removal step one more 





2.12 Colony-forming-units (CFU) assay 
 
  StemMACS HSC-CFU Media (Miltenyi Biotec 130-091-280) have been 
optimized to maximize growth and differentiation of progenitor cells and 
allow the formation of distinct colonies by the growth of a single-cell clonal 
progeny. The frozen HSC-CFU Media was thawed overnight at 4°C and then 
mixed completely by shaking the bottle vigorously. After 10 minutes, the 
turbid semi-solid HSC-CFU Media became clear as the air bubbles generated 
by shaking rose to the top. Approximately 1000 single and live cells after the 
negative selection by Dead cell removal kit were mixed completely with 1 ml 
HSC-CFU medium by syringe attached to a 16-gauge blunt-end needle.  1.1 
ml suspension was added into one well of 6-well plate.  The plate was rotated 
gently to spread the suspension evenly. The plate was then incubated for 14 
days and staining with iodonitrotetrozolium chloride (Sigma) for overnight. 
The colony number was counted by using GELCOUNT (Oxford Optronix). 
Triplicates were performed for each sample, and three independent 
experiments were conducted. 
 
2.13 Transwell migration and invasion assay 
 
  24-well FluorBlok transwell inserts (#351152, BD Biosciences) with a pore 
size of 8 µm and special 24-well plates (cat#353504, BD Biosciences) were 
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used for Transwell migration and invasion analysis.  For invasion assay, the 
inserts were coated with 80 µl of 250 ng/ml growth factor reduced matrigel 
(cat#356231, BD Biosciences) on the upper surface for 4 to 6 hours at 37ºC 
before seeding the cells. For migration assay, the coating step was omitted. 
Approximately 2.5 to 5 × 10^4 cells in 200 µl RPMI or DMEM containing 
0.25% FBS were seeded into the upper chamber of each insert.  750 µl RPMI 
or DMEM containing 10% FBS were added outside the chamber as 
chemoattractant. Inserts were fixed after 24 hours of incubation at 37°C by 
using 3.7% formaldehyde for 20 minutes at room temperature.  After several 
washes, the inserts were stained with 25 µg/ml propidium iodid for 30 minutes 
at room temperature in the dark.  The migrated and invaded cells in 10 
individual fields beneath the inserts were scanned and counted with Cellomics 
ArrayScan VTI (Thermo Scientific Inc.). Triplicates were conducted for each 
sample, and at least three independent experiments were performed. 
 
2.14 Cell adhesion assay 
 
  Cell adhesion assay is a microwell plate-based assay to quantify the cell 
adhesion capacity. Basically, purified ECM proteins are used to coat the 
desired tissue culture plate prior to the cell seeding. Subsequently, the cells are 
allowed to bind to the ECM proteins and then the non-adherent cells were 
removed by gentle wash. The remaining cells can be quantified by many 
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different methods. In this study, 96-well optical bottom plates (Costar 3917) 
were coated with 10 µg/ml Fibronectin (Sigma) for overnight at 4 °C.  The 
plates were washed three times using PBS prior to seeding the cells. 
Approximately 1000 TF-1a cells were seeded into each well and treated by 
ADR or Ara-C 50 nM for 48 hours with or without I-3 (100 nM) for 24 hours. 
After the drug treatment, the wells were gently washed by PBS three times to 
remove the unattached cells. 100 µl PBS and 50µl of CellTiter Glo reagent 
were added into the well to lyse the cells as mentioned in section 2.5. 
MicroLumat Plus LB96V system (BERTHOLD TECHNOLOGIES) was used 
for the quantification of the remaining adherent cells. 
 
2.15 Western blot analysis 
 
  Cells were harvested and washed twice with cold PBS. For whole cell lysate 
extraction, 30 to 100 µl of radioimmunoprecipitation assay lysis buffer (50 
mmol/l Tris-HCl pH7.4, 1 mmol/l EDTA, 150 mmol/l NaCl, 1% Nonidet P-
40, 0.5% sodium deoxycholate, and proteinase inhibitors) was used to lyse the 
cell pellet on ice for half an hour. The cell lysate was vortexed for 10 seconds 
at 5 minutes interval. Subsequently, the cell lysate was sonicated for 5 seconds 
for 3 times every 5 minutes, followed by centrifugation at 13,200 rpm for 10 
minutes at 4ºC. The cleared supernatant was collected and transferred to a 
fresh tube. The protein concentrations were measured by Bradford protein 
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assay kit (Bio-Rad, Hercules, CA) and SUNRISE plate reader (Tecan). Whole 
cell lysate (20-30 µg) was separated by 8% to 12% SDS-PAGE gel with a 
mini-gel apparatus (Mini-Protean II, BioRad), then transferred onto a PVDF 
immobilon membrane (Millipore) using Trans-Blot SD Semi-Dry transfer cell 
(Bio-Rad). Membranes were then blocked 3% BSA (Sigma) or 5% non-fat 
milk (Bio-Rad) for 1 hour. After blocking, the membranes were incubated 
with primary antibodies for 1 hour, followed by secondary antibodies 
conjugated with HRP for 1 hour. The membranes were incubated with 
Chemoluminescent ECL Substrate (Amersham) for 5 minutes and signals 
were developed with X-ray film (Kodak, USA).  
 
  The following primary antibodies were used in this study. Cleaved PARP, 
EZH2, p-ERK (T202/204), p-AKT (S473), p-Stat1(T701), p-Stat3(T705), p-
Stat5(T694) and SLUG (Cell Signaling, Danvers, MA); Bim, E-cadherin, 
Survivin (BD Biosciences); Bcl-xL, Bcl-2, Mcl-1 and Vimentin (Santa Cruz); 
H3K27me3, H3K9me3, H3K4me3, H3K79me2, H4K20me3 and total H3 
(Upstate Biotechnology); and  actin (Sigma-Alrich) were used as primary 
antibodies. Anti-rabbit and anti-mouse horseradish peroxidiselinked whole 





2.16 Immunofluorescence confocal microscopy 
 
  MB231 cells at a density of 1.5 x 10^5 cells/well were seeded on 8 mm 
coverslips in 12-well plates.  After 24 hours, MB-231 cells were treated with 
I-3 1µM 24 hours followed with SAHA 1µM 48 hours before harvesting. Cells 
on coverslips were rinsed with PBS, then fixed with 3.7% paraformaldehyde 
in PBS for 10 minutes at room temperature, followed by permeablized with 
0.2% Triton-X100 for another 10 minutes. After blocking with 10% FBS in 
PBS for 1 hour at room temperature, cells were incubated with primary 
antibody E-cadherin (BD Biosciences) in a 1:50 dilution 1 hour at room 
temperature, followed by 3 times washes with PBS. Next, the cells were 
incubated with florescent-labeled secondary antibodies Alexa Fluor 488 
(Invitrogen) in a 1:1000 dilution 1 hour followed by 3 washes with PBS in 
dark. 4',6-diamidino-2-phenylindole (DAPI) 15 minutes at 1:1000 dilution was 
used for nuclear staining. The coverslips were then mounted in Fluorsave 
(CalBiochem) before examined by confocal microscopy (Zeiss LSM510).  
 
2.17 Plasmid transformation 
 
PLKO.1-control plasmid, PLKO.1-E-cadherin shRNA, PLKO.1-EZH2, 
psPAX2 packaging plasmid and pMD2.G envelope plasmid were ordered 
from Addgene (Cambridge, MA). 50 µl of One Shot® TOP10 competent E. 
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coli cells (Invitrogen) was mixed gently with 10 ng aboved plasmid DNA in 5 
µl volume and incubated on ice for 30 minutes. The mixture was subsequently 
subjected into a 42ºC in a water bath for 30 seconds and the tube was 
immediately transferred on ice for 2 minutes. The mixture was then mixed 
with 150 µl warm SOC medium and cultured at 37ºC for 1 hour shaking at 280 
rpm. After 1 hour recovery, 100 µl mixtures were spread onto LB agar plate 
which contained 100 µg/ml of ampicillin. The plate was then incubated at 
37ºC overnight.         
 
2.18 Plasmid midi-prep 
 
  Single colony was picked up from the agar plate (from Section 2.17) and 
amplified into 3 ml LB medium containing 100 µg/ml ampicillin with shaking 
at 280 rpm 37ºC for 8 hours. After the incubation, the starter culture was 1:500 
diluted into 50 ml selective LB medium and cultured at 37ºC with vigorous 
shaking at 280 rpm for overnight. The next day, plasmids were extracted from 
bacteria using QIAprep® spin Midiprep kit. Bacterial culture was centrifuged 
at 4000 rpm for 20 minutes at 4ºC. The bacterial pellet was resuspended with 4 
ml of buffer P1 containing 100 µg/ml RNase A and lysed with 4 ml of buffer 
P2 for 5 minutes. 4 ml of cold Buffer P3 was added into the mixture for 
neutralization. The neutralized product was poured into a barrel of the 
QIAfiltered cartridge and incubated for 10 minutes at room temperature. At 
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the same time, QIAGEN-tip 100 was equilibrated with 4 ml buffer QBT.   
After 10 minutes incubation, the cleared lysate was pushed and filtered 
through QIAfiltered cartridge by the plunger and transferred into the 
equilibrated QIAGEN-tip 100. The lysate went through QIAGEN-tip by 
gravity flow. Then, QIAGEN-tip was washed twice with 10 ml of QC buffer. 
Plasmid DNA was eluted with 5 ml of QF buffer and next was precipitated 
with 3.5 ml of isopropanol by centrifuged at 13,200 rpm for 30 minutes. The 
resulting DNA was washed with 2 ml 70% ethanol and spun down at 13200 
rpm for 10 minutes at 4 ºC. The DNA pellet was air-dried for 10 minutes 
before reconstituted with Nuclease-free water. The quantity and the quality of 
the plasmid DNA were evaluated by Nanodrop ND-1000. 
 
2.19 Lentivirus infection and stable cell line construction 
 
  To generate E-cadherin small hairpin RNA interference stable cell line in 
MB231 cells, 293T cell line, a human embryonic kidney cell line was used for 
lentivirus production.  6 x 10^5 cells/well of 293T cells were seeded into 
collagen I coated 6-well plate (BD Biosciences). After 18 hours, the cell 
density reached about 70 to 80% confluence. Either 4 µg of PLKO.1-E-
cadherin or PLKO.1 control together with 3 µg packaging psPAX2 plasmid 
and 1 µg pMD2.G envelope plasmid were transfected into 293T cells with the 
facilitation of 20 µl Lipofectemin 2000 (Invitrogen). After 4 to 6 hours, the 
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transfection medium was replaced with fresh culture medium.  After 48 hours, 
the medium containing the lentivirus particles was collected and filtered 
through a 0.45µm filter unit to remove the cell debris. The filtered virus 
supernatant with polybrene 8µg/ml (Sigma) was added into the wells of target 
MB231 cells, which were seeded 24 hours before virus infection. The plates 
containing virus supernatant and target cells were spun down for 45 minutes at 
1800 rpm at room temperature to facilitate the virus infection.  After 
centrifugation, the plates were incubated at 37 ºC incubator for 48 hours 
before puromycine (2µg/ml) selection. The puromycine selection was carried 
out for 2 weeks and the survival colonies were pooled and maintained in 
culture medium with puromycine (1 µg/ml). The knock down efficiency was 
verified by Western blot analysis using E-cadherin antibody. 
   
2.20 Transient transfection of small interfering RNA (siRNA) 
 
  3 x 10^5 cells/well MB-231 cells were seeded into 6-well plate 18 hour prior 
to the siRNA transfection. 5 µl of siRNA targeting either EZh2 siRNA (20 µM) 
or non-specific control siRNA and 4 µl RNAiMax (Invitrogen) were diluted in 
100 µl OPTI-MEM medium (Invitrogen) separately and incubated for 5 
minutes. The two diluents were mixed and incubated for another 20 minutes 
before adding into 800 µl P/S free culture medium containing well. The 
transfection medium was changed with fresh complete medium 4 to 6 hours 
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post transfection. After 24 hours post transfection, the transfected cells were 
reseeded for drug treatment and further analysis. EZh2 siRNA (5’-
GACUCUGAAUGCAGUUGCU-3) and non-specific control siRNA were 
purchased from 1st Base (Singapore).  
 
2.21 Chromatin Immunoprecipitation (CHIP) assay  
 
  Cells were expanded in T150 flask before harvest. Firstly, cells were fixed 
with 3.7% paraformaldehyde for 15 minutes with gentle shaking. Fixed cells 
were then neutralized by 2 mM Glycine for 5 minutes. After washes twice in 
PBS, the cells were harvested by scrapping. The cell pellets were lysed in 300 
µl SDS lysis buffer (1% SDS, 5 mM EDTA, 50 mM Tris.HCl, pH 8) on ice 
then subjected to sonication step (30 seconds on followed by 30 seconds off 
for 6 minutes). After sonication, the cell lysate was spun down at 3200 rpm for 
10 minutes at 4 ºC and the supernatant was transferred into a 15 ml Falcon 
tube containing 3 ml of dilution buffer (1% TritonX100, 2 mM EDTA, 20 mM 
TrisHCl, pH8, 150 mM NaCl). 200 µl BSA blocked Protein A beads (Zymed) 
was added into the diluted nucleate lysate and incubated for 4 hour at 4 ºC for 
preclearing. Precleared chromatin was incubated with 10 µg specific antibody 
or non-specific IgG for overnight at 4 ºC. The next day, 75 µl protein A beads 
were added into the tube and incubated for another 2 hours. 
Immunoprecipitated complex with protein A conjugated beads were spun 
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down at 1000 rpm for 3 minutes and washed with 5 ml of TSEI buffer (0.1% 
NP40, 1% Triton X100, 2 mM EDTA, 20 mM TrisHCl pH8, 150 mM NaCl) 
once, followed by 5 ml of TSEII (0.1% SDS, 1% TritonX100, 2 mM EDTA, 
20 mM TrisHCl pH8, 500 mM NaCl) once, 5 ml of Buffer III (0.25M LiCl, 
1% NP40, 1% sodium deoxycholate, 1 mM EDTA, 10 mM TrisHCl pH8) 
once, and finally in 5 ml of TE Buffer (2 mM EDTA, 10 mM TrisHCl pH8). 
Beads were washed ten minutes each time. The precipitated chromatin was 
eluted with 240 µl  SDS Elution Buffer (1% SDS, 10 mM EDTA, 50 mM 
TrisHCl pH8) and  shaked at 65 ºC for 30 minutes. After centrifuging at 1000 
rpm for 3 minutes, the supernatant was transferred and de-crosslinked at 65 ºC 
overnight. The next day, immunoprecipitated DNA was purified using PCR 
purification kit (Qiagen).  The purified DNA was quantitated by conducting 
real-time PCR using KAPA SyBr Fast qPCR kit (KAPA Biosystems). The 
enrichment of specific region of genomic DNA was assessed relative to the 
input DNA followed by normalization to the respective IgG control values. 
The following primary antibodies were used in CHIP assay. H3K4me3, 
H3K9/14ac, H3K27me3 and H3K9me3 were purchased from Upstate. The 






2.22 Total RNA extraction 
 
  Cell pellets were collected by centrifuging at 1000 rpm for 3 minutes. 0.7 ml 
QiAzol lysis reagent (Invitrogen) was added to lyse the cells followed by the 
addition of 140 µl chloroform and mixed by vortexing for 15 seconds. Next, 
centrifugation at 13,200 rpm at 4°C for 15 minutes was conducted to separate 
RNA, DNA, and proteins from the cell contents. After centrifugation, the 
upper aqueous phase (300 µl) was transferred to fresh eppendorf tube followed 
by addition of 1.5 volumes (450 µl) of 100% ethanol and mixed well. To 
purify RNA, RNeasy mini kit (Qiagen) was used. Briefly, the samples were 
transferred to the column to allow RNA binding and flow through were 
accelerated by centrifugation at 13,200 rpm for 30 seconds. Columns were 
washed once with 700 µl RWT buffer and twice with 500 µl RPE buffer. 
Finally, RNA was eluted with 40 µl RNAse-free water. RNA concentration 
and purity were assessed using Nanodrop ND-1000. 
 
2.23 cDNA conversion and quantitative real-time PCR 
 
  In order to conduct real-time PCR, total RNAs were reverse transcribed and 
converted into single-stranded complementary DNA (cDNA) using High 
Capacity cDNA Reverse Transcription Kits (Applied Biosystems). In this 
converting experiment, 1 µg of total RNA  samples were diluted into 25 µl 
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nuclease-free water and mixed with 25 µl PCR master mix containing 5 µl of 
10 x random primers , 5 µl of 10 x reverse transcription buffer, 2 µl of 25 x 
dNTPs, , and 2.5 µl of MultiScribeTM reverse transcriptase. This 50 µl mixture 
was subjected in PCR machine using the programme of 25ºC for 10 minutes, 
followed by 37ºC for 2 hours. The cDNA product can be kept at 4ºC for short 
term. 
 
  To perform semi-quantitative real-time PCR, 4.4 µl of 10-fold diluted cDNA 
samples were added together with 0.4 µl gene-specific primer mix (10 µM) to 
5 µl of 2X master mix of KAPA SYBR® FAST qPCR Kits (Kapa 
Biosystems). The reaction mix was amplified and quantified with PRISM 
7900 Sequence Detection System (Applied Biosystems) using the programme 
of 95 ºC for 3 minutes followed by 40 cycles of  95 ºC for 5 seconds and 60 ºC 
for 30 seconds. Three independent experiments were performed and samples 
were normalized to the levels of housekeeping gene18S. Data was analyzed by 
using ABI SDS 2.2 software (Applied Biosystems). The sequences of the 
primers were listed in Appendix 5. 
 
2.24 Microarray gene expression data analyses 
 
  Illumina Gene Expression Sentrix® BeadChip HumanRef-8_V3 was used to 
perform Gene expression profiling.  
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2.24.1 RNA amplification and labeling 
 
  Total RNA was isolated as described in section 2.22. Illumina® 
TotalPrepTM-96 RNA Amplification Kit was used for RNA amplification and 
labeling. 500 ng RNA diluted in 11 µl nuclease-free water was mixed with 9 
µl reverse transcription master mix containing 4 µl dNTP mix, 2 µl 10X first 
strand buffer, 1 µl RNAse inhibitor, 1 µl T7 oligo (dT) primer, and 1 µl 
ArrayScriptTM reverse transcriptase. The reaction was conducted in a PCR 
thermocycler at 42ºC for 2 hours for the first strand cDNA synthesis. To 
produce the second strand cDNA, 20 µl first stranded cDNA product was 
mixed with 80 µl second strand reaction mix consisting of 10 µl second strand 
buffer, 63 µl nuclease-free water, 4 µl dNTP mix, 1 µl RNase H and 2 µl DNA 
polymerase. The reaction was performed at 16 ºC for 2 hours. Next, 100 µl 
cDNA was mixed with 180 µl cDNA pure for the purification. The cDNA 
bound with the magnetic beads in the cDNA pure was washed with 150 µl 
cDNA wash buffer twice. After air-dry, purified cDNA was eluted with 20 µl 
prewarmed Nuclease-free water and 17.5 µl elution products were transferred 
into PCR tube for the RNA labeling. To label cRNA with Biotin, 7.5 µl master 
mix of IVT (2.5 µl T7 10 x reaction buffer, 2.5 µl biotin-NTP mix, and 2.5 µl 
T7 enzyme mix) was mixed with above 17.5 µl purified cDNA and incubated 
at  42 ºC for overnight.  Next, the biotin-labeled cRNA was purified using 
cRNA pure and finally eluted with 40 µl prewarmed cRNA elution buffer. The 
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  Before hybridization, buffer GEX-HCB and GEX-HYB were preheated at 58 
ºC for 10 minutes to dissolve the salts. 750 ng cRNA in 5 µl was mixed with 
10 µl GEX-HYB and incubated at 65ºC for 5 minutes. After cooling down to 
the room temperature, 15 µl above mixture was loaded into Illumina 8-sample 
Sentrix® BeadChip. The BeadChip was sealed into a Hyb chamber and 
incubated at 58 ºC for 18 hours for the hybridization. 
 
2.24.3 Wash and scan BeadChip 
 
  After the hybridization, the BeadChip was transferred from the Hyb chamber. 
The coverseal on BeadChip was removed in the E1BC wash buffer and the 
BeadChip was washed with High-Temp wash buffer at 55ºC for 10 minutes, 
followed by E1BC buffer 10 minutes at room temperature, 100% ethanol for 
10 minutes and lastly E1BC buffer for 10 minutes. After washes, BeadChip 
was blocked with 4 ml E1buffer for 10 minutes. After blocking, BeadChip was 
incubated with 3 ml 1:1000 diluted steptavidin-Cy3 for 10 minutes. The 
BeadChip was finally washed with E1BC buffer then subjected to air-dry by 
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centrifugation at 1000 rpm for 4 minutes. The dried BeadChip was scanned 
using Illumina BeadArray Reader. 
 
2.24.4 Gene expression profiling and Ingenuity Pathway Analysis (IPA) 
 
  The scanned images Illumina BeadArray Reade were processed using 
Illumina GenomeStudioTM and the generated data were imported into 
GeneSpringGX (Agilent Technologies) for further analysis.  Using 
GeneSpring software, Illumina single color was chosen for experimental type 
and signals were normalized to median expression. Fold changes (2 fold as a 
cut-off) were evaluated by comparison to an appropriate control. To generate 
heatmaps, normalized data log2 values were processed by Cluster using 
hierarchical analysis and visualized by Treeview software. The finalized 
genesets were imported into Ingenuity Pathway Analysis (IPA) 
(www.ingenuity.com) for gene ontology analysis. IPA results showed the 








2.25 Mouse xenografts and drug treatment 
 
  The female athymice BALB/c nude mice (5-8 week-old) were housed in the 
Biological resource Centre. Mice were implanted subcutaneously (s.c.) in both 
sides of flank with 5 x 106 MOLM-14 cells. When tumors reached around 100 
mm3, the mice were randomized into four groups (10 mice per group) and I-3 
at three different doses (30, 60 and 90mg/kg) was administered though 
intraperitoneal (i.p.) injection as qd x 5d/w for 3 weeks in these recipients, 
with vehicle treatment as the control. To monitor the tumor progression, tumor 
diameters were measured every 3-4 days with caliper and tumor volumes were 
calculated per data time point. Meanwhile, the body weight of mice was 
monitored overtime. All the raw measurements were recorded as mean ± 
SEM. Unpaired two tailed t test was used to evaluate the statistic significance. 
  The sublethally irradiated NOD/SCID mice (5-8 week-old) were used to 
evaluate the effects of I-3 on disseminated leukemic disease. 1 x 10^6 MOLM-
14 cells were transplanted into the mice through lateral tail vein injection. I-3 
(60 mg/kg) was administered through intraperitoneal (i.p.) injection two days 
after the tumor engraftment as q2d/w for 3 weeks. Body weight of mice was 
measured every 2 to 3 days. Survival analysis was performed using the 
Kaplan–Meier estimator and log-rank test. The relative hazard ratio (HR) 
between different groups was calculated based on a Cox proportional hazards 
model and is presented as HR (95% CI). Unpaired two tailed t test was used to 
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calculate the statistic significance of the body weight changes of different 
groups of mice. 
 
  The female athymice BALB/c nude mice (4- 6 week-old) were used to 
evaluate the in vivo effects of I-3 on lung metastatic MB231 subline LM2, 
also called MB231-LUC that express luciferase reporter. 1 x 10^6 MB231-
LUC cells were transplanted into the mice through lateral tail vein injection. I-
3 was administrated at day 1 following inoculation with two different 
schedules, I-3 (90mg/kg) Q2d i.p and I-3 (90mg/kg) Qd i.p. For luciferase 
labeled MB231-LUC cells, development of metastases was monitored by 
bioluminescent imaging (BLI) with the IVIS Imaging System (Xenogen) and 
analyzed with Living Image software (Xenogen). All raw measurements were 
recorded as mean ± SEM. Survival analysis was performed using the Kaplan–
Meier estimator and log-rank test. Unpaired two tailed t test was used to 
calculate the statistic significance of the body weight changes of different 
groups of mice. 
 
  All animal work above was performed in accordance with animal 
experiments guidelines of Singapore. 
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2.26 Statistical analysis 
 
  Statistical analysis of this study was performed using GraphPad PRISM. All 
values are expressed as mean ± SEM (standard error of mean) of at least three 
independent experiments. Significance was evaluated by unpaired two tailed t 


















CHAPTER 3: CHARACTERIZATION OF ANTI-

















3.1 In vitro potency of I-3 in human cancer cell lines 
 
  To profile the cellular sensitivity of I-3 in human cancer cells, a large panel 
of cancer cell lines, including 32 solid tumors cell lines and 83 blood cancer 
cell lines, was evaluated for their responses to I-3. An ATP-based cellular 
viability assay was used to evaluate the viable cell numbers based on 
quantification of the ATP present in the cells, which signals the presence of 
metabolically active cells. A half maximal effective concentration (EC50) was 
used to define the sensitivity of I-3 to individual cell lines. To calculate EC50, 
nonlinear regression sigmoidal dose response curves were generated using 
GraphPad PRISMTM. The X values were the logarithm of the concentration of 
I-3 and the Y values were response percent of DMSO control. The results 
showed that human cancer cell lines exhibited heterogenous responses to I-3, 
with some cell lines were more sensitive than others. In general, it was noticed 
that I-3 seemed to be more potent in blood cancer cell lines than in solid tumor 
cell lines. As shown in Figure 3.1, there were 9 out of total 32 of solid tumor 
cell lines (28.13%) and 65 out of 83 blood cancer cell lines (78.37%)  that had  
EC50 below 10µM (Appendix 1 and 2). It also showed that the median EC50 of 
the solid tumor cell lines was 25.1µM, which was much higher than that of 
blood cancer cell line (3.14µM). Of notice, a significant number of AML cell 
lines were found to be highly sensitive to I-3, with EC50 < 1µM. This 






Figure 3.1 EC50 profile of I-3 in human cancer cell lines  
Bar graphs showing EC50 of I-3 measured in a panel of solid (A) and blood (B) 
cancer cell lines using cell viability assay. 1000 cells of individual cell lines 
were seeded into 96-well plates in triplicates and I-3 at 10 different doses was 
added 24 hours post cell seeding. Proliferation was measured after 96 hours 
treatment of I-3 using an ATP based cell viability assay. EC50 of I-3 was 
calculated by nonlinear regression (curve fit) using GraphPad PRISM 
software. Data represent the means of EC50 of I-3 measured in three 







3.2 I-3 is more potent than HDAC inhibitor suberoylanilidehydroxamic 
acid (SAHA) and DNA methylation inhibitor 5-aza-2’-deoxycytidine 
(Decitabine, Dacogen, DAC) in AML cell lines 
 
  The response of AML to I-3 was secondarily validated by focusing on a 
panel of 10 well-established AML cell lines. Most of these AML cell lines 
were relative sensitive to I-3, with an EC50 < 1 µM. Among them, MV-4-11, 
MOLM-14 and TF-1 cells were found to be most sensitive to I-3, each with an 
EC50 < 200 nM (Figure 3.2A). To compare the potency of I-3 with other 
epigenetic drugs, SAHA and DAC, which were the FDA approved drugs for 
cancer treatment, were included for analysis. The result showed that the 
median EC50 of I-3 was much smaller than that of SAHA or DAC in the 10 
AML cell lines (Figure 3.2B). In the top three I-3 sensitive cell lines, the EC50 
for SAHA and DAC were much higher (Figure 3.2C). Therefore, we conclude 
that I-3 is more potent than SAHA and DAC in most of the 10 AML cell lines 
tested. 
 
3.3 I-3 induces apoptosis in AML cells  
 
  Next, the ability of I-3 to induce apoptosis in the above 10 AML cell lines 
was evaluated. To achieve this, fluorescence-activated cell sorting (FACS) 
based sub-G1 DNA content was measured to assess the apoptotic cell death in 
response to various doses of I-3 for 72 hours. Two groups of cell lines with 
different sensitivity were discernible. MV4-11, MOLM-14, TF-1, KG-1 and 
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Kasumi-1 were found to be sensitive to I-3 with 40 to 70% of cell death, while 
THP-1, HL-60, Mono-Mac-1and KG-1a were relatively resistant to I-3 with 
less than 30% cell death (Figure 3.3A). As increased Caspase 3 activity was a 
hall mark for apoptosis, the FACS measurement of caspase 3 activity was 
further used to confirm the apoptosis in MOLM-14 and MV4-11 cells. The 
cells were treated with various doses of I-3 for 72 hours and then stained with 
active Caspase 3 antibody followed by FACS analysis to determine the 
percentage of cells positive for active Caspase 3. The result showed that I-3 
treatment induced marked activation of Caspase 3 in the two cell lines in a 
dose dependent manner, validating the ability of I-3 for apoptosis induction in 
AML cells (Figure 3.3B).   
 
 
A                                                                      B    
 

















Figure 3.2 I-3 inhibits cell proliferation in AML 
 
A. Bar graph showing EC50 of I-3 measured in a panel of AML cell lines using 
cell viability assay. 
B. Dot plot showing EC50 of I-3, SAHA or DAC measured in the same panel 
of AML cell lines as in A using cell viability assay. The short lines represent 
the median EC50 of each compound in the AML cell line panel. 
C. Table showing EC50 (µM) of I-3, SAHA or DAC measured in the same 
panel of AML cell lines as in A and B. 
Data are mean±SEM; n = 3; *P < 0.05, **P < 0.01, ***P < 0.001, unpaired 
two tailed t test.  
 
Cell lines I-3 SAHA DAC 
MV-4-11 0.062 0.424 0.084 
MOLM-14 0.111 0.397 4.46 
TF-1 0.181 1.08 3.76 
HL 60 0.242 1.72 9.55 
KG-1 0.292 1.02 0.031 
THP-1 0.319 1.073 0.104 
Mono-Mac-1 0.318 0.578 4.083 
TF-1a 0.375 1.104 1.761 
Kasumi-1 0.416 1.205 0.072 
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Figure 3.3 I-3 induces apoptosis in AML cells 
A. Bar graphs showing sub-G1 percentage of 10 AML cell lines treated with 
indicated concentrations of I-3 for 72 hours, followed by propidium iodide 
(PI) staining and fluorescence-activated cell sorting (FACS) analysis.  
B. Bar graphs showing the percentage of cells positive for active Caspase 3 in 
MOLM-14 and MV4-11 cells treated with indicated concentrations of I-3 for 
72 hours, followed by active Caspase 3 antibody staining and FACS analysis.  
Data are mean±SEM; n = 3; *P < 0.05, **P < 0.01, ***P < 0.001, unpaired 
















3.4. I-3 suppresses the colony growth of AML cells on soft agar 
 
  To investigate whether I-3 can achieve durable growth inhibition, a 14-day 
colony growth assay on soft agar was conducted. It was found that I-3 induced 
a dramatic growth inhibition in multiple AML cell lines, including MOLM-14, 
KG-1 and HL-60. The EC50 of I-3 determined by the soft agar assay was in 
general consistent with that obtained via the previous cell viability assay as 
shown in Figure 3.2A. Collectively, these in vitro data demonstrated the robust 





Figure 3.4 I-3 suppresses the AML growth on soft agar 
Representative images of soft agar assay conducted in MOLM-14, KG-1 and 
HL-60 cells. 1000 cells were mixed with I-3 in semi-solid media and 
incubated for 2 weeks. Colony growth was assessed and EC50 of I-3 was 
calculated by nonlinear regression (curve fit) using GraphPad PRISM. EC50 of 
I-3 of each cell line was indicated in the brackets. Data represent the means of 
EC50 of I-3 measured in three independent experiments, with each experiment 




3.5. The therapeutic effect of I-3 in AML mouse models 
 
  To evaluate the anti-cancer effect of I-3 in vivo, a MOLM-14-derived 
subcutaneous xenograft tumor mouse model was used. In this model, 5 x 10^6 
of MOLM-14 cells were injected into Balb/c nude mice subcutaneously (s.c.) 
to form a tumor around 100 mm3 in size. After that, I-3 at three different doses 
(30, 60 and 90mg/kg) was administered though intraperitoneal (i.p.) injection 
as qd x 5d/w for 3 weeks in these recipients, with vehicle treatment as the 
control. I-3 administration markedly decreased tumor growth in mice in a 
dose-dependent manner (Figure 3.5A, left). Meanwhile, the body weight of 
mice was monitored overtime. It was found that I-3 at even 90mg/kg failed to 
cause significant body weight loss, suggesting that I-3 administration was well 
tolerated in these recipient mice (Figure 3.5A, right). 
 
  Subsequently, the efficacy of I-3 in a more therapeutically relevant model of 
AML was tested, in which 1 x 10^6 of MOLM-14 cells were injected through 
tail vein of sublethally irradiated NOD/SCID mice resulting in disseminated 
leukemic disease. I-3 (60mg/kg) was administered through intraperitoneal 
(i.p.) injection two days after the tumor engraftment as q2d/w for 3 weeks. The 
median survival was as follows: control (36 days); I-3 (42 days). The Kaplan–
Meier survival plots showed that AML-bearing mice treated by I-3 had 
expanded life span compared with untreated ones (Figure 3.5 B, left). As in 
112 
 
the first animal model, I-3 was well tolerated and no overt toxicity was 
observed (Figure 3.5B, right). 
 
  Taken together, our results showed that I-3 possesses potent anti-AML 
























Figure 3.5 Therapeutic effects of I-3 in AML mouse models 
A. Subcutaneous xenograft tumor growth of MOLM-14 cells in Balb/c mice 
treated with I-3. 5 x 10^6 of MOLM-14 cells were injected into mice 
subcutaneously (s.c.). I-3 at three different doses (30, 60 and 90mg/kg) was 
administered through intraperitoneal (i.p.) injection as qd x 5d/w for 3 weeks 
in these recipients from day 8 to day 23 after transplantation, with vehicle 
treatment as control. The graphs show the tumor sizes (left) and body weight 
change (right). Data are mean±SEM, *P < 0.05, **P < 0.01, ***P < 0.001, ns 
represents no significance, unpaired two tailed t test.  
B. Kaplan–Meier curves of NOD/SCID mice treated with I-3. 1 x 10^6 of 
MOLM-14 cells were injected into sublethally irradiated NOD/SCID mice 
through tail vein. I-3 (60mg/kg) was administered through i.p. injection as 
q2d/w for 3 weeks in these recipients from day 2 after transplantation, with 
vehicle treatment as control. The graphs showed the survival rate (left) and 
body weight change (right) during I-3 treatment. Data are mean±SEM, ***P < 
0.001, ns represents no significance, log-rank (Mantel-Cox) test conducted.  
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3.6 I-3 works as a selective but not specific histone methylation inhibitor 
in AML cell lines 
 
  It has been previously reported that DZNep is a histone methylation inhibitor 
that can deplete oncogenic PRC2 components and associated H3K27me3. In 
breast cancer cells, this effect has led to reactivation of EZH2 suppressed 
target genes which are associated with apoptosis, which is not seen in normal 
cells (Tan, Yang et al. 2007). To evaluate the overall effects of I-3 on histone 
lysine methylation in AML cell lines, a sensitive MOLM-14 treated with 
increasing doses of I-3 from 0.25µM to 1µM for 48 or 72hours, together with 
a resistant cell line KG-1a treated with I-3 at 5µM were harvested for Western 
blot analysis. Consistent with the above FACS-based analysis, I-3 induced 
apoptosis in MOLM-14 but not in KG-1a cells, as evidenced by showing 
increased cleavage of poly (ADP-ribose) polymerase (PARP), which is a 
Caspase 3 substrate for apoptosis. The treatment of I-3 resulted in marked 
reduction of EZH2, H3K27me3 and H4K20me3 and to lesser extent on 
H3K4me3 and H3K79me2 in a dose-dependent manner in both MOLM-14 
and KG-1a cells. In contrast, H3K9me2 and H3K9me3 were not affected by I-
3 (Figure 3.6), which is consistent with the previous report for DZNep in 
breast cancer (Tan, Yang et al. 2007) and AML cells (Zhou, Bi et al. 2011). 
Thus, like DZNep, I-3 works as a selective but not specific histone 
methylation inhibitor in AML cell lines and its inhibitory effects on bulk 
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Figure 3.6 Effects of I-3 on EZh2 and histone methylation 
 
Western blot analysis showing the level of cleaved PARP, EZh2 and a series 
of histone methylation marks in MOLM-14 and KG-1a cells treated by I-3 at 







3.7. Effects of I-3 on transcriptome in AML  
 
  Our histone methylation profile of I-3 detected by Western blot analysis 
revealed that the resistant cell phenotype was not due to the inability of I-3 to 
inhibit the suppressive marks, such as H3K27me3 and H4K20me3, as the 
inhibition of these two markers were evident in a resistant cell line KG-1a. It 
was thus hypothesized that the cellular sensitivity to I-3 may be associated 
with the differential gene expression changes between sensitive and resistant 
cell lines following the I-3 treatment. Accordingly, the genome-wide gene 
expression profiling using Illumina BeadChips System was performed in three 
sensitive (MOLM-14, MV4-11 and TF-1) and three resistant (Mono-Mac-1, 
KG-1a and THP-1) cell lines with or without I-3 treatment for 48 hours. 
Significance Analysis of Microarrays (SAM) analysis on the expression data 
identified 547 genes that were differentially expressed following I-3 treatment 
between sensitive and resistant cell lines using 10% false discovery rate (FDR) 
cutoff. Among them, 327 genes were found to be upregulated and 220 genes 
were downregulated in sensitive cell lines but not in resistant cell lines (Figure 
3.7A). To identify the pathways related to the gene expression changes, both 
upregulated and downregulated gene sets were subjected to Ingenuity pathway 
analysis (IPA). The result showed that PI3K/AKT and MEK/ERK pathways 
were implicated in both gene sets (Figure 3.7B). Aberrant activation of 
canonical survival pathways, such as the RAF/MEK/ERK and PI3K/AKT 
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cascades was frequently observed in AML (Milella, Precupanu et al. 2005; 
Kornblau, Tibes et al. 2009). Hence, IPA results raised a possibility that I-3 
may affect RAF/MEK/ERK and PI3K/AKT cascades in sensitive cell lines but 





















Figure 3.7 Significance Analysis of Microarrays (SAM) and Ingenuity 
Pathway Analysis (IPA) of differential genesets between sensitive and 
resistant cell lines  
A. A heat map of differential genesets between sensitive and resistant cell 
lines with I-3 treatment. Three sensitive (MOLM-14, MV4-11 and TF-1) and 
three resistant cell lines (Mono-Mac-1, KG-1a and THP-1) were treated with 
I-3 at 1 or 5uM for 48 hours. Total RNA was isolated for microarray and SAM 
analysis. 327 genes were up-regulated and 220 genes were down-regulated 
upon I-3 treatment in sensitive cells relative to resistant cells using 10% false 
discovery rate (FDR) cutoff. 
B. Ingenuity Pathway Analysis (IPA) of differentially up-regulated geneset 
(upper) and down-regulated geneset (lower) showing their strong connections 




3.8. Effect of I-3 on multiple oncogenic signaling pathways in AML 
 
  To validate the IPA prediction, five sensitive cell lines (MOLM-14, MV4-11, 
Kasmusi-1, KG-1 and TF-1) in parallel with the four resistant cell lines (HL-
60, Mono-Mac-1, THP-1 and KG-1a) were treated with I-3 (5µM) for 8, 24 or 
48 hours and harvested for Western blot analysis. It was found that I-3 induced 
a strong cleavage of PARP in sensitive cell lines but not in resistant cell lines, 
suggesting that I-3 triggered apoptotic cell death in AML cell lines through 
caspase activation. Downregulation of EZh2 can be found in both sensitive 
and resistant cells as expected. Furthermore, I-3 treatment induced significant 
suppression in the signaling pathways of PI3K/AKT and MEK/ERK in 
sensitive cell lines, especially in MOLM-14 and MV4-11, but not in resistant 
cell lines. The suppression of p-AKT (S473) and p-ERK (T202/204) can be 
detected as early as 8 hours and the change of signal was the strongest at 24 or 
48 hours. However, such suppression cannot be observed in resistant cell lines 
(Figure 3.8A). It is well known that aberrant upregulations of PI3K/AKT and 
MEK/ERK signaling are frequently observed in myeloid malignancies and 
function as  major oncogenic signaling pathways to promote the growth and 
survival of cancer cells. In addition to deregulated PI3K/AKT and MEK/ERK 
signaling in AML, JAK/STAT pathways were also known to play important 
roles in AML progression (Daver and Cortes 2012). The differential decreased 
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p-STAT1, p-STAT3 and p-STAT5 were also observed in sensitive cell lines 



























Figure 3.8 Effects of I-3 on multiple oncogenic signaling pathways in 
AML cell lines 
A.Western blot analysis showing the effects of I-3 on PI3K/AKT and 
MEK/ERK signaling pathways in both sensitive cell lines (left) and  resistant 
cell lines (right). The panel of AML cell lines were treated with I-3 (5uM) for 
8, 24 and 48 hours and the cells were harvested for Western blot analysis 
using p-ERK (T202/204) and p-AKT (S473) antibodies.  
B. Western blot analysis showing the effects of I-3 on JNK/STAT signaling 
pathways in both sensitive cell lines (left) and  resistant cell lines (right). The 
panel of AML cell lines were treated with I-3 (5uM) for 48 hours and the cells 
were harvested for Western blot analysis using p-STAT1, p-STAT3 and p-




  To identify the key apoptosis regulator(s), a panel of Bcl-2 family members 
(such as Bcl-2, Bcl-xL, Mcl-1, Bim, Bax, Bak, etc.) as well as several 
apoptosis related molecules (such as Survivin, XIAP, etc) were screened. It 
was found that I-3 could induce strong Bim upregulation but Survivin 
downregulation in sensitive cell lines but not in resistant cell lines. It has been 
known that Bim, encoded by the BCL2L11 gene, is a pro-apoptosis Bcl-2 
family member. There are three major isoforms of Bim due to alternative 
splicing. BimEL is the longest (22.0kDa), followed by BimL (15.8kDa), and 
BimS (12.3kDa). Our Western blot data showed that all the three Bim 
isoforms were induced by I-3 with BimS showing the most significant 
upregulation. This was consistent with the report that the three Bim isoforms 
have different pro-apoptotic potencies and BimS has the strongest potency to 
promote apoptosis (Bouillet, Zhang et al. 2001). Additionally, we found that 
an anti-apoptosis molecule, Survivin was downregulated by I-3 in almost all 
the sensitive cell lines but not in resistant cell lines (Figure 3.9A). To 
investigate whether the changes of Bim isoforms and Survivin occurred at the 
mRNA level, qRT-PCR was conducted using primer pairs targeting the 
common region of the three Bim isoforms and Survivin transcripts, 
respectively. It was found that neither Bim nor Survivin transcripts changed 
after I-3 treatment (Figure 3.9B). Therefore, we concluded that upregulation of 
BimS and downregulation of Survivin at the protein level correlated with I-3 








Figure 3.9 I-3 upregulates Bim but downregulates Survivin in sensitive 
but not resistant cell lines 
A. Western blot analysis showing the protein levels of Bim and Survivin in 
AML cell lines panel treated with I-3 for 48 hours as indicated  
B. Quantitative RT-PCR (qRT-PCR) analysis of the mRNA level of Bim and 
Survivin in MOLM-14 and MV4-11 treated with I-3 for 48 hours as indicated. 
Primers pair located at the common region of the three Bim isoforms was used 





  To validate the clinical relevance of the results observed in cell lines, primary 
cells from four AML patients were treated with I-3 (5µM) in parallel with 
MOLM-14. The dose response curves of I-3 showed that the primary cells 
from AML patients exhibited varied sensitivity to I-3 in terms of anti-
proliferation effect. The EC50 of I-3 in these four patients ranged from 0.96µM 
to 13.43µM (Figure 3.10 upper). The most sensitive patient sample AD353 
and the most resistant sample AD409 were selected along with MOLM-14 
treated by I-3 (5µM) 48hours for Western blot analysis. As expected, robust 
PARP cleavage was observed in AD353 and MOLM-14 cells but not in 
AD409. P-AKT (S473) and p-ERK (T202/204) were significantly suppressed 
in sensitive AD353 sample treated by I-3, although to a much lesser extent to 
MOLM-14 under I-3 treatment. However, there was no change or even 
slightly upregulation of p-AKT (S473) and p-ERK (T202/204) in the resistant 
cells of AD409, which was consistent with the results of resistant cell lines 
treated by I-3 (Figure 3.10 lower). Our results suggested that the changes in p-
AKT (S473) and p-ERK (T202/204) might serve as surrogate markers for 
predicting the response of I-3 to AML patients and guide the selection of 
subset of patients for I-3 treatment in the future.  
 
  Taken together, our data demonstrated that I-3 targeting multiple signaling 
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Figure 3.10 I-3 suppresses PI3K/AKT and MEK/ERK pathways in AML 
primary cells from patients  
The frozen primary AML patient blasts were recovered for 24 hours and the 
dead cells were removed using Dead Cell Removal Kit just before I-3 
treatment. The blasts were treated for 96 hours for cell viability assay and 48 
hours for Western blot analysis. The diagrams showed the drug response 
curves of AML patient blasts towards I-3 (upper), measurement of EC50  of I-3 
using cell viability assay (central) and Western blot analysis of AML patient 
blasts as well as MOLM-14 with I-3 treatment (lower) using cleaved PARP, p-
ERK (T202/204) and p-AKT (S473) antibodies. Each data point in the plots of 
drug response curves of I-3 represents the mean ±SEM of six replicates at 
each specified concentration of I-3.  
 
 























3.9 I-3 reduces CD34+CD38- leukemia stem cells (LSC) population 
enriched by chemotherapy  
 
  Since cancer stem cells in any cancers represent a small percentage, it is 
technically challenging to isolate and identify LSCs from patient samples. 
Various reports demonstrated LSCs could be isolated and enriched from 
established leukemia cell lines (Hu, Tang et al. 1999; She, Niu et al. 2012). 
TF-la, a well-established AML cell line appears to be an excellent model for 
studying human primitive myeloid progenitor cells (Hu, Moscinski et al. 
1998). In 1999, it was reported that only rare AML cells characterized by a 
CD34+/CD38- phenotype were capable of generating leukemia in immuno-
deficient mice (Lapidot, Sirard et al. 1994). Since then, increasing evidence 
demonstrated that LSCs are enriched in CD34+CD38- population in the 
majority of AML patients. In this study, TF-1a cells were stained with CD34-
APC and CD38-FTIC antibodies and subjected for FACS analysis. It was 
found that majority of TF-1a cells were CD34 high and CD38 low, which was 
consistent with the previous report (Hu, Moscinski et al. 1998). For the 
consistency of the experiments, the basal level of CD34+CD38- percentage of 
untreated TF-1a cells was set as 20% for all the experiments. TF-1a cells were 
treated with increasing doses of I-3 from 20nM to 500nM for 72 hours and 
harvested for the analysis of the change of the percentage of CD34+CD38- 
population after treatment. It was found that I-3 treatment depleted 
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CD34+CD38- population of TF-1a cells efficiently in a dose-dependent 
manner. To compare the potency of I-3 on TF-1a CD34+CD38- population 
with other epigenetic compounds, TF-1a cells were also treated with HDAC 
inhibitor SAHA or DNA methylation inhibitor decitabine (DAC) as I-3. 
Unexpectedly, it was found SAHA or DAC could even increase CD34+CD38- 





Figure 3.11 I-3 reduces the basal level of CD34+CD38- subpopulation in 
TF-1a 
Bar graphs showing FACS analysis of the proportion of CD34+CD38- 
population in TF-1a after the single treatment with I-3, SAHA or DAC as 
indicated. TF-1a cells were treated with I-3, SAHA or DAC respectively for 
72 hours. Following this, the cells were stained with CD38-FITC and CD34-
APC antibodies sequentially and then subjected to FACS analysis. Data are 





Chemotherapy is the first-line treatment option for AML patients. 
Combined treatment of cytarabine (Ara-C) with anthracycline (such as ADR) 
have remained largely unchanged for 40 years (Yates, Wallace et al. 1973). 
Although complete remissions can be achieved in almost 70% of patients, 
substantial proportion of AML patients subsequently relapse and 60% 
eventually die due to the disease (Fernandez, Sun et al. 2009; Mandelli, 
Vignetti et al. 2009). It was widely believed that AML recurrence was due to 
the resistance of LSCs towards the standard chemotherapy (Roboz and 
Guzman 2009; Goardon, Marchi et al. 2011). Hence, targeting both bulky 
blasts and LSCs are critical for eradication of the disease. To investigate the 
effect of I-3 on chemotherapy enriched LSCs, TF-1a cells were treated with 
Ara-C (20nM) or ADR (50nM) with or without I-3 (100nM) for 72 hours and 
harvested for CD34/CD38 staining and FACS analysis. The results were 
represented graphically in Figure 3.12 A. It was found that both Ara-C and 
ADR induced dramatic increases of CD34+CD38- population, while I-3 
abrogated such elevation significantly (Figure 3.12B). To rule out the 
possibility that depletion of CD34+CD38- population by I-3 was due to 
synergistic cell killing effect of I-3 with chemotherapy, DNA content was 
examined and analyzed by FACS. It was found the combined treatment of I-3 
with either ADR or Ara-C caused insignificant cell death, with sub-G1 less 
than 30% in all the treatment groups (Figure 3.12C). To investigate the long-
term effect of I-3 on the CD34+CD38- population induced by chemotherapy, 
129 
 
TF-1a cells were treated with I-3 for 14 days and it was found that I-3 could 
drastically deplete Ara-C induced CD34+CD38- population even at a low 
concentration of 20nM (Figure 3.12D). Furthermore, the potency of I-3 on 
chemotherapy induced CD34+CD38- population in TF-1a was compared with 
SAHA and DAC. It was found that I-3 was much more potent than DAC or 
SAHA to deplete CD34+CD38- population induced by Ara-C or ADR (Figure 
3.12E). We concluded that I-3 could potently diminish chemotherapy induced 
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Figure 3.12 I-3 reduces chemotherapy induced CD34+CD38- 
subpopulation in TF-1a  
 
A. Representative FACS histogram profiles of CD34+CD38- cell population 
in TF-1a cells treated with I-3 alone or combination with either Ara-C or 
ADR. TF-1a cells were treated with I-3 (100nM) for 24 hours, followed by 
Ara-C (20nM) or ADR (50nM) for 48 hours. After the treatment, the cells 
were stained with CD38-FITC and CD34-APC antibodies sequentially and 
then subjected to FACS analysis.  
B. Bar graphs showing the proportion of CD34+CD38- population in TF-1a 
treated as in A 
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C. Bar graphs showing subG1 percentage of TF-1a cells treated as in (A). Cell 
death was measured by PI staining and FACS analysis.  
D. Bar graphs showing the proportion of CD34+CD38- population in TF-1a 
treated with I-3 (20nM) with or without Ara-C (20nM) for 14 days.  
E. Bar graphs showing the percentage of CD34+CD38- cell population in TF-
1a cells with I-3 (100nM), SAHA (100nM) or DAC (100nM) alone or 
combination with Ara-C (100nM) or ADR (50nM).  
Data are mean±SEM; n = 3; *P < 0.05, **P < 0.01, ***P < 0.001, unpaired 

















3.10 I-3 inhibits the colony forming capacity of LSCs in vitro 
 
  In addition to phenotypic study above, colony-forming-unit (CFU) assay was 
performed to functionally evaluate I-3 effects on LSCs. CFU assay is known 
as a golden standarded in vitro assay to study hematopoietic stem/progenitor 
cells and it is also considered as a commonly used assay for Leukemia 
stem/progenitor cells. Basically, CFU assay is performed by plating single cell 
suspension at low cell density in methylcellulose-based medium supplemented 
with appropriate combinations of cytokines, which support the proliferation 
and differentiation of individual progenitor cells, resulting in the formation of 
discrete colonies. TF-1a cells were treated with I-3 100nM with or without 
chemotherapys (Ara-C 20nM or ADR 20nM) for 2 weeks. During this period, 
the dead cells under each condition were removed by using Dead Cell 
Removal Kit (Miltenyi Biotec) and only surviving cells with equal numbers 
were seeded for CFU assay for each treatment condition. As expectedly, it was 
found that there were more colonies formed after Ara-C or ADR treatment 
than untreated control, which was consistent with the perception that LSC are 
more resistant to chemotherapy than the bulk leukemic blasts (Goardon, 
Marchi et al. 2011). More strikingly, it was observed that I-3 significantly 
inhibited Ara-C or ADR enriched colonies, which reinforced the hypothesis 
that I-3 targeted LSC by inhibiting colony formation capacity of TF-1a cells in 
a long-term basis (Figure 3.13A). Under the same condition, SAHA showed 
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no effect at all to diminish chemotherapy-enriched colony forming units. 
Interestingly, DAC exerted stronger inhibitory effect on the colony formation 
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Figure 3.13 I-3 inhibits chemotherapy induced Colony Formation Units 
(CFU) in vitro 
 
A. Colony Formation Unit (CFU) assay showing the effects of I-3 on basal or 
chemotherapy induced colony formation capacity of TF-1a cells. TF-1a cells 
were treated with I-3 (100nM), ADR (20nM), Ara-C (20nM) alone or 
combination for 2 weeks. The medium and drugs were replenished every 3 to 
4 days and the dead cells were removed by Dead Cell Removal Kit. 1 x 10^3 
live cells were seeded with semi-solid colony formation medium and 
incubated for 2 weeks before enumeration. Representative images of the 
colony formation of TF-1a were shown on the left and bar graphs were shown 
on the right for the colony numbers.  
B. Colony Formation Unit (CFU) assay showing the representative images of 
the colony formation showing the effects of I-3, SAHA or DAC on basal or 
chemotherapy induced colony formation capacity of TF-1a cells. TF-1a cells 
were treated as in A.   
C. Bar graphs showing the colony numbers as in B.  
Data are mean±SEM; n = 3; *P < 0.05, **P < 0.01, ***P < 0.001, ns means no 








3.11 I-3 abrogates chemotherapy-induced mesenchymal-like conversion in 
TF-1a cells 
 
Interestingly, a rapid emergence of a small proportion of TF-1a cells with 
spread morphology was observed after even 24 hours of Ara-C treatment. 
More importantly, the mesenchymal-like conversion induced by Ara-C was 
depleted completely by the treatment of I-3 at 100nM (Figure 3.14A). Since 
the mesenchymal phenotypic switches coincide with increased metastasis of 
cancer cells (Thiery 2002; Kang and Massague 2004), the migration, invasion 
and cell adhesion capacity of TF-1a cells were evaluated. It was found that 
Ara-C triggered a significant number of migratory and invasive cells, while I-3 
abrogated this chemotherapy induced motility and aggressiveness efficiently 
(Figure 3.14B, left and central). The comparison of I-3 with SAHA or DAC 
was conducted and it was found that SAHA had no effects of anti-migration or 
anti-invasion of TF-1a at all and DAC exerted significant although with milder 
effects (Figure 3.14C). There are accumulating evidences indicating that 
increased adhesion is associated with a highly migratory and invasive 
phenotype (Huttenlocher and Horwitz 2011). Our data also showed that I-3 






           
 














Figure 3.14 I-3 abrogates chemotherapy induced mesenchymal-like 
conversion in TF-1a  
 
A. Representative images of TF-1a cells treated with I-3 alone or combination 
with Ara-C. TF-1a cells were treated with I-3 (100nM) for 24 hours, followed 
by Ara-C (50nM) for 48 hours. 
B. Bar graphs showing transwell migration assay (left), invasion assays 
(central) and adhesion assays (right) conducted on TF-1a cells treated as in A. 
C. Bar graphs showing transwell migration assay (left) and invasion assays 
(right) conducted on TF-1a cells treated with I-3, SAHA or DAC with or 
without Ara-C.   
Data are mean±SEM; n = 3; *P < 0.05, **P < 0.01, ***P < 0.001, ns means no 







3.12 I-3 inhibits chemotherapy induced adhesion molecules in TF-1a cells 
 
  To further characterize the underlying mechanism how I-3 targeted 
chemotherapy induced leukemia stem cells (LSC) subpopulation in TF-1a 
cells, a common set of genes induced by chemotherapy, which can be 
suppressed by I-3 in CD34+CD38- TF-1a cells was sought to be determined. 
To this end, TF-1a cells were first undergone CD38 negative selection 
followed by CD34 positive selection. It was found the percentage of 
CD34+CD38- cells was enriched significantly from 20% (unsorted) to nearly 
50% after the double selection (Figure 3.15A). The double-selected TF-1a 
cells (CD34+CD38-, also labeled as CD34+ in short) were treated with I-3 
(100nM) for 24 hours, followed by Ara-C (50nM) for 48 hours. Next, the cells 
were stained with CD38-FITC and CD34-APC antibodies for FACS analysis. 
It was found that Ara-C further induced an increase of CD34+CD38- 
population from 50% to 80% while I-3 dramatically diminished this 
upregulation to around 10% in CD34+ TF-1a cells.  Similarly, there were 
increases of CD34+CD38- population by Ara-C and decrease by I-3 in both 
unsorted cells and CD34- cells (Figure 3.15B). To further characterize CD34+ 
TF-1a cells, a growth assay and DNA content analysis by PI staining were 
performed in CD34+ cells in parallel with unsorted (US) and CD34- cells. The 
relatively higher percentage of G1 phase in CD34+ cell (42.22%) compared 
with the ones in US (37.83%) and CD34- cells (30.38%) (Figure 3.15D) may 
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explain the relatively slower growth rate of CD34+ cells compared with US 
and CD34- cells (Figure 3.15C). Our observation that CD34+ TF-1a cells 
grow much slower than US and CD34- cells was consistent with the reports 
that cancer stem cells have a slow rate of cell turnover (Lapidot, Sirard et al. 
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A. Representative FACS profiles of three populations in TF-1a cells, before 
sorting (unsort), after CD34 positive (CD34+) or CD34 negative sorting 
(CD34-) using MACS® Separations system.  
B. Bar graphs showing percentage of CD34+CD38- cell population in 
unsorted (US), CD34+ and CD34- TF-1a cell populations treated with I-3 
(100nM) with or without Ara-C (50nM) for 72 hours.   
C. Growth curves of unsorted (US), CD34+ and CD34- TF-1a cell populations 
without any treatments up to 8 days. 
D. A diagram showing the DNA content profiles of unsorted (US), CD34+ 
and CD34- TF-1a cells populations without any treatments. 
 
 













  CD34+ TF-1a cells were treated with I-3 (100nM) for 24 hours followed by 
Ara-C or ADR (50nM) for 48 hours and harvested for microarray to analyze 
the global changes of gene expression. Using GeneSpring software, 2495 
genes were found to be up-regulated in the geneset of Ara-C vs. I-3+Ara-C; 
2506 genes were up-regulated in the geneset of Ara-C vs. I-3; 2592 genes 
were up-regulated in the geneset of Ara-C vs. DMSO. Using Venn diagram, 
1868 genes were commonly up-regulated in the three genesets as mentioned 
above (Figure 3.16A). These 1868 genes were considered to be induced by 
Ara-C that can also be repressed by I-3. Subsequently, we followed the same 
strategy to uncover a set of 1198 ADR induced genes (Figure 3.16B). Using 
Venn diagram, Ara-C induced geneset was overlapped with ADR induced 
geneset to obtain a common set of 720 genes termed as chemotherapy induced 
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Figure 3.16 Venn diagram analyses of the common geneset induced by 
Ara-C and ADR in CD34+ TF-1a cells  
 
A. Venn diagram showing 1868 overlapping genes of the three genesets as 
indicated to obtain Ara-C upregulated genes in CD34+ TF-1a cells. Cells were 
treated with I-3 (100nM) for 24 hours with or without Ara-C (50nM) for the 
following 48 hours and gene expression was profiled using Illumina 
BeadArray system. 2495 genes were up-regulated in the geneset of Ara-C vs. 
I-3+Ara-C; 2506 genes were up-regulated in the geneset of Ara-C vs. I-3; 
2592 genes were up-regulated in the geneset of Ara-C vs. DMSO; 1868 genes 
were commonly up-regulated in the three genesets; cut-off: 2   
B. Venn diagram showing 1198 overlapping genes of the three genesets as 
indicated to obtain ADR upregulated genes in CD34+ TF-1a cells. Cells were 
treated with I-3 (100nM) 24 hours with or without ADR (50nM) for the 
following 48 hours and gene expression was profiled using Illumina 
BeadArray system. 1539 genes were up-regulated in the geneset of ADR vs. I-
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3+ADR; 1588 genes were up-regulated in the geneset of ADR vs. I-3; 1557 
genes were up-regulated in the geneset of ADR vs. DMSO; 1198 genes were 
commonly up-regulated in the three genesets; cut-off: 2 
C. A Venn diagram showing 720 overlapping genes of Ara-C upregulated 






































  These 720 genes were subjected to Ingenuity Pathway Analysis (IPA) and it 
was found that the categories of “Cellular Movement” and “Cell-To-Cell 
Signaling and Interaction” appeared among the top five “Bio Functions” 
(Figure 3.17A). Among the top ten canonical pathways which were 
significantly associated with chemotherapy response, “Leukocytes 
Extravasation Signaling”, “IL-8 Signaling” and “Integrin Signaling” were of 
particular interests (Figure 3.17B). The networks analysis indicated that 
integrins and AKT signaling pathways were highly associated with 
chemotherapy induced geneset (Figure 3.17C). Additionally, other signaling 
pathways, such as NF-κB, ERK, and STAT5 have also been implicated with 
chemotherapy responsive genes by IPA (data not shown). All of these 
suggested signaling pathways have been implicated in tumor growth, 
metastasis, drug resistance, cancer recurrence and cancer stem cells. The 
successful mitigation of the malignant signaling triggered by chemotherapy in 






















Figure 3.17 Ingenuity Pathway Analysis (IPA) of chemotherapy induced 
geneset  
A. The diagram showing the top five Bio Functions of commonly upregulated 
720 genes by Ara-C and ADR suggested by IPA.  
B. The diagram showing the top ten canonical pathways of commonly 
upregulated 720 genes by Ara-C and ADR suggested by IPA.  
C. The diagrams showing Integrins and AKT are highly associated networks 












Accumulating evidence has suggested that leukemic cancer cells in contact 
with bone marrow (BM) stromal cells and extracellular matrix (ECM) 
components may acquire resistance to chemotherapy by a process known as 
cell adhesion-mediated drug resistance (CAM-DR) (Li and Dalton 2006). The 
most characterized adhesion molecules are integrins (ITGs). The majority of 
integrins bind to ECM proteins, such as fibronectin (encoded by gene FN1), 
collagen and laminin, etc. Integrins have long been implicated in cell 
adhesion, cell activation, cell motility and tumor invasion (Pulido, Elices et al. 
1991; Jensen, Belch et al. 1993). The microarray data showed that multiple 
members of integrins (both α and β subunits) were found to be upregulated by 
chemotherapy, which was consistent with the reports that chemotherapy 
induced overexpression of integrin subunits that mediate chemoresistance via 
cellular adhesion (Damiano, Cress et al. 1999; Damiano and Dalton 2000). 
Our microarray results revealed that I-3 single treatment decreased the level of 
integrins, while Ara-C triggered a dramatic rise of integrins expression. More 
importantly, Ara-C induced integrins upregulation can be suppressed by I-3 
efficiently (Figure 3.18A, left). Also, multiple ECM ligands of integrins, 
especially laminin family exhibited similar expression pattern as integrins 
based on microarray data (Figure 3.18A, right). 
 
  To validate the microassay results, qRT-PCR validation of 20 representative 
genes were performed using primers detecting multiple members of integins, 
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series of other adhesion molecules (such as FN1, laminins, collagens, CDH1, 
CD44, PECAM1, ICAM1, ECM1 and VCAN, etc), various cytokines, 
chemokines and numerous matrix metalloproteases (MMPs) (such as CCL5, 
CCL23, IL-8, MMP-2 and MMP-9) as well as EMT related genes (such as 
TGFBI and FN1) which have been implicated in cancer progression, 
metastasis and drug resistance. It was found the majority of these tested 
molecules were induced by Ara-C and such elevation was markedly 
suppressed by I-3 (Figure 3.18C). Of note, CD44, which is a cell-surface 
glycoprotein involved in cell–cell interactions and is highly expressed in 
breast cancer stem cells (Jensen, Belch et al. 1993) has also been recognized 
as a key regulator of AML LSCs (Jensen, Belch et al. 1993). It was found that 
CD44 was upregulated by Ara-C while downregulated by I-3. Cellular 
membrane staining of CD44 and FACS analysis confirmed the expression 
pattern of CD44 at protein level (Figure 3.18B).  
 
  Collectively, it was found that I-3, which simultaneously target both AML 
bulky blasts and CD34+CD38- LSCs enriched cells as well as the tumor 









                                     









Figure 3.18 I-3 abrogates chemotherapy induced multiple cell-cell and 
cell-ECM interacting molecules 
 
A. Bar graphs showing averaged normalized expression values of 46 Integrins 
(left) and 24 Laminins (right) from microarray data of CD34+ TF-1a cells 
treated with I-3 (100nM) with or without Ara-C (50nM) for 72hours 
B. Bar graph showing the percentage of CD44+CD24+ cells in CD34+ TF-1a 
cells treated as in A through FACS analysis 
C. Bar graphs showing qRT-PCR validation of 20 representative genes as 






  In this study, various anti-AML effects of I-3 including growth inhibition, 
pro-apoptosis, eliminating Leukemia Stem Cells (LSCs) and targeting drug 
resistance were evaluated. It was found that I-3 exhibited strong inhibition on 
cell growth and induced robust apoptotic cell death through significant 
suppression of multiple oncogenic signaling pathways, such as PI3K/AKT, 
MEK/ERK, etc. Downregulation of Survivin and upregulation of BimS at 
protein level were correlated with I-3 sensitivity in AML cell lines. 
Interestingly, we demonstrated I-3 efficiently abrogated chemotherapy 
enriched LSCs by inhibiting the LSC colony forming capacity and may also 
inhibit chemotherapy induced drug resistance through the perturbation of LSC 
cell adhesion in bone marrow niches. Our results demonstrated the unique 
features of I-3 as a novel chromatin remodeling compound and suggested that 
targeting both bulk leukemic cells and leukemia stem cells by I-3 may 

















CHAPTER 4: ANTI-CANCER EFFECTS OF I-3 IN 












4.1 Effect of I-3 on EMT and E-cadherin expression of breast cancer 
MDA-MB-231 cells 
 
  The previous study in our lab has shown that breast cancer cell lines 
exhibited a varied sensitivity to DZNep.  While the estrogen receptor (ER) 
positive luminal type cell lines like MCF-7, MDA-MB-468, SK-BR-3, and 
T47D are sensitive to DZNep-induced apoptosis, ER negative basal-like cell 
lines like MDA-MB-231 and BT549 are resistant to DZNep (Sun, Chan et al. 
2009). As basal-like breast cancer cells are highly invasive and metastatic, 
which is highly associated with the epithelial-mesenchymal-transition (EMT), 
the ability of I-3 to affect EMT, invasion, and metastasis of f breast cancer 
cells both in vitro and in vivo was evaluated.  
 
  MDA-MB-231 (thereafter called MB231) is a mesenchymal-like aggressive 
breast cancer cell line that is most invasive and metastatic among the breast 
cancer cell lines and thus is often used to study breast cancer invasion and 
metastasis. MB231 cell adopts a spindled-like morphology with a bipolar 
shape and extended protrusions at both ends of the body. After I-3 (5µM) 
treatment, MB231cells exhibited cobble stone-like epithelial morphology, 
indicative of reverse of EMT. In contrast, a control compound, named K1, 
which has a similar structure as I-3 but does not have a DZNep-like activity, 
as determined by the previous SAR analysis, failed to induce the reversal of 
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EMT (Figure 4.1A). Consistent with the morphological changes, I-3 induced 
the expression of epithelial marker E-cadherin expression in MB231 cells 
(Figure 4.1B).   
 
              A 
 
                                         B 
 
 
Figure 4.1 Effect of I-3 on EMT and E-cadherin expression in MB231 
cells 
 
A. Representative images showing that I-3 (5µM) for 72 hours results in 
dramatic morphological changes in MB231 cells, while the inactive analog K-
1 could not. 
B. Western blot analysis showing the expression levels of E-cadherin in 




4.2 Effects of I-3 on invasion and migration of MB231 cells in vitro 
 
  Since EMT is associated with invasion, migration and metastasis, the in vitro 
effects of I-3 on invasion and migration of MB231 cells were further 
determined. The result shows that I-3 treatment impaired the migration and 
invasion capabilities of MB231 in a dose dependent manner (Figure 4.2).  
 
 
   
 
 
Figure 4.2 I-3 inhibits migration and invasiveness of MB231 in vitro 
Migration (left) and invasion (right) assay showing I-3 inhibits the motility 







4.3 Effects of I-3 in breast cancer metastasis in vivo  
 
  To test the therapeutic potential of I-3 as an anti-metastasis agent, a lung 
metastatic MB231 subline (LM2) (also called MB231-LUC) that express 
luciferase reporter was employed. Tail vein injection of 1 x 10^6 MB231-LUC 
cells resulted in lung metastasis in nude mice. I-3 was administrated at day 1 
following inoculation with two different schedules, I-3 (90mg/kg) Q2d i.p and 
I-3 (90mg/kg) Qd i.p. Bioluminescent imaging (BLI) measurement revealed 
significant reduction in lung metastasis under I-3 treatment with either 
schedule compared with controls at week 5 after injection of MB231-LUC 
(Figure 4.3 A, B) without significant body weight loss (Figure 4.3 D). 
Interestingly, the schedule of I-3 Qd appeared more efficacious to inhibit lung 
metastasis compared with I-3 Q2d. The reduced metastasis provided a 
significant survival advantage in the recipient mice. I-3 Qd treatment more 
significantly prolonged survival of mice than I-3 Q2d (Figure 4.3 C), which 
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Figure 4.3 I-3 treatment inhibits MB231 lung metastasis in mice 
 
A. BLI curves of lung metastasis development in BALB/c nude mice injected 
via the lateral tail vein with 1x10^6 MB231 LUC. I-3 (90mg/kg) was 
administrated (i.p.) as indicated.  
B. Representative BLI images of mice at 5 wk post injection from A.  
C. Kaplan–Meier analysis of mice from A.  
D. Body weight change of mice from A.  
Data are mean±SEM, *P < 0.05, **P < 0.01, ***P < 0.001, ns means no 
significance, unpaired two tailed t test conducted for A; log-rank (Mantel-





4.4 The suppression of E-cadherin is associated with histone modifications 
in MB231 
 
Loss of E-cadherin is the hallmark of EMT and previous studies have 
identified a number of epigenetic mechanisms leading to E-cadherin 
repression in cancer cells, including EMT-inducing transcription repressors, 
DNA methylation, and PRC2 repression. To determine the mechanism of E-
cadherin repression in MB231 cells, chromatin immunoprecipitation (CHIP) 
assay coupled with quantitative PCR were utilized to evaluate the chromatin 
state of E-cadherin locus. Epithelial like MCF7 cells that expressed a high 
level of E-cadherin (Figure 4.4 A), was used as a control. A panel of nine pairs 
of primers covering a > 6kb region across the transcription start site (TSS) of 
E-cadherin was used to evaluate the presence of H3 marks (Figure 4.4 B), 
such as the active marks H3K9/14ac (H3AC) and H3K4me3 as well as the 
repressive marks H3K27me3 and H3K9me3. The results revealed that the two 
activating marks H3K9/14ac (H3AC) and H3K4me3 were highly enriched in 
the E-cadherin promoter of MCF7, while the repressive marks H3K27me3 and 
H3K9me3 were almost absent. In contrast, the E-cadherin promoter of MB231 
exhibited much lower occupancy of the two active markers but higher 
enrichment of repressive markers compared with MCF7 (Figure 4.4C). In 
other words, the repressive chromatin structure enriched with H3K27me3 and 
H3K9me3 marks correlated with repression of E-cadherin in MB231 cells. 
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Conversely, the active chromatin status with abundant enrichment of 
H3K9/14ac (H3AC) and H3K4me3 correlated with high expression of E-
cadherin in MCF7. Of further notice, the E-cad promoter carries a typical 
bivalent histone methylation state, namely H3K4me3 and H3K27me3, which 
is associated with a low level of gene expression (Jiang, Tan et al. 2008; Sun, 
Chan et al. 2009).  
 
 
                                            
 

















Figure 4.4 E-cadherin promoter of MB-231 is regulated through histone 
modifications  
A. RT-PCR data showing E-cadherin is suppressed in MB231 but highly 
expressed in MCF7. 
B. Diagram showing the nine primer pairs located 4k surrounding the 
transcription start site of E-cadherin for CHIP assay. 
C. CHIP assay showing the occupancy of four histone 3 (H3) marks including 
H3K9/14ac (H3AC), H3K4me3, H3K9me3 and H3K27me3 on E-cadherin 
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4.5 I-3 synergies with HDAC inhibitor SAHA to induce reversal of EMT 
and E-cadherin induction 
 
  The above ChIP analysis suggested a bivalent chromatin markers associated 
with the E-cadherin repression in MB231 cells. As we have previously shown 
that genes repressed by a bivalent chromatin is highly sensitive to a combined 
treatment of DZNep and HDAC inhibitor (Jiang, Tan et al. 2008; Sun, Chan et 
al. 2009; Yang, Karuturi et al. 2009), the combinatorial effects of a low dose 
of I-3 in combination with SAHA was further investigated. The result showed 
that I-3 at 1µM synergized significantly with HDAC inhibitor SAHA at 1µM 
to induce a remarkable reversal of epithelial-mesenchymal-transition (EMT). 
These cells became large and flat with compact cell-cell interaction (Figure 
4.5A). As expected, E-cadherin was synergistically induced by I-3 (1µM) 
combined with SAHA (1µM) both at mRNA level (Figure 4.5B) and protein 
level (Figure 4.5C). The induction of E-cadherin was also verified by 
immunofluorescent confocal analysis, which shows a strong detection of E-
cadherin localized both in cytosol and cellular membrane upon the combined 
treatment of I-3 with SAHA (Figure 4.5D). 
 
It is well-established that E-cadherin can be repressed by multiple 
transcriptional repressors, such as SNAI1, Slug, ZEB1, ZEB2, TWIST 1, 
TWIST2, etc., which target E-cadherin promoter (Kang and Massague 2004; 
Peinado, Olmeda et al. 2007). Series of reported transcriptional repressors of 
E-cadherin were evaluated and it was found that none of them was affected 
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significantly by the combined treatment of I-3 with SAHA (Figure 4.5B). This 
suggested that reactivation of E-cadherin by the combination treatment was 
not a result of modulating these repressors of E-cadherin. Moreover, the two 
main mesenchymal markers Vimentin and Fibronectin remained largely 
unchanged (Figure 4.5C). 
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Figure 4.5 Combination of I-3 with SAHA induces dramatic 
morphological changes of a reversal of EMT and E-cadherin induction in 
MB231 cells  
 
A. Representative images showing that I-3 (1µM) for 24 hours followed by 
SAHA (1µM) for 48 hours results in marked morphological changes in 
MB231 cells.  
B. qRT-PCR analysis of the expressions of a series of EMT markers and 
regulators in MB231 cells treated with I-3 with or without SAHA.  
C. Western blot analysis showing the expression levels of E-cadherin, 
Vimentin and SLUG in MB231 cells treated with I-3 in combination with 
SAHA for 48 or 72 hours.  
D. Immunofluorescent confocal microscopy showing cellular membrane 
localization of E-cadherin in MB231 cells treated with I-3 with or without 
SAHA. E-cadherin was probed with anti-E-cadherin antibody (green) and 











4.6 The combination of I-3 and SAHA induces greater inhibition on 
invasive and migration which is in part through E-cadherin induction 
   
  Consistent with the combinatorial effects of I-3 and SAHA on EMT and E-
cadherin, I-3 combined with SAHA caused greater inhibitory effects on 
MB231 migration and invasion capacity (Figure 4.6A). To validate a 
functional role of E-cadherin in this process, stable MB231 cell lines that 
express an E-cadherin shRNA or a negative control shRNA through lentivirus 
transduction were constructed. As shown in Figure 4.6B, E-cadherin induction 
by the combination treatment was markedly abolished in E-cadherin shRNA 
cells as compared with the control shRNA (shNC) cells. Accordingly, both the 
anti-migratory and anti-invasive efficacy of the combined treatment of I-3 
with SAHA was compromised in shE-cad MB231 cells (Figure 4.6C), 
suggesting E-cadherin induction played at least a partial role in the anti-












                                        




Figure 4.6 Combination of I-3 with SAHA attenuates migration and 






A. Migration (left) and invasion (right) assays showing I-3 combined with 
SAHA synergistically impairs the motility and invasiveness of MB231 cells in 
vitro 
B. Western blot analysis showing knockdown efficiency of shRNA of E-
cadherin in MB231 cells. E-cadherin can be induced by the combined 
treatment of I-3 with SAHA in shNC cells but not shE-cad cells. 
C. Migration (left) and invasion (right) assays showing the inhibition of 
metastasis capacity of MB231 cells in vitro by the combined treatment of I-3 
with SAHA can be restored in part through the knock down of E-cadherin. 
Data are mean±SEM; n = 3; *P < 0.05, **P < 0.01, ***P < 0.001, unpaired 



















  In this study, MB231, a highly aggressive breast cancer cell line, has been 
used to evaluate whether I-3 alone or combined with HDAC inhibitor SAHA 
can affect its invasive capacity. It was found I-3 alone significantly induced 
reversal of epithelial-mesenchymal-transition (EMT) and consequently 
inhibited the metastatic property of MB231 both in vitro and in vivo in a dose 
dependent manner. E-cadherin, the most important epithelial marker, was 
found significantly induced by I-3 at both mRNA and protein level. Our 
results also suggested that the chromatin status was associated with E-cadherin 
repression in MB231. It was found that the repressive marks H3K27me3 and 
H3K9me3 were highly enriched in E-cadherin promoter region, whereas the 
two major activating marks H3K9/14ac and H3K4me3 were absent, 
suggesting that the repression of E-cadherin in MB231 was probably regulated 
through histone methylation and histone deacetylation.  
 
  Since it was found that the E-cad promoter in MB231 cells carried a typical 
bivalent histone methylation state (namely H3K4me3 and H3K27me3), E-
cadherin would probably be highly sensitive to a combined treatment of I-3 
and HDAC inhibitor SAHA. It was found that combination of I-3 with SAHA 
synergistically induced E-cadherin and significantly inhibited the invasiveness 
of MB231 cells in vitro. The anti-invasive efficacy of I-3 combined with 
171 
 
SAHA was compromised after E-cadherin knock-down. Our findings 
demonstrated the importance of targeting E-cadherin in metastatic breast 
cancers and underscored the feasibility of combinatorial treatment of I-3 with 








































  We have previously reported that DZNep is a histone methylation inhibitor 
that can deplete oncogenic PRC2 complex and induce strong apoptosis in 
cancer cells but not in normal cells. To develop DZNep analogues toward 
druggability, we have collaborated with ICES (Institute of Chemical and 
Engineering Sciences of Singapore) to develop DZNep analogues through 
phenotype-based structure and activity relationship (SAR) analysis. This 
collaboration led to a number of DZNep analogues that have shown promising 
results. One of these compounds, named I-3, showed comparable cellular 
activity with DZNep but much lower toxicity in mice. My project aims to 
characterize the anti-cancer effects of I-3 in various cancer models, 
particularly in acute myeloid leukemia (AML) and aggressive breast cancer, 
and to understand its mechanisms in growth inhibition, pro-apoptosis, 
targeting leukemia stem Cells (LSCs), as well as inhibiting chemoresistance 
and metastasis. 
 
5.1 I-3 inhibits bulk blasts of AML 
  Acute myeloid leukemia (AML) is characterized by clonal expansion of 
immature malignant myeloid hematopoietic cells. AML is the most common 
acute leukemia affecting adults, and its incidence increases with age. Although 
chemotherapy is capable of producing complete remission (CR) in almost 70% 
of patients, many of them will ultimately relapse and succumb to their disease. 
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Thus, there is great necessity to develop novel therapeutics for AML, such as 
targeted therapy and epigenetic therapy. One of the aims of this study is to test 
the anti-cancer efficacy of I-3 in AML using both in vitro and in vivo mouse 
models.  The results showed that I-3 was able to induce robust anti-
proliferative and pro-apoptotic effects in multiple AML cell lines and primary 
AML cells from patients. Consistent with DZNep, I-3 resulted in marked 
reduction of EZH2 and a series of bulk histone methylation marks such as 
H3K27me3 and H4K20me3 and to lesser extent on H3K4me3 and H3K79me2 
in both sensitive MOLM-14 and resistant KG-1a cells (Tan, Yang et al. 2007; 
Zhou, Bi et al. 2011). Thus, like DZNep, I-3 worked as a selective but not 
specific histone methylation inhibitor in AML cell lines. Since we have 
observed I-3 inhibitory effects on bulk histone methylations in both I-3 
sensitive and resistant AML cell lines, we reasoned that the global histone 
methylation inhibition effect of I-3 may not be the primary mechanism 
responsible for the differential responsiveness of AML cells to I-3. We thus 
hypothesized that the cellular sensitivity to I-3 may be associated with 
differential gene expression changes between sensitive and resistant cell lines 
following the I-3 treatment. The genome-wide gene expression profiling 
revealed that I-3 elicited a comprehensive gene expression changes linked to a 
number of oncogenic signaling pathways (such as PI3K/AKT, MEK/ERK and 
JAK/STATs) whose inhibition seemed to be correlated with its sensitivity in 
both AML cell lines and primary AML cells. Acting as a histone methylation 
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inhibitor, I-3 probably specifically inhibited the histone methylation of the 
chromatin of the differential genesets in sensitive cells but not in resistant 
cells, which needs to be verified by ChIP-seq. Interestingly, downregulation of 
Survivin and upregulation of Bim at the protein level but not transcriptional 
level were also correlated with I-3 sensitivity in AML cells, suggesting the 
complexity of mode-of-action of I-3 to target AML. Thus, it is possible that 
the anti-cancer effect of I-3 in AML may arise from its effects on multiple 
oncogenic signaling pathways, leading to apoptotic response through a 
concomitant downregulation of Survivin and upregulation of Bim. Although 
more AML patient samples are needed to consolidate this finding, our results 
suggested that the changes in p-AKT (S473) and p-ERK (T202/204) as well as 
the upregulation of Bim and the downregulation of Survivin in response to I-3 
in an ex vivo test might serve as surrogate markers for evaluating the response 
of I-3 to AML patients. Moreover, this panel of putative biomarkers may also 
provide values for guiding the AML patient selection for I-3 treatment in the 
future. 
 
5.2 I-3 targets LSCs and chemoresistance in AML 
  Furthermore, I-3 also targeted leukemia stem cells (LSCs) in AML. It is 
generally accepted that LSCs are enriched in CD34+CD38- population in the 
majority of AML patients and LSCs are considered to contribute to disease 
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progression and relapse (Matsunaga, Takemoto et al. 2003; Dean, Fojo et al. 
2005). I-3 could efficiently reduce chemotherapy-induced CD34+CD38- 
population in TF-1a cells and functionally inhibit the colony forming capacity 
of LSCs in vitro.  
 
  Numerous studies reported that EMT crosstalks with metastasis, cancer stem 
cell and drug resistance (Mani, Guo et al. 2008; Ahmed, Abubaker et al. 2010; 
Wang, Li et al. 2011). A recent study has described the existence of a small 
population of leukemic cells that exhibit a stemness EMT-like phenotype and 
responsible for drug resistance in chronic myelogenous leukemia (CML) 
(Puissant, Dufies et al. 2012). Consistently, in our study, it was found that the 
chemotherapy agent Ara-C triggered a rapid emergence of a subpopulation of 
TF-1a cells with mesenchymal properties such as increased adhesion, motility 
and invasiveness. More importantly, it was found that I-3 significantly 
abrogate this EMT-like conversion as well as cell adhesion, migration and 
invasive properties induced by chemotherapy. 
 
  Accumulating evidences suggest that leukemic stem cells (LSCs) in contact 
with bone marrow (BM) stromal cells and extracellular matrix (ECM) 
components may acquire resistance to chemotherapy by a process known as 
cell adhesion-mediated drug resistance (CAM-DR). It was further 
demonstrated that CAM-DR as a process resulting from chemotherapy 
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induced overexpression of integrin subunits that mediate chemoresistance via 
cellular adhesion (Damiano, Cress et al. 1999; Damiano and Dalton 2000). 
Ligand binding induces integrin clustering that forms the multi-protein 
complex necessary to activate the multiple signaling pathways (i.e. FAK and 
ILK pathways and the downstream signaling such as MEK/ERK and 
PI3K/AKT) involved in cell survival, migration, cell cycle progression and 
gene transcription etc (Miyamoto, Teramoto et al. 1996; Matsunaga, 
Takemoto et al. 2003). More recently, it has been reported that integrin β2 
mediates spleen tyrosine kinase (Syk)/STAT signaling and promotes the 
survival of LSCs (Oellerich, Oellerich et al. 2013). Interestingly, Integrin β3 
was found to be critical for murine MLL-AF9 acute myeloid leukemia (AML) 
by regulating the homing of LSCs to bone marrow and repressed LSC 
differentiation via the intracellular kinase Syk (Miller, Al-Shahrour et al. 
2013).  
 
  To further characterize this EMT-like phenotype and to determine the 
molecular players responsible for the exacerbated adhesive and invasive 
properties as well as the possible chemoresistance associated with this cell 
phenotype, genome-wide expression profiles of TF-1a cells treated with Ara-C 
alone or in combination with I-3 were evaluated. Microarray data analysis 
revealed that a group of adhesion molecules and their corresponding ligands 
(such as integrins, collagens, laminins, fibronectine, CD44, PECAM1, 
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ICAM1, etc.); multiple cytokines, chemokines and matrix metalloproteinases 
(MMPs) (such as CCL5, CCL23, IL-8, TGFBI, MMP-2 and MMP-9) as well 
as EMT related genes (such as TGFBI, TGFBR2 and FN1) that regulate 
vascular transmigration and permeability were significantly induced by Ara-C. 
The IPA analysis indicated that integrins, AKT signaling and Leukocytes 
extravasation signaling were highly associated with chemotherapy induced 
geneset. Additionally, other signaling pathways, such as NF-κB, ERK, and 
Stat5 have also been suggested by IPA (data not shown). All of these signaling 
pathways have been implicated in metastasis, survival, drug resistance, cancer 
recurrence and cancer stem cells. Intriguingly, upregulation of the above 
mentioned molecules can be efficiently diminished by I-3. It was postulated 
that TF-1a cells treated by Ara-C may utilize the similar mechanism of 
leukocytes to extravasate endothelium vasculature and disseminate and 
infiltrate into other organs, such as spleen, lymph nodes and BM. Increased 
integrins and their related ECM ligands as well as other adhesion molecules, 
for instance, CD44 facilitated TF-1a cells to lodge in BM niches and acquired 
de novo drug resistance through activation various oncogenic signaling 
pathways, such as PI3K/AKT, NF-κB and MEK/ERK to evade the 
cytotoxicity by chemotherapy. The successful mitigation of CAM-DR 





  Despite the promising results, the underlying mechanism of anti-AML effect 
of I-3 remained unclear. Using AML cell line models, we also compared I-3 
with two other epigenetic drugs, DNA methylation inhibitor Decitabine and 
HDAC inhibitor SAHA in various anti-cancer aspects in AML. Our results 
demonstrate I-3 as a novel chromatin remodeling compound is more potent to 
suppress AML than DAC and SAHA. 
   
5.3 I-3 inhibits breast cancer cell EMT and invasion partially through E-
cadherin induction 
 
  E-cadherin is a central adhesion molecule located at cell-cell junctions and is 
generally defined as a guardian of the epithelium phenotype. Loss of E-
cadherin expression is a hallmark in EMT and is considered a crucial step in 
the progression from benign to invasive carcinoma. Strategies to reverse 
epigenetic silencing of E-cadherin might therefore be useful in cancer 
metastasis. In this study, it was found I-3 synergized strongly with a HDAC 
inhibitor SAHA to induce significant morphological changes of mesenchymal-
epithelial transition (MET) and concurrently inhibited the motility and 
invasiveness of MB231. E-cadherin was found to be significantly induced by 
I-3 alone or in combination with SAHA at both mRNA and protein levels. 
Furthermore, it was found that the anti-invasive efficacy of I-3 in combination 
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with SAHA was compromised under E-cadherin knock-down condition in 
MB231 cells. 
 
  Previous studies have identified multiple means leading to E-cadherin 
repression in cancer cells, such as transcriptional repression, DNA 
methylation and histone modification. A series of well characterized 
transcriptional repressors of E-cadherin, such as SNAI1, Slug, ZEB1, ZEB2, 
TWIST1 and TWIST2 were evaluated and it was found that none of these 
factors were affected significantly by the combined treatment of I-3 with 
SAHA. This suggested that reactivation of E-cadherin by the combination 
treatment is not a result of modulating these repressors of E-cadherin. 
Interestingly, it was reported that DZNep inhibited invasion in a prostate 
cancer cell line, DU145 through downregulation of SNAI1 and TGFBR2, two 
master regulators of EMT in prostate cancer cells (Baritaki, Chapman et al. 
2009; Lenferink, Cantin et al. 2010). However, DZNep seemed not to up-
regulate E-cadherin in DU145 cells (Crea, Hurt et al. 2011), suggesting 
DZNep may be able to upregulate other anti-metastatic genes rather than E-
cadherin to inhibit invasiveness of cancer cells. 
 
  To determine if histone modifications were associated with its repression in 
MB231, CHIP assay coupled with quantitative PCR were utilized to 
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characterize potential involved histone marks. Our data suggested that the 
repressive marks H3K27me3 and H3K9me3 were highly enriched in E-
cadherin promoter of MB231, whereas the two major activating marks 
H3K9/14ac (H3AC) and H3K4me3 were almost absent, suggesting E-cadherin 
repression in MB231 might mainly be regulated through histone modification. 
Clearly, then, we cannot yet provide any simple answer to the question of how 
E-cadherin was induced by I-3 combined with SAHA in MB231 due to the 
multiple contributing factors that work cooperatively to suppress E-cadherin 
transcriptional activity. But it is most probably that histone modification such 
as histone methylation and histone deacetylation are important for E-cadherin 
transcriptional silencing. 
  To determine whether E-cadherin induction by I-3 combined with SAHA 
through regulation of EZH2, MB231 cells were treated with EZH2 siRNA 
followed by SAHA treatment. Unexpectedly, it was found that there was no 
induction of E-cadherin in EZH2 depleted cells compared with non-specific 
control cells with or without SAHA treatment (data not shown). These results 
suggested E-cadherin may not be solely suppressed by EZH2 and associated 
H3K27me3. It was reported that HDAC complexes recruiting transcriptional 
repressors such as SNAI1 or Slug to suppress E-cadherin during EMT and 
cancer metastasis (Batlle, Sancho et al. 2000; Cano, Perez-Moreno et al. 
2000). Thus, in MB231 cells, E-cadherin induction by I-3 plus SAHA maybe 
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result from much more complicated changes of chromatin structure than 
expected. 
 
  Due to the high heterogeneity of breast cancer, our analysis was further 
extended to other TNBC breast cancer cell lines to determine whether E-
cadherin is regulated differentially in these cells. E-cadherin was found to be 
repressed in all TNBC cell lines tested such as MB231, BT549, MB436, 
HSS578T, MB157 and SUM159PT (data not shown). Given the complexity 
and heterogeneity of epigenetic mechanism in gene inactivation, it was 
postulated that the underlying silencing mechanism of E-cadherin in different 
TNBC cell lines may not be same. As combinatorial drug treatment targeting 
distinct epigenetic processes might act in synergy to give rise to maximal E-
cadherin reactivation, TNBC cell lines were treated with I-3 alone or in 
various combinations with a DNMT inhibitor Decitabine and a HDAC 
inhibitor SAHA/TSA. E-cadherin reactivation was evaluated by both qRT-
PCR and Western blot analysis. Three different E-cadherin responsive patterns 
to the combination treatment were observed. The first pattern (I-3 plus HDAC 
inhibitor) presented in MB231. Synergistic induction of E-cadherin by I-3 and 
SAHA suggested that E-cadherin in MB231 appeared to be mainly repressed 
by a synergistic effect of both histone methylation and deacetylation. In 
MB231, DNA methylation was also involved in the epigenetic mechanism 
183 
 
although it seemed to be less significant.  The second pattern of E-cadherin 
induction (decitabine alone) can be observed in BT549 and MB436. E-
cadherin induction in these two cells appeared to be sensitive to decitabine, 
but not to I-3, the HDAC inhibitor or I-3 plus HDAC inhibitor, indicating that 
DNA methylation is the dominant mechanism responsive for E-cadherin 
silencing. The third pattern of E-cadherin induction (DAC plus HDAC 
inhibitor) presented in HSS578T and SUM159PT. E-cadherin induction 
appeared to be sensitive to the combined treatment of DAC plus HDAC 
inhibitor, but not to the single treatment or other combinations. The 
coordination between histone deacetylation and DNA methylation seemed to 
be the primary mechanism responsive for E-cadherin repression in HSS578T 
and SUM159PT cells. Our data suggested that combinatory epigenetic 
modulation of E-cadherin may represent a promising therapeutic approach to 
target cancer metastasis. 
 
5.4 Characterization of mode-of-action of I-3 
 
  As we’ve known, DZNep is a potent inhibitor of S-adenosylhomocysteine 
(AdoHcy) hydrolase (Chiang and Cantoni 1979; Liu, Wolfe et al. 1992). 
Inhibition of AdoHcy hydrolase results in the cellular accumulation of 
AdoHcy, which in turn causes by-product inhibition of S-adonosyl-L-
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methionine (AdoMet)-dependent reactions, including those carried out by 
many histone methyltransferases (HMTs) and other proteins. Hence, it is not 
surprising that I-3 as a DZNep analogue functioned as a non-specific HMT 
inhibitor to suppress H3K27me3 as well as H3K4me3 and H4K20me3 in 
cancer cells. 
 
  It is clear that the depletion of PRC2 proteins after DZNep treatment is not 
achieved via transcriptional inhibition since DZNep treatment did not affect 
their mRNA levels. Instead, it is at least in part mediated through proteosomal 
degradation since proteosome inhibitors can restore PRC2 protein expression 
(Tan, Yang et al. 2007). A recent study further demonstrated that one of the 
DZNep-induced ubiquitin ligases, PRAJA1, directly ubiquitinates individual 
PRC2 subunits and leads to their proteasomal degradation (Zoabi, Sadeh et al. 
2011). However, other studies have shown that another AdoHcy hydrolase 
inhibitor, adenosine dialdehyde also caused a decrease in EZH2 protein levels 
and a global decrease in histone methylation, including H3K27me3 in cancer 
cells (Miranda, Cortez et al. 2009), similar to what has been shown with 
DZNep. This implied that the degradation of EZH2 and subsequently the 
decrease in H3K27me3 levels were not specific to DZNep and that DZNep 
was probably not directly inhibiting EZH2. Therefore, the inhibition of EZH2 
observed in cells treated with I-3 was probably due to an increase in AdoHcy 
levels, which then indirectly inhibited EZH2.  
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  Since I-3 depleted EZH2 similarly as DZNep in various cancer cells, it was 
postulated that at least part of the effects of I-3 may be due to EZH2 
downregulation. However, in this study, it was surprising to find that in either 
AML cell lines or MB231 cells, knockdown of EZH2 cannot phenocopy the 
effect of I-3 to inhibit AML or induce E-cadherin in MB231 cells (data not 
shown), suggesting depleting EZH2 is insufficient to represent the most 
critical effect of I-3 in our two tested cancer models. Rather, its potency may 
be linked to a multi-targets effect which results in inhibition of multiple 
oncogene signaling pathways.  
 
  Since DZNep was a potent inhibitor of S-adenosylhomocysteine hydrolase 
(AHCY), it is necessary to evaluate whether this enzyme was truly involved in 
the regulation of histone methylation and whether it is the relevant drug target 
of I-3.  AHCY gene knockdown by siRNA in several cancer cell lines did not 
affect any tested histone methylation marks, nor did it induce apoptosis. Thus, 
inhibiting AHCY alone does not seem to be able to explain the effects of 
DZNep/I-3 on both histone methylation and apoptosis. Thus, it is likely that 





5.5 Significance of the study 
The results presented in this study shows that I-3 is able to target both 
leukemic and leukemia stem cells in AML. Compared with two other 
epigenetic drugs, DNA methylation inhibitor Decitabine and HDAC inhibitor 
SAHA, I-3 exhibited much higher potency to suppress AML in various anti-
cancer aspects. Importantly, I-3 is able to target chemotherapy-induced 
leukemia stem cell enrichment as well as an invasive phenotype both of which 
have been linked to drug resistance and disease recurrence. Thus, I-3 in 
combination with chemotherapy may provide a novel therapeutic approach for 
refractory AML patients. In breast cancer, I-3 alone or in combination with 
SAHA can inhibit the metastatic properties of aggressive MDA-MB-231 cells 
both in vitro and in vivo. Mechanistically, this anti-invasive effect is 
associated with its ability to reverse EMT by inducing E-cadherin expression. . 
As we’ve known that there is no targeted therapy for TNBC, which has 
notably high recurrence and mortality rate due to the distal metastasis. Our 
results may suggest that I-3 alone or combined with other epigenetic 
compounds may represent a novel therapeutic approach to target the 
metastasis of TNBC.  
  Taken together, I-3 as a new generation epigenetic compound has provided 
impressive activity capable of exerting multifactorial anti-cancer activities 
including inhibiting multiple oncogenic signaling pathways in AML, targeting 
LSC and chemoresistance, anti-metastasis in breast cancer. Regardless of the 
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exact mechanism of I-3, its intriguing anti-cancer effects make it a promising 
cancer drug candidate for further investigation.   
  
5.6 Future prospects 
  The effects of anti-LSC and chemoresistance of I-3 were demonstrated in 
vitro by several lines of evidence. Firstly, I-3 abrogated chemotherapy induced 
CD34+CD38- subpopulation in TF-1a cells. Secondly, it was found that the 
colony formation ability of chemotherapy enriched LSCs can be suppress by I-
3. Thirdly, I-3 significantly diminished a subpopulation of mesenchymal-like 
TF-1a cells induced by chemotherapy.  Lastly, genome-wide expression 
profiling of TF-1a cells revealed that a panel of adhesion molecules, numerous 
cytokines, chemokines and matrix metalloproteinases (MMPs) and EMT 
related genes were induced by Ara-C and such elevation was significantly 
suppressed by I-3. To further validate the feasibility of I-3 in clinical practice, 
AML mouse model which enable the study of I-3 on anti-cell adhesion 
mediated-drug resistance (CAM-DR) in a physiological microenvironment is 
still necessary. Firstly, an AML disease model will be initiated by injecting 
TF-1a cells or other AML cell lines stably transduced with a Luciferase 
reporter into lethally irradiated recipient mice through tail vein. To investigate 
the effect of I-3 on AML recurrence after conventional chemotherapy in mice, 
a simple chemotherapy regimen involving co-administration of cytarabine and 
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doxorubicin will be established. I-3 will be given before or together with 
chemotherapy. Chemotherapy will be stopped once luciferase signals 
disappear completely. Mice will be monitored for disease recurrence by 
analysis of peripheral blood and bioluminescence for the luciferase signal. We 
hope this mouse model will provide a preclinical relevant system for further 
characterize I-3 action on chemoresistance in AML. 
  Future studies should also systematically investigate more TNBC cell lines 
both in vitro and in vivo to further preclinically evaluate the effects and 
mechanisms of I-3 on TNBC progression and metastatic spreading.  BD trans-
well assays will be conducted to evaluate the anti-invasiveness effect of I-3 on 
more TNBC cell lines in vitro. Genome-wide expression profiling will be 
conducted to reveal the potential metastases related genes that induced by I-3 
alone or in combination with SAHA. In order to further analyze the anti-
metastasis effect of I-3 on TNBC cell lines in a more clinical relevant setting, 
primary tumors from TNBC cell lines tagged with luciferase reporter will be 
established in mice via mammary fat pad transplantation. Once the primary 
tumors have reached considerable sizes (for example, 400-500 mm3), the 
tumors will be surgically removed. It has been reported that orthotopic 
transplantation of TNBC cell lines has the high possibility of distant metastatic 
spread especially if the primary tumors are surgically resected (Kubota 1994; 
Fidler 2006). Immediately after the surgery, I-3 with or without cytotoxic 
agent anthracyclines or taxanes will be administered into mice. The progress 
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of the metastasis will be monitored by bioluminescent imaging.  
 
As we’ve known, DNA methyltransferase and histone deacetylasei 
inhibitors have been approved for the treatment of some hematological 
malignancies (Szyf 2009). However, the efficacy of epigenetic therapy in solid 
tumors still needs to be proved. This may be explained by the fact that solid 
tumor cells are confined to a niche that is less reachable by these drugs. 
DZNep is a highly water soluble, hydrophilic drug with a negative partition 
coefficient (log P = −1.38), a feature that makes it difficult to reach to certain 
areas of the body. Therefore, the development of more lipophilic pro-drugs 
congeners, such as alkyl esters of DZNep, is warranted (Crea, Hurt et al. 
2011). Moreover, pharmacokinetic studies showed that DZNep has a very 
short in vivo half-life and only poorly distributes into peripheral tissues, 
probably due to its hydrophilic nature (Coulombe, Sharma et al. 1995). For 
this reason, a pegylated DZNep formulation has been recently developed and 
this novel formulation displayed improved pharmacokinetic profile in a rat 
model (Sun, Li et al. 2012). More recently, it was reported that an engineered 
nanoparticle for spatiotemporal release of DZNep followed by a cytotoxic 
agent gemcitabine produced pronounced chemosensitization and dose-




Taken together, I-3 is emerging as a promising strategy for cancer 
epigenetic therapy with improved biosafety compared with DZNep. In the 
future, better analogs of DZNep/I-3 with more lipophilicity, prolonger half-life 















































Appendix 1: EC50 of I-3 measured in solid tumors 
 





















HCC 2998 3.81E-05 

















Appendix 2: EC50 of I-3 measured in blood cancers 
 




































































































































Appendix 3: Information of primary AML cells from Patients 
 
Patient ID  EC50 of I-3 (µM) FAB subtypes  Sources  
AD267 4.32 M1  Bone Marrow (BM)  
AD353 0.96 MDS  Bone Marrow (BM)  
AD362a 4.06 MDS  Peripheral Blood (PB) 
























Appendix 4: Oligonucleotide Primers of E-caherin for Chromatin 
Immunoprecipitation (CHIP) assay 
 











































Appendix 5: Oligonucleotide Primers for quantitative real-time PCR 
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